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ABSTRACT
Pharmacokinetic Factors in the Neurotoxicities of p-Bromophenylacetylurea and m- 
Dinitrobenzene
Jinsheng Xu, MRC Toxicology Unit, University of Leic^ter, Leicester
Conventional approach^ to the study o f neurotoxicants focus exclusively on the direct 
action o f neurotoxicants on the nervous system. In 6ct, phannacokinetic and metabolic 6ctors can 
greatly modify the effect o f neurotoxicants This thesis presents die investigations of the 
pharmacokinetic and metabolic 6ctors in chemical-induced neurotoxicities, p-
Bromophenylacetyliuea (BPAU) and m-dinitrobenzene (m-DNB) were selected as model 
neurotoxicants. Wistar (LACP) and F344 rats, and the analytical techniques of HPLC, MS and 
NMR were u ^  in the present studies.
This study has dcmcmstratcd that metabolism and pharmacokinetic behaviour o f BPAU and 
m-DNB significantly modified their neurotoxicity. Three metabolites o f BPAU, 3-hydroxy-5-(4- 
bromophenyl)-1,3 -diaz^ientane-2,4-dione (M l), 4-<4-bromo-phenyl)-3-oxapyrrolidme-2,5-dione 
(M2) and 3-methyl-5-(4-bromophenyl)-l,3-diaza- pentane-2,4-dicne (M3), were identified and 
charaterised in this study. Phenylmethaifêsulfonyl fluoride (PMSF) i^ c h  can intensify BPAU- 
induced neuropathy signiflcandy delayed BPAU elimination, increased M l levels in tissues and 
decreased M2 concentration in serum This metabolic interaction and ncurotoxic synergy between 
the two conqiounds represent a disdnct model in the mechanistic studies o f the promotion of delayed 
neuropathy. The present study also showed that 1-year old rats which are more susceptible to 
BPAU-induced neuropathy produced more M l and less M2 than 6-week old rats.
In vivo and in vitro studies in this thesis also demonstrated that m DNBoan be metabolised 
in brain. The major metabolite was 3-nrtroanilme (3-NA). An activated intermediate, 3- 
nitrosonitrobenzene (3-NNB) was detected in the cultured astrocytes and endothelial cells. This 
suggests that metabolic activation may play an inqx>rtant role in m-DNB-induced neurotoxicity. The 
infusion-lesion model revealed that once a concentratirm threshold fbi /n-DNB is exceeded, the time 
which 772-DNB is maintained above that diroohold is a more inqiortant flictor in producing brain 
lesions than a higher transient concentration.
This study has demonstrated that pharmacokinetic approaches have a great potential in 
understanding chonical-induccd neurotoxicity.
Key words: p-brornophenylac^lurea (BPAU), m-dinitrobenzene (m-DNB), phenylmethanesulflmyl 
fluoride (PMSF), neurotoxicity, pharmacokinetics, metaboUsm, rat
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ABBREVIATIONS
3-AA: 3^Aminoaceta]iilide.
4-A-2-NP: 4-Amino-2-mtrophenol.
2-A-4-NP: 2-Amino-4-mtrophenol.
AUC: Area under concentration-tinie curve.
BPAU:
CNS:
Co:
Q:
2,4-DAP:
DMEM:
m-DNB:
HPLC:
ip:
iy;
Min;
M l:
M2:
M3:
h:
k:
3-NA:
p-Bromophenylacetylurea.
Central nervous system.
Concentration of test agent at time t = 0.
Concentration of test agent at time t.
2,4-Diacetaminophenol.
Dulbecco's Modified Eagle's Medium. 
m-Dinitrobenzene.
High-pressufe liquid chromatography.
Intraperitoneal injection.
Intravenous injection,
Minute(s).
3 -Hydroxy-5-(4-bromophenyl)-1,3 -diazapentane-2,4-dione;common 
name: N'-hydroxy-p-bromophenylacetylurea, HBPAU. 
4-(4-Bromophenyl)-3-oxapyrrolidine-2,5-dione. 
3-Methyl-5-(4-bromophenyl)- l,3-diazapentane-2,4-dione; common
name: N’-methyl-p-bromophenylacetylurea* MBPAU.
Hour(s).
Rate constant.
3-Nitroaniline.
11
3-NAA: 3-Nitroacetamlmê.
3-NNB: 3-Nitrosonitrobenzene.
PMSF: Phenylmethanesulfonyl fluoride.
P .O .: Peroral.
Td: The time from the end of infusion to decline to a certain
concentration.
Ti: Infusion time.
Tm: The time maintaining a test agent above a certain concentration.
ti/2 : Half life,
t: Time,
V: Apparent distribution volume.
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SECTION I INTRODUCTION
1.1 Phannacokinetics in toxicology
Humans and other animals are exposed to many potentially toxic drugs or 
other chemicals either from industry, the environment or from food contamination. 
These compounds are generally called xenobiotics which are defined as the 
compounds that are foreign to the normal metabolism of the body (Caldwell, 1995). 
Not all xenobiotics are toxic, but those i^ c h  are may exhibit their toxic effect on 
target tissues in several ways, see FIG 1-1. Any
Metabolism
Absorption
Xenobiotics
Distribution Persis tence
Toxicity
Biochemical
responses
FIG 1-1. Factors influencing toxicities of xenobiotics.
adverse effects produced by xenobiotics are ultimately the results of the interactions 
between target tissues and the agents. The study of toxicity has historically been
19
associated with the toxic effects of toxicants on target tissues and molecules. In fact, 
other, non-target processes, in one way or another, markedly modify the toxic effects 
of xenobiotics. For example, different species, ages, sexes as well as different 
individual tissues in an animal can have different responses to a given toxicant. To 
understand these susceptible differences we need to know what animals do to the 
xenobiotics as well as y/hat xenobiotics do to animals. Phannacokinetics may be 
defined as what the body does to foreign compounds (Benet, 1995) as it deals with 
the absorption, distribution and elimination of xenobiotics. So, pharmacokinetics 
plays an important role in understanding how body factors modify susceptibilities to 
toxicants.
Pharmacokinetics is the mathematical description of the rates of absorption, 
distribution, metabolism and excretion (ADME) of a drug. It was originally 
established to describe drug behaviour in the body. From the toxicology point of 
view, most drugs are also toxicants; this distinction merely depending on their 
dosage. On the other hand, most toxicants are not drugs. So when the principles of 
pharmacokinetics are used in toxicology, they are also termed toxicokinetics. Both 
pharmacokinetics and toxicokinetics were based on the same mathematical 
principles. In the present context, the terms pharmacokinetics and toxicokinetics will 
be used interchangeably.
Toxicokinetics has emerged as an invaluable tool in the conduct and 
interpretation of drug safety data (Chasseaud, 1993, Clark and Smith, 1984, Dayan, 
1994 and 1995, and Kato, et a/., 1993, Takacs, 1995). The disciplirie of its scope has 
been defined by the Second International Conference on Harmonization (ICH-2) 
(1993): “Toxicokinetics is defined as the generation of pharmacokinetic data, either
20
as an integral of component in the conduct of non-clinical toxicity studies or in 
specially designed supportive studies, in order to assess systemic exposure. These 
data may be used in the interpretation of toxicology findings and their relevance to 
clinical safety issues.” The other useful definition was given by Chasseaud, “The 
primary purpose of toxicokinetics is to provide information on the rate, extent, and 
duration of exposure of test anim al species to the test compound during the course of 
a toxicity study.” (Chasseaud, 1993).
Plasma is a more easily accessible matrix than other tissues in both animals 
and humans and is, therefore, convenient to use in monitoring body exposure to 
xenobiotics. However, plasma concentrations of a xenobiotic or its metabolite(s) 
may not reflect the concentrations at the target sites. Also, a toxic response may not 
be directly associated with plasma kinetics because of the differences in receptor 
binding, distribution and metabolic capacity (Igarashi, 1994; Cayen, 1995). 
Therefore, the toxic effect directly depends on the concentration of the toxicant or its 
metabolite(s) at the target site and on the sensitivity of the target tissues ( Monro, 
1994; Caldwell, 1995; Cayen, 1995). Thus pharmacokinetic information about 
xenobiotics in individual target tissues is important in understanding the interactions 
between targets and xenobiotics.
1.2 Bàsic concepts in pharmacokinetics
1.2.1 Absorption and bioavaüabüity
Absoiption is the process which leads to the entry of a xenobiotic into the 
systemic circulation of the body (CaldweU* 1995). Thus absorption is the beginning 
of the kinetic process of xenobiotics in the body The dosing routes and regimen
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significantly influence the kinetics of xenobiotics (Gibaldi and Perrier, 1982). 
Therefore, the dosing route and regimen must be carefiilly considered in 
pharmacokinetic studies. There are several routes by which drugs are commonly 
administered. These may be classified as either intravascular or extravascular 
(Rowland and Tozer, 1980). Intravascular admiinstration refers to the placement of a 
drug directly into the blood, either intravenously or intra-arterially. The xenobiotics 
given through extravascular adm inistration have to undergo an absorption process. 
The percentage of an absorbed xenobiotic is between 0%-100%. In fact, few 
xenobiotics can be absorbed either 100 % or 0 % through extravascular routes 
(Gibaldi and Perrier, 1982). The real absorbed amount is usually expressed as 
bioavailability (F).
Bioavaüabüity is defined as the fi-action of the dose reaching the systemic 
circulation in an unchanged form following administration by any route (Benet, 
1995). When a Xenobiotic is administered orally, the bioavaüabüity may be less than 
unity for several reasons: incomplete absorption, liver clearance prior to entry into 
the systemic circulation, and enterohepatic cycling with incomplete re-absorption 
following elimination into the büe.
1.2.2 Disposition
Once absorbed, a xenobiotic is delivered to all tissues at a rate determined by 
local blood flow or vascular permeability. Distinction between distribution and 
elimination is oflen difficult. Disposition is the term used when this distinction is not 
desired or is difficult to obtain. Disposition may be defined ^  aU the processes that
22
occur subsequent to the absorption. By definition, the components of disposition 
include distribution and elimination (Rowland and Tozer, 1980).
1.2.2.1 Distribution
Distribution is the process of reversible transfer of a xenobiotic to and fi’om 
the site of measurement. Any xenobiotic that leaves the site of measurement and 
does not return has undergone elimination, not distribution (Rowland and Tozer, 
1980).
The factors modifying thé distribution of xenobiotics include the 
physiochemical properties of the xenobiotics, the physiological and biochemical 
constitutions of organs or tissues, blood supply and lipid content of tissues. Fat and 
central nervous system (CNS) are rich in lipid. So lipophilic compounds readily 
distribute and accumulate in these tissues. Liver, brain, heart and kidney have high 
regional blood flows. A toxicant can quickly reach equilibration between blood and 
these tissues.
1.2.2.2 Apparent volume of distribution
The volume of distribution is the measure of the apparent space in the body 
available to contain the xenobiotics. It relates the amount of xenobiotic in the fluid 
measured. This volume does not necessarily refer to an identifiable physiological 
compartment but merely to the fluid volume which would be required to account for 
all the compound in the body (Gibaldi and Perrier 1982).
If the drug is given by iv injection, the apparent volume of distribution (V) 
can theoretically be estimated by the following equation:
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V = amount of drug in body / C (1)
where Ç is the concentration of a xenobiotic in blood.
The volume of distribution depends on many factors such as pKa of the 
compound, the degree of plasma protein binding, the partition coefficient of the 
xenobiotic in the fatty tissues, differences in regional blood flow, as well as the 
degree of binding to other tissues within the body (Caldwell, et a l, 1995; Rowland 
and Tozer, 1980).
1.2.2.3 Elimination
Elimination is the irreversible loss of xenobiotic from the site of 
measurement. The conversion of one chemical species to another and the excretion 
of the chemically unchanged drug are the irreversible loss (Rowland and Tozer, 
1980).
1.2.2.4 Systemic clearance
Systemic clearance (CLg) is a measure of the body's ability to eliminate 
xenobiotiçs. It is the rate of elimination by all routes relative to the concentration of 
xenobiotics in any biological fluid. It refers to die volume of blood or plasma which 
would be completely cleared of xenobiotics, and can be expressed as a volume per 
unit of time.
CL = rate of elimination / C (2)
C: the concentration of xenobiotic in any biological fluid.
Clearance is usually further defined as blood clearance (CLy), plasma 
clearance (CLp), or clearance based on unbound or free compound concentration 
(Clu). These concepts will not be described here.
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1.2.2.5AUC
Area under the concentration-time curve (AUC) is an important parameter in 
relation to clearance (CL) and distribution volume (V). Their relationships are 
expressed as following
AUC = amount eliminated/CL = k.dose/C (3)
or
AUC = doseA/^k (4)
where k is elim ination  rate constant and C is drug concentration.
1.2.2.6 Half-life (T1/2)
In the single compartment model, half-hfe (ti/2) is the time it takes for the 
concentration to be reduced by 50 %. However, when the xenobiotic concentration 
in the body is described by two or more compartments, each disposition phase has a 
characteristic halfrlife. The estimation of Xm will be described in 1.2.3.1.
1.2.3 Models and compartments
The distribution of a drug in the body is so complex that one cannot expect to 
achieve anything approaching a complete mathematical description. It is therefore 
necessary to make various simplifying assumptions and to replace the actiial system 
with a model system which is rigidly defined and simple enough to be described 
mathematically. Many aspects of pharmacokinetics are based on model systems 
(Gibaldi and Perrier 1982).
1.2.3.1 One compartment model
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This is the simplest model and regards the body water as one well-stirred 
volume with no subdivision, i.e. as one compartment of uniform xenobiotic 
concentration throughout. This model has many limitations, but Üiere is a terminal 
phase in the élim ination of most drugs when the plasma concentration declines 
according to a single compartment model.
In the case of intravascular injection, suppose that the elimination of a 
xenobiotic follow first order kinetics, the following relationship is established:
-dD/dt = kD (5)
D: the amount of à xenobiotic in the body at time t; dD: the small amount of the 
xenobiotic eliminated ôver an instant of time d$; dD/dt: the elimination rate; k: 
elimination rate constant that defines the overall rate of elimination of the xenobiotic 
by all routes. The negative sign indicates that the amount of drug decreases with 
time.
Equation (5) can be integrated to give the equation (6) so as to show how the 
amount of a xenobiotic changes with time,
D, = D«e^ (6)
Do: the amount of the xenobiotic in the body at time t = 0, or, in units of 
concentration,
C, = Coe-'“ (7)
where Co is the concentration of the xenobiotic in plasma at time t= 0 and Q  is the 
concentration at time t.
In natural logarithms,
lnC,=lnCoe'“ (8)
converting (8) into common logarithms (InC = 2.303logC):
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logCt = logCo-kt/2.303 (9)
This is the equation of a straight line, being of the form y = Bx + A, and a 
plot of the logarithm of plasma concentration against time after a dosage can often 
exhibit a terminal linear section of slope equal to -k/2.303 from which k can be 
calculated.
Generally, the half-life is determined from plasma or tissue concentration 
measurements during the terminal or elimination phase. The relationship of the 
elimination rate constant k to the half-life (ti/2) of a xenobiotic can be derived from 
rearranging Equation (9) and giving
t = 2.303/k.log(Co/Ct) (10)
When Ct decreases to the half of the original concentration within the time ti/2, the 
following relationship can be established:
ti/2 = 2.303/k.log2 = 0.693/k (11)
In the case of a xenobiotic given through extravascular routes, an absorption 
phase exists. Thus the description of the concentration change of a xenobiotic in the 
body can be modified by the absorption phase. The concentration Q at any time t can 
be estimated by
C, = Co(e'“- e '^  (13)
Co can be obtained by ( k a F X o )  / [ V ( k a - k ) ] .  Where k a  is the rate constant of absorption 
phase; Xo is the dosage; F is the bioavailability; and V is the apparent distribution 
volume. Therefore, Equation 13 can be transformed to the following form 
Q  = (k.FXo)/[V(k.-k)(e-^-e'^] (14)
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The parameters and constants of the absorption phase can be estimated by 
using the residual technique given by Gibaldi and Perrier (1975) which will not be 
described here.
1.2.3.2 Two compartment models 
In two compartment models, the body consists of two separate volumes and 
xenobiotics undergo reversible distribution between the two compartment which are 
most simply regarded as the plasma and the tissues. Behaviour of this type is seen 
immediately following the rapid intravenous injection of most drugs. The drug in the 
two compartments can ultimately attain a state in which the concentration of a 
xenobiotic declines at the same fractional rate. Under these conditions, the plasma 
concentration of a xenobiotic finally declines according to a single compartment 
model.
There are three patterns in the two-compartment models which are shown in 
FIG 1-2 (Gibaldi and Perrier, 1975). As shown in FIG 1-2, FIG 1-2A assumés that 
the xenobiotic is strictly eliminated fi'om the central compartment, FIG 1-2B 
assumes that the xenobiotic is strictly eliminated from the peripheral compartment 
and FIG 1-2C is assumed that the xenubiulic is elim inated firom both the central and 
peripheral compartments.
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A. Elimination from  cen tra l com p artm ent. B. Elimination from  peripheral com partm ent.
rxi2
1
kzi
kio kgo
C. Elimination from  both  com p artm eh ts.
1: R ep re sen ts  cen tra l com p artm ent.
2: R ep re sen ts  peripheral com partm ent.
0: R ep re sen ts  elim ination, 
k: R ep re sen ts  ra te  co n sta n t.
FIG 1-2 Three patterns of two-compartment models.
In the two compartment model, the eoncentration (Q) of a xenobiotic at any 
time t can be estimated by 
C, = Ae'“  + Be^*
where A (=Ci) is the concentration of the xenobiotic in central compartment at time 
t=0, a  is the elimination rate constant of the xenobiotic from central compartment, B 
(=C2) is the concentration of the xenobiotic in peripheral compartment at time t==0 , P 
is the elimination rate constant of the xenobiotic from peripheral compartment.
In pattern FIG 1-2A, the rate constants can be estimated by 
k2 i = (pA + oB)/(A + B)
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kio = ap  /(k2 i) 
ki2  = a  + P - k2 i" kio
In patter FIG 1-2B, the rate constants can be obtained by 
ki2  = (PA + aB)/(A + B) 
k2o = ap/(ki2) 
k2 i= a  + P - ki2 - k2o
In the pattern of FIG 1-2C, the rate constants can not be calculated in the 
above ways. The reason has been described by Gibaldi and Perrier (1975). It will not 
be discussed here.
1.2.3.3 Three compartment and other models 
Models based on three or more compartments are often necessary to provide a 
more accurate interpretation of the experimental observations. Physiological models 
have also been introduced and these relate to the known blood flow to various organs 
and seek to describe the drug concentration profile in different tissues (Bischoff and 
Dedrick, 1968; Martin, 1986). These models are not described here.
1.3 Metabolism:
The absorbed xenobiotics may undergo elimination unchanged, retention 
unchanged, spontaneous chemical transformation and enzymatic metabolism. 
Highly polar or volatile substance are likely to be eliminated unchanged. In contrast, 
non-polar, highly hpophihc compounds may be retained for longer periods in tissue 
lipids (CaldweU, çt al, 1995). Some compounds may undergo spontaneous
chemical changes: this may include hydrolysis at the appropriate pH and reaction
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4 > V with nucleophilic or electropMIic centres in tissue macromolecules (Testa, 1983).
But for most compounds, enzymatic metabolism is the major way for them to be 
elim inated from body tissues. This enzymatic metabolism includes Phase I 
(oxidation, reduction, hydrolysis) and Phase II (conjugation) reactions. Phase I 
reaction introduces or uncovers a frmctional grpup suitable for subsequent 
conjugation or for excretion.
1.3.1 Phase I metabolism
Oxidative metabolism'. The most important enzyme system involved in Phase 
I oxidative metabolism is cytochrome P450, the terminal oxidase component of the 
microsomal electron transfer system. The electrons required are supplied by the 
closely associated enzyme NADPH^cytochrome P450 reductase, a flavoprotein that 
transfers 2 electrons to cytochrome P450 from NAD(P)H (CaldweU, et al., 1995). 
The cytochromes P450 which are responsible for the oxidation of many xenobiotics 
are an enzyme superfamily consisting of a number of related isoenzymes, all of 
which possess an iron protoporphyrin IX as prosthetic group. There are 10 
mammalian gene families comprised of 18 subfamilies (Nebert, et a l, 1991). The 
most important enzymes involved in xenobiotic metabolism belong to the lA, 2B, 
2C, 2D, and 3A subfanülies. The individual enzymes are thought to metabolise 
substrates via the same catalytic mechanism (Guengerich and Macdonald, 1990). But 
they tend to show selectivity toward substrates (Caldwell, 1995).
The another major enzyme involved in xenobiotic metabolism is flavin- 
containing monooxygenase (FMO) which is a oxygen- and NADPH-dependent 
microsomal flavoprotein. It catalizes the N-oxidation of secondary and tertiary
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amines and the S-oxidation of thiols and thiourea as well as hydrazine derivatives 
(Paulsen, et a l, 1974; Ziegler, 1988, 1990; Parkinson, 1996)
Reductive metabolism: Even though microsomal cytochrome P-450 is 
classified as oxygenase, it also catalyses the reductive biotranformation of certain 
xenobiotics, for example, azo reduction, aromatic nitro reduction and reductive 
dehalogenation as well as the reduction of arene oxides, N-oxides, and all^l halides. 
Both the flavoprotein enzyme, NADPH-cytochrome P-450 reductase, and the 
terminal oxidase, cytochrome P-450, are involved in these reductions (Sipes and 
Gandolfi^ 1991). The very low redox potential, broad substrate specificity, and 
strong ligand binding of these systems allow the donation of electrons to electron- 
accepting xenobiotics, which results in a reduction rather than the predominant 
oxidative biotransformation (Sipes and Gandolfi, 1991).
Reductive metabolism may detoxify a xenobiotic, but it often results in more 
toxic products or reactive intermediates. For example, numerous nitro compounds 
uudergo reduction to amino derivatives, which can then be oxidized to toxic N- 
hydroxyl metabolites (Parkinson, 1996). Carbon tetrachloride and holothone arc two 
classic examples of cytochrome P-450-catalyzed reductive bioactivation to free 
radical intermediates (Sipes and Gandolfi^ 1991).
The other oxidation-feduction enzymatic systems include aldehyde/ketone 
reductase and alcohol dehydrogenase. Aldehydes, ketones, and alcohols are 
functional groups that produced from the oxidation of carbon or the hydrolysis of 
ester linkages. In addition, they are frequent functional groups that appear in drugs 
and other xenobiotics. These functional groups are often further biotransformed in 
the body by oxidation or reduction (Sipes and Gandolfi, 1991; Parkinson, 1996).
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1.3.2 Phase n  metabolism
Metabolites or intermediates of xenobiotics may further react with 
endogenous components to form conjugates. Conjugation reactions may be divided 
into 2 distinct groups according to the source of energy for the reactions (Caldwell, 
1980): the energy derived from the activated endogenous conjugating agent and the 
energy derived by prior metabolic activation of the xenobiotics. For example, the 
energy of the reaction of glucuronic acid, sulphate, méthylation, and acétylation is 
derived from the endogenous conjugating agents, and the energy of glutathione and 
amino acid conjugations is derived from the metabolic activation of xenobiotics 
(Caldwell, et al., 1995; Parkinson, 1996).
The important enzymes involved in phase H reaction include glucuronyl 
transferase, glutathione-S-transferases, N-acetyltransferase, epoxide hydrolase, 
methyltransferase (0-, N- and S- forms) and sulfotransferase (Commandeur, 1995; 
Caldwell, 1995; Parkinson, 1996). They all have their own specific substrates.
1.3.3 Metabolism of xenobiotics in brain
Liver is the main site of metabolism of xenobiotics. Many Cxtrahepatic tissues 
are also capable of metabolising foreign compounds. It has been demonstrated that 
brain has major Phase I and Phase II enzymes and is actively involved in 
metabolising xenobiotics (Haglund, 1984; Lowndes, 1994; Ravindranath, et al., 
1995; Bhagwat, et a l, 1995). Whole brain microsomal P450 levels are 
approximately 2.5-4 % of the liver (Wafner, 1988). However, mitochondrial P450 
content in brain is significantly higher than the microsomal P450 content, in contrast 
to the liver (Walther, et al, 1986; Bhagwar, et a l, 1995). Brain exhibits regional
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differences in the distribution of P450. Maximal P450 levels have been detected in 
olfactory lobes, cerebellum and brain stem (Anandatheerthavarada, et a l, 1993). The 
other major metabolising enzyme in brain is FMO. It has been demonstrated that 
FMO exists in neuronal cell bodies and localises in microsomes (Bhamre, 1993).
Glutathione S-transferases (GSTs), a Phase II enzyme family, also exist in 
brain. The cell^specific distribution of the GSTs varies according to isoforms of 
GSTs. For example, p-GST was mainly detected in astroglial cells (Abramovitz et 
a l, 1988; Gammer, et a l, 1989), tt-GST was observed in myelin and myelinating 
cells (Tansey and Cammer, 1991) and a-GST was found in neurons (Carder, et al., 
1990; Johnson, et a l, 1993). All these isoforms also exist in other cell types in the 
nervous system but their activities greatly vary from cell type to cell type or from 
region to region.
1.4 Features of the central nervous system
1.4.1 Interrelationships between neurons and neuroglia 
The mammalian nervous system is an extensively organised tissue. Nervous 
tissue consists of two cell-types: nerve cells, or neurons, and several types of glial 
cells, or neuroglia (including astrocytes, oligodendrocytes, microgha, and 
ependymal ceUs). Neurons are excitable cells which process internal and external 
information and directly or indirectly control or co-ordinate physical and 
biochemical activities. Whereas neuroglia play an important role in supporting and 
protecting neurons and participating in the neural activity, development, nutrition, 
defence and repair processes of the central nervous system. Due to the physiological 
and biochemical differences between neurons and neurogha, they may interact in
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the neurotoxicities induced by neurotoxicants in different ways. For example, 
neuroglia may be the first target of some neurotoxiconts and the neuronal damage 
may be a secondary event due to the fimctional failure or loss Of support cells. On 
the other hand, neurotoxicants may be biotransformed into either detoxified or 
activated forms in neuroglia before they reach neurons. As a result, neuroglia may 
reduce or increase toxic potentials of neurotoxicant to neurons. Therefore the 
interactions between the two classes of cells in phyriological. functions and 
metabolism of xenobiotics ultimately determine the balance between resistance and 
susceptabihty to functional or morphological damage in the brain,
1.4.2 Blood-brain barrier
In the central nervous system, the tight junctions between the endothelial 
cells form a integrated membrane barrier known as the blood-brain barrier which 
prevents the entry of proteins and other water-soluble substances of low molecular 
weight (Risau and Wolburg, 1990). The blood-brain barrier plays an important role 
in protecting the brain fi’om exposure to some toxic substances. However, some 
areas in the CNS have no blood-brain barrier, namely the choroid plexus, 
neurohypophysis, media eminance, pineal gland, area postrema, and subfornical 
organ. The tight junctions in these areas are formed between the ependymal cells. In 
addition, sensory and autonomic ganglia are not protected by blood-tissue barriers, 
their neurons thus being particularly exposed to neurotoxins. However, peripheral 
nerve has a somewhat less effective barrier : the perineurium forming a connective 
tissue sheath. The iimer layers of perineurial cells are coimected by tight junctions 
(Rechthand and Rapoport, 1987).
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However, certain lipophilic compounds can simply diffuse through 
endothelial cells of brain capillaries by a trans-cellular route and penetrate into the 
brain (Ravindranath, 1995). The permeability is proportional to the lipid/water 
partition coefficient. Brain, spinal cord and peripheral nerves are the organs with the 
highest lipid concentration after adipose tissue. It is evident that lipid solubility of 
toxicants plays a fundamental role in their neurotoxicities (Lefauconnier and 
Bouchaud, 1994). Therefore, the physical, characteristics of the blood-brain barrier 
cannot provide sufficient protection for the CNS from lipophilic toxicants, for these 
the xenobiotic metabolic systems in the barrier provide the major defence (Ghersi- 
Egea, et al., 1994).
1.4.3 Regeneration ability
As is well known, unlike other cells, neurons can not be replaced once they 
are lost from the adult nervous ^ te m . Although some glia cells can repair the 
injury, they can not functionally replace neurons. Therefore any damage to neurons 
in the central nervous system will cause irreversible functional loss. This feature 
makes the nervous system particularly vulnerable to neurotoxicant-induced damage^
1.4.4 Regional heterogeneity and selective vulnerability in brain
Over 100 years ago, the German pathologist Franz Nissl did a series of 
experiments in order to identify cellular changes specific to each of a variety of 
toxicants. He observed that the administration of particular agents consistently 
resulted in characteristic injury to neurons of defined area of the brain. These studies 
stimulated later pathologists to propose the hypothesis that the cells in particular
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regions of the brain, by virtue of unique biochemical or anatomic features, are 
vulnerable to intoxication by certain classes of xenobiotics and not by others. This 
theory became known as pathoclisis (Vogt, et. al., 1922).
During the past two decades, the basis of pathocliris has become clearer. 
Brain exhibits tremendous regional heterogeneity and each region displays 
specialised and selective functions. Its heterogeneity may present in different levels. 
The differences in lipid content and metabolic capacity and specificity of different 
regions or cell types are aU responsible for the selective susceptibility to 
neurotoxicants. For example, myelin is rich in lipids vhich comprise 75 to 80 
percent of the dry weight of CNS myelin. The major lipid molecules in myelin are 
cholesterol, cerebroside sulphate, sphingomyelin, ethanolamine glycero-
phosphatides (EGP), serine gjycerophosphatides (SGP) and choline
glycerophosphatides (CGP). Small amounts of lipids such as phosphatidyl glycerol, 
polyglycerol phosphatides, phOsphatidic acid, galactosyl-diglyceride, ceramide, and 
cholesterol esters also present (Finean, 1960). Therefore myelin is particularly 
important in the distribution of lipophilic substances in the central nervous system. 
For example, the distribution of toluene, a lipophilic compound, in brain correlates 
weU with the Upid contents in different regions of brain (Gospe, 1988).
The heterogeneity in metabolic ability and specificity may be due to the 
differences in the presence of metabolising enzyme systems, or the efficiency of 
these systems (Lowndes, et al., 1994). The level of glutathione in the brainstem is 
lower than that in other regions (Ravindranath, et a/., 1989). The presence of high 
amounts of P450 in brainstem coupled with the low levels of glutathione may render 
the brainstem particularly vulnerable to damage through P450-mediated
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bioactivation of xenobiotics to reactive eleçtrophilic metabolites (Ravindranath, 
1989; 1995).
It has been demonstrated that the distribution of certain cytochromes P450 are 
highly dependent on the isoform of the enzyme, brain region and cell type. For 
instance, CYP2E1, an isoenzyme of cytochromes P450, is mainly found in neurons 
but not in güa (Hansson, et al., 1990; Anandatheertiiavarada, et a l, 1993). However, 
there are important exceptions, it being present in cerebellar Bergman güa, but not in 
Purking’s cells for example (Lowndes, et a l, 1994). In certain brain regions, 
CYP2B1 appears restricted to güa ceUs while in other regions neurons also contain 
appreciable amounts of this enzyme (Volk, et a l, 1991). The other major drug 
metaboüsing enzyme FMO mainly locates in neuronal ceUs (Bhamre, et a l, 1993). 
The difference in the distribution of metaboüsing enzymes is perhaps the most 
important factor in regional vulnerabiüty to specific neurotoxicants, but is at present 
very incompletely understood.
There is no doubt that the heterogeneity of brain is the basis of selective 
neurotoxicities of neurotoxicants.
1.5 Approaches of this study
Conventional studies in neurotoxicology focus on what neurotoxicahts do to 
the nervous system. In fact, systemic factors and the nervous system itself can 
greatly modify the toxicities of neurotoxic agents. Their interaction causes particular 
damages in the nervous system. The purpose of this thesis is to investigate the 
significance of these modifying factors in the case of two model agents, p~ 
Bromophenylacetylurea (BPAÜ) and m-dinitrobenzene (m-DNB). Pharmacokinetics
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plays an important role in describing how body factors influence neurotoxicant 
behaviour. The concentration, persistence and metabolism of neurotoxicants as well 
as the primary biochemical events at target sites are responsible for neurotoxicant- 
induced injury. BPAU and m-DNB were selected as model neurotoxicants for this 
study. BPAU is widely used as a model compound in studying delayed neuropathy 
(details see the Introduction of Section 2). m-Dinitrobenzene (m-DNB) can 
selectively cause brain stem damage (details see the Introduction of Section 3). 
Both were suspected to be subject to significant metabolic transformation and, 
therefore, they were chosen as model neurotoxicants to investigate the metabolic and 
pharmacokinetic factors in their neurotoxicities.
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œCTTOAT 2  METABOLISM AND PHARMACOKINETIC 
FACTORS IN /»-BROMOPHENYLACETYLlJREA-INDUCED 
NEUROPATHY
2.1, INTRODUCTION
/ 7-Bromophenylacetylurea (BPAU) was originally synthesised as one of a 
series of halogenated congeners of phenylacetylurea (Phenurone, Abbott chemicals), 
see FIG 2-1, an antiepileptic agent, to search for a more effective anticonvulsive 
drug (Diezel and Quadbeck, 1960 ).
I
^ ^ ^ C H 2 “ 4 -N H “ C -N H 2 
a. P h eny lace ty lu rea
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b. B ro m o p h en y lace ty lu rea  (BPAU]
CI“^ ^ “CH2"^ "NH-E-NH2
c. C h lo ropheny lace ty lu rea  (CPAU)
o o
, l - ^ ^ ^ C H 2 -& -N H -& -N H 2  
d. lo dopheny lace ty lu rea
0 0
F-^-C H 2-6-N H -6-N H 2 
e. F lou ropheny lace ty lu rea
FIG 2-1. Phenylacetylurea and its derivatives
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Although its anticonvulsive effect was better than other derivatives of 
phenylacetylurea, it produced serious delayed ataxia and paralysis in rats (Diezel 
and Quadbeck, 1960). A further study which was done by Cavanagh (1968) showed 
that BPAU-induced delayed neuropathy in rats was clinically similar to organic 
phosphorous compounds induced delayed neuropathy (OPIDN) in chicken. Rats 
were more susceptible to BPAU neurotoxicity than other species. Therefore, BPAU 
has widely been used as a model compound in mechanistic studies of delayed 
neuropathy in rats by many researchers though it is not commercially available 
(Canavagh, 1968; Fossom, 1985; and Nagata, 1986).
2.1.1 Physiochemical properties of BPAU
BPAU is a white crystalline solid. The molecular structure of BPAU is 
shown in FIG 2-Ib. Its chemical formula is C9 H9 0 2 N2Br and molecular weight is 
257. The melting point of BPAU is at 230-231 °C (Jakobsen, 1981). BPAU is very 
poorly soluble in water and common organic solvents such as ethanol, methanol, 
acetone, chloroform and glycerinfoimal. It dissolves well in dimethylsulphoxide 
(DMSO), which is the commonly used vehicle for administration.
2.12 p-Bromophenylacetylurea-induced neurotoxicity
BPAU can induce a typical delayed ataxia in rats. The animals developed 
paralysis in hindlimbs after a ‘silent’ period of 7-10 days after dosing (Diezel and 
Quadbeck, 1960; Canavagh, 1968 ). The clinical feature of delayed ataxia was not 
observed on rabbit, guinea-pig, and chicken, which suggests that there are species 
differences in susceptibility to BPAU neurotoxicity (Canavagh, 1968). The clinical
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severity of delayed ataxia and the silent period before its development depends on 
dosage. Either double or single doses of 400, 200, or 100 mg/kg BPAU can induce 
different degree of clinical ataxia and/or paralysis in rats (Diezel & Quadbeck, 
1960; Canavagh, 1968; Fossom, 1985; Nagata, 1986). In addition, similar clinical 
changes were also produced when rats were given daily oral doses of 10 or 40 
mg/kg BPAU for two or six months (Fossom, 1985). Therefore, either a higher 
bolus dose (100-400 mg/kg) or long-term repeated lower doses (10-40 mg/kg/day 
for 2-6 moths) induced the same target damage. This suggests that BPAU may show 
some accumulation in target tissues. Pharmacokinetically, a single large dose can 
produce a instant high level in target tissues but long-term repeated lower doses 
allow the toxicant to accumulate in target tissues until it exceeds a certain threshold 
and trigger toxic damage. In addition, age differences of sensitivity to BPAU have 
also been documented. Adult rats are more sensitive to BPAU than young ones 
(Canavagh, e/ûr/., 1968; Chen, e/ûf/., 1971).
Axonal degeneration, particularly of distal axons, is the distinctive character 
of BPAU axonopathy. It shows the Wallerian-Iike degeneration (Canavagh, et ai, 
1968). The earliest pathologic changes were detectable 7 days after BPAU dosing. 
Distal myelinated axons showed mild swelling, enlargement of mitochondria, and 
irregularly arranged membranous trabeculae made up vesicles and tubules. The 
severity of these changes increased with time. By 3 weeks, rats showed 18 to 50 per 
cent loss of axons in the distal phrenic nerve (Troncoso, 1982). Anatomically, long 
fibres are more sensitive than short fibres (Canavagh, et al., 1968). A decreased 
number of nerve fibres, and myelinated axons containing osmiophilic accumulations 
were also observed after chronic intoxication with lower daily doses of 10 or 40
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mg/kg BPAU for 2 or 6  months. BPAU can also cause degeneration in ganglionic 
cells in the anterior horns of the lumbar and lower thoracic spinal cord in rats 
(Potkonjak, 1965). The dorsal columns showed loss of axons and gliosis; cervical, 
thoracic, and lumbar levels of spinal cord showed greater amounts of degeneration 
in the rostral regions of ascending tracts, and in caudal regions of decending tracts 
14-17 days after dosing (Cavanagh, et a/., 1968).
BPAU can cause a reduction in the amount of protein transported 
retrogradely. This suggests that retrograde axonal transport was affected (Nagata,
1986). Fast axonal transport were affected in both sensory and motor nerves 
(Nagata, 1986; Oka, 1990). Electrophysiological studies showed that the decrease in 
amplitude of muscle action potential induced by BPAU agreed well with the 
severity of ataxia (Jakobsen, 1981). This also provides an index of peripheral nerve 
damage.
The mechanism of BPAU-induced delayed neuropathy is not known. A 
reduction in amino acid incorporation into proteins during the period before the 
onset of paralysis due to BPAU was found in spinal ganglia (Cavanagh, 1971). The 
toxic effects of BPAU can be reduced or even prevented by the co-administration of 
1, l,3-tricyano-2-amino- 1-propene (TAP), which is now used for the treatment of 
hypothyroidism (Potkonjak, 1965). TPA can increase the quantity of ribonucleic 
acid in nerve cells (Egyhazi, 1961) and induce the regeneration of cut nerve in dogs 
and rabbits (Davanzo, 1963). BPAU did not cause changes in glucose-dependent 
lactate production (LoPachin, 1984) nor alter energy utilization (Brünijoin and 
Mintz, 1984). These observations suggest that the biochemical lesion caused by 
BPAU does not impair energy metabolism.
43
Of the derivatives of halogenated phenylacetylurea, see FIG 2-1 , only p- 
chloro- and /?-brominated forms exhibited serious neurotoxicity (Diezel and 
Quadbeck, 1960; Brimijoin and Nagata, 1986). This implies that the chemical 
properties of the halogenated phenylacetylureas may play an important role in their 
neurotoxicities because it may significantly modify the absorption, distribution and 
metabolism of these compounds as well as the specificity and susceptibility of target 
sites.
2.1.3 Phenylmethanesulphonyl fluoride and 'promotion'
A non-neurotoxicant can exaggerate the neurotoxicity induced by 
neurotoxicants. This phenomenon was originally observed in organophosphorous 
compound induced neuropathy (OPIDN) and has been termed ‘promotion’ 
(Veronesi and Padilla, 1985; Pope and PadiUa, 1990; Lotti, et al, 1991). 
Phenylmethanesulfonyl fluoride (PMSF) is a commonly used potentiator. PMSF is 
widely used as a protease inhibitor in protein purification to protect proteins from 
degradation. It can inhibit serine proteases, including chymotrypsin, trypsin, 
thrombin, thiol protease such as papain (Keesey, 1987). It can also inhibit some 
non-protease enzymes such as human erythrocyte acetylcholinesterase, human liver 
arylsulfatase A (Keesey, 1987). The inhibition mechanism of PMSF on enzymes 
lies on its sufrbnating the active serine residue in the active site of a protease 
(Keesey, 1987).
The mechanism of OPIDN is believed to relate to irreversible inhibition or 
‘ageing’ of neuropathy target esterase (NTE). Similar to organophosphates, PMSF 
can also inhibit NTE, but itsett does not induce delayed neuropathy. The LD50 of
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PMSF is 200 mg/kg in mice by ip dose and 500 mg/kg in rat by oral dose (Keesey,
1987). When PMSF was given before exposure to an organophosphate, it protected 
animals from OPIDN. The protective effect of PMSF was thought to be due to its 
reversible occupation of NTE, thereby preventing subsequent binding with the 
organophosphate. However, when PMSF was given after the organophosphate, it 
enhanced OPIDN. These data suggested that PMSF can act at a site other than NTE 
to promote OPIDN (Fioroni et al, 1995). This promotion site(s) is still unknown. 
BPAU does not inhibit NTE (Johnson, 1969) but can induce clinically delayed 
ataxia similar to OPIDN and its neuropathy can also be intensified by PMSF (Ray & 
Johnson, 1992). The mechanism of promotion is not known yet.
2.1.4 Approaches of this study
As reviewed above, BPAU represents a distinct category of neurotoxicant 
and has widely been used as a model compound in studying delayed neuropathy. 
Several factors, for example, age, dosing regimen as well as a non-neurotoxicant 
PMSF, can significantly modify its neurotoxicity. The mechanism of its 
neurotoxicity is not yet known. So far, the clinical features, histopathology and 
electrophysiology of BPAU-induced neuropathy have been well described but its 
metabolism and pharmacokinetics have not been studied. The studies of metabolism 
and pharmacokinetics may provide important information for a better understanding 
to its neurotoxicity. Therefore, this part of the thesis investigated the roles of 
metabolic and pharmacokinetic factors in BPAU-induced delayed neuropathy and 
its modification by the both age and PMSF.
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2.2. EXPERIM ENTS
2.2.1 Chemicals
p-Bromophenylacetylurea (BPAU) was synthesised by Dr A. R. Mattocks 
(MRC Toxicology Unit); phenylmethanesulphonyl fluoride (PMSF) was purchased 
from Koch-Light Laboratories LTD; acetonitrile (HPLC grade) and diethyl ether 
were obtained from Sigma; dimethyl sulphoxide (DMSO) was purchased from 
BDH; glycerinfoimal, methanol, trichloroacetic acid and ammonium acetate were 
obtained from Fisons.
2.2 2 Phaimacokinetics of BPAU
2.2.2.1 Animals and procedures
Groups of 4 female F344 rats, weight 170-210 g, were given a single i.p. 
dose of 150 mg/kg BPAU in DMSO. All the animals were kept in plastic cages with 
stainless steel grill tops and free access food and water. The room temperature in 
animal house was 2 2  ± 1 °C. The animals were killed at either 1 , 2, 4, 6  ^ 1 2 , 18, 24, 
48, or 72 hour(s) after dosing. Two rats were used as control and given the same 
volume of DMSO as test groups. They were killed at either 6  or 18 hours after 
administration,
2.2.2.2 Sample preparation for the determination of BPAU and its 
metabolites
Animals were killed by the inhalation of carbon dioxide. Blood samples were 
collected from the heart immediately after death of animals. Brain, spinal cord,
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liver, and muscle were dissected, weighed, and stored at - 2 0  °C. Before analysis, 
they were thawed and homogenised in a mixture of methanol and DMSO (95 : 5 by 
volume) at 100 mg tissue per ml solution. Blood was centrifuged at 3000g for 10 
min. 1 ml serum was taken and then mixed with 4 ml methanol/DMSO solution. In 
addition, five samples of fi-esh serum were spiked with 5 mg BPAU per ml to study 
the recovery of this analytical system. These samples were also mixed with 
methanol/DMSO solution (1:4) as stated above. AU samples were centrifuged with 
an Eppendorf centrifiige at 9000 g for 5 min and the supernatant kept for HPLC 
analysis at - 2 0  °C for up to 4 weeks. The supernatant of brain or spinal cord was 
filtered with a syringe filter (0.2 pm) before injection into HPLC, see 2.2.2.3.
2.2.3 HPLC analytical conditions
2.2.3.1 Gradient
HPLC system: Waters HPLC system with a ControUer 600, a tunable 
absorb^ce detector 486, and an autosampler plus^ T.17. JThe^colunm was ;a S5 0DS2- 
250 X 4.6 mm (Spherisorb); and the detector wavelength: 240 nm. The mobile phase 
(A= 0.1 M ammonium acetate, pH = 6.5, B = acetonitrile) used a gradient: 25 % B 
linear to 50 % B within 10 min and then maintaining 50 % B fi’om 10 to 20 min; 
and a flow rate at Iml/min. The injected volume of each sample was 25-50 pi. The 
HPLC profiles of BPAU and its metabolites are shown in FIG 2-2.
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FIG 2-2, HPLC profiles of BPAU and its metabolites - gradient condition
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2.2.3.2 Isocratic
HPLC system: Philips, Pye Unicam with a PU4010 pump ( LDC/Milton) and 
a Roy Spectromonitor III. Column: S5 0DS2 250 x 4.6 mm (Spherisorb); 
Wavelength: 240 nm; Mobile phase: 32% acetonitrile in 0.1 M ammonium acetate 
for BPAU and its metabolite Ml analysis, 23 % acetonitrile in 0.1 M ammonium 
acetate for the determination of metabolites M l, M2, and M3; Velocity: Iml/min; 
The injected volume of each sample: was 25-50 pi. HPLC profiles of BPAU and its 
metabolites are shown in FIG 2-3.
P e a k  2 (M2)
Spinal cord
Serum Peak 2 (M2)
. Peak 1 (Ml)
BPAU
Peak 1 (Ml);
10203 0
Time (min)1020
Time (min)
FIG 2-3. HPLC profiles of BPAU and its metabolites - isocratic condition
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2.2.4 BPAU metabolism m vzvo
2.2.4. 1  Sample preparation
Three metabolites were detected in tissues, serum and urine by HPLC, see 
FIG 2-2. They were temporarily designated M l, M2 and M3 respectively. In order 
to do further study, they were purified. Liver and blood were collected from rats 
killed at either 18 or 24 hr after dosing for M l and M2 purification. The procedures 
are as stated in 2.2.2.2. Urine was obtained from rats kept in metabolic cages from 
12 to 48 hr after dosing for metabolite purification, especially for M3 purification.
2.2.4.2 Pre-extraction
M l: Liver was thawed and homogenised in a mixture of methanol and 
DMSO (95:5) at 100 mg tissue per ml solution. The homogenate was centrifuged at 
6000 g for 20 min. The supernatant was concentrated under reduced pressure with a 
Rotovaper-R in 37 °C water bath for about 40 min to allow methanol evaporated 
and then stored at 4 °C overnight. Then it was centrifiiged with an Eppendorf 
centrifuge at 9000 g for 5 min to get rid of insoluble residue. The supernatant was 
kept and diluted with an equal volume of distilled water for extraction by diethyl 
ether. Then it was extracted with equal volume of diethyl ether 3 times. The 
extraction was concentrated again by evaporating diethyl ether with a Rotovaper-R 
for 30 min. The residue of the extraction was diluted with an equal volume of 21 % 
acetonitrile. The solution was kept at 4 °C overnight, then centrifuged with an 
Eppendorf centrifuge at 9000 g for 5 min. The supernatant was kept for the isolation 
of M l by HPLC.
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M2: Serum was mixed with methanol/DMSO (95 : 5) at 0.2 ml serum per ml 
solvent and centrifuged at 6000 g for 20 min. Further procedures as for M l.
M3: All the collected urine was pooled and centrifuged at 6000 g for 20 min. 
The supernatant was kept and extracted with an equal volume of diethyl ether three 
times. Further procedures were as for M l.
2 2.4.3 Purification of BPAU metabolites
HPLC analytical conditions were as stated in 2.2.2.3. A 500 pi lo(^ was used 
for metabohte isolation. The mobile phase for metabolite analysis was 23 % 
acetonitrile for M l purification and 2 1  % acetonitrile in 0 . 1  M ammonium acetate 
for metabolite M2 and M3 purification. The injection volume for purification was 
250-350 pi.
M l or M3: The peak finctions containing M l or M3 were collected and 
pooled into a glass bottle. Ihe botfie was placed in a 25 °C water bath and blown 
with nitrogen for 40 min to allow acetonitrile to evaporate.;After that, the rest of the 
solution was extracted with an equal volume of diethyl ether three times. Then the 
extraction was concentrated by evaporatmg diethyl ether with a Rotovaper-R at 
room temperature for 30-40 min. The residue was dissolved in 5-10 ml of 23 % 
acetonitrile and purified for the second time by HPLC and the peak fiactions were 
collected and extracted again as above. Then ether residue firom this second 
purification was placed in a glass test tube and dried with nitrogen.
M2: The peak fiaction was collected and pooled in a glass bottle. Then it was 
blown with nitrogen in 37 °C water bath for 40 min, diluted with 0.1 M ammonium 
acetate (1:1) and filtered through a cartridge (Bond Elut C18, Varian). When all of
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the diluted solution had been filtered, the cartridge was washed with 2  ml water and 
M2 was then washed off with 5 ml methanol. The methanol eluate was then dried 
with nitrogen.
2.2.4.4 Mass spectrum analysis of metabolites
BPAU and purified M l, M2 and M3 were analysed by mass spectrometry 
(MS). Mass spectra were obtained on a V.G.70-SEQ instrument (Fisons 
Instruments, VG Analytical, Manchester, UK.) of EBqQ geometry. All samples 
were ionised by negative ion fast atom bombardment (FAB) using xenon as die 
source of fast atoms. The primary beam impacted on the sample at 8.5 keV with a 
beam flux equivalent to 1 A. The secondary ions produced were accelerated to 8  
keV from the source region and analysed in the first mass spectrometer (EB) using a 
scan speed of 5s.decade"  ^ at a resolution of 1500. Samples, in chloroform, were 
analysed by dissolving 2 pi of sample in 2 pi of 3-amino-1,2-propanediol (Aldrich 
Chemical Co.Inc.), which served as the FAB-MSmatrix.
2.2.4.5 Nuclear magnetic resonance (NMR)
BPAU and its purified metabolites M l, M2 pr M3 were dissolved in DMSO. 
Scanning was carried out on a BRUKER ARX 250 instrument. The scanning times 
varied with the sample quantity.
2.2.5 Animal model of BPAU-induced delayed neuropathy and its time-dependent 
promotion by PMSF
2.2.5. 1  Animals and procedures
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Groups of 6  female Wistar rats (LACP), weight 170-210 g, were given two 
daily oral doses of 150 mg/kg BPAU in DMSO. Time-dependent promotion was 
studied by giving a single dose of 100 mg/kg PMSF in glycerinformal at either 1 day 
before the first BPAU dose (PMSF-Id-BPAU) or 4 hours (BPAU-4hr-PMSF), 1 day 
(BPAU-1 d-PMSF) or 4 days (BPAU-4d-PMSF) after the second BPAU dose. A 
BPAU only control group were given two dafiy oral doses of 150 mg/kg BPAU and 
the same volume of glycerinformal (solvent) as the above groups 4 hours after the 
second BPAU dose. A PMSF only control group was given two daily oral doses of 
an equal volume DMSO (solvent) and a single ip dose of 100 mg/kg PMSF in 
glycerinformal 4 hours after the second DMSO dose. The rats were kept in stainless 
steel cages with free access to food and water. Glass dishes with food were placed 
on the floor of cages for disabled rats from day 7 after BPAU dosing. Room 
temperature was maintained at 22 ± 1 °C. Natural light and dark cycles were 
adopted for the whole duration of the experiment. Animals were examined and 
weighed every day.
2.2.5.2 Evaluation of ataxia, slope test, and body weight
2.2.5.2.1 Ataxia scores:
The evaluation of ataxia was based oil a 0 -10 point system (Johnson & Ray, 
1993): 0: Normal; 1: Body sways when walking; 2: Legs extended or splayed when 
walking; 3: Slow to pick up hind legs when walking; 4: Clear signs of hind hmb 
weakness; 5: Occasionally drags a leg when walking; 6 : Hind legs splayed out 
behind body; 7: Some additional forelimb weakness; 8 : Rats cannot lift 350 g with 
forelimbs; 9: Difficulty in righting body; and 10: Full ataxia, unable to right body.
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2.2.5.2.2 Slope test:
A wooden board (82 x 40 cm) was placed horizontally. Each rat was placed 
on the centre of the board and one end of the board was elevated slowly until the rat 
began to slip down. Then the height which the end reached was recorded. The 
height was converted into the angle of the slope. The test was repeated three times 
and the mean value recorded. If the rat attempted to move off the board during the 
test, the result was discarded and a new test made.
2.2.5.2.3 Body weight:
Each rat was weighed and recorded every day or every other day.
These three measures were made for every day or every two days from 1 day 
before intoxication to 80 days after intoxication. All animals were terminated by 
inhalation of carbon dioxide at the end of the experiment.
2.2.6 Effects of PMSF on the metabolism and pharmacokinetics of BPAU
2.2.6.1 On metabolism
2.2.6.1.1 Animal and procedures
Four groups of 5 female F344 rats were given two daily po dose of 150 
mg/kg BPAU. Two test groups were given 100 mg/kg PMSF at either 1 day before 
the first BPAU dose or 4 hours after the second BPAU dose. Two control groups 
were given the same volume of glycerinformal (solvent) as test groups at 4 hours 
after the second BPAU dose One of the two control groups was killed at 6  hours 
after the second BPAU dose, which was used as peak control because BPAU
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reached its peak value in tissues at 6  hours after dosing. Other groups were killed at 
24 hours after the second BPAU dose.
2.2.6.1.2 Sample preparation 
Animals were killed by carbon dioxide. Blood of each animal was collected 
immediately after death. Brain, spinal cord, liver, and muscle were removed, 
weighed, and stored at - 2 0  °C. For sample preparation and analysis see 2 .2 .2 . 2  and
2.2.2.3.
2.2.6.2 On pharmacokinetics
2.2.6.2.1 Animal and procedures
Two groups of 5 female F344 rats, weight 250-280 g, were dosed with 150 
mg/kg BPAU. One group of them was given 100 mg/kg PMSF 4 hours after BPAU. 
All the animals were kept in metabolic cages with free access to food and water. 
Blood samples of 30-50 pi were taken by pricking the tail tips of rats at 6 , 12, 24, 
48, 72, 96 and 122 hours after BPAU dosing.
2.2.6.2.2 Sample preparation and analysis
Whole blood of 30-50 pi was mixed with 0.2 ml methanol/DMSO. AU 
.samples were centrifuged with an Epéndof centrifuge at 9000 g for 5 min and the 
supernatant was kept for HPLC analysis. For analytical conditions see 2.2.2.2 and
2.2.2.3.
2.2.7 Age differences in BPAU metabolism
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Four 6 -week old female F344 rats and four 1 year old rats were given a 
single oral dose of 150 mg/kg BPAU by gavage. They were killed by carbon dioxide 
at 18 hours after dosing. Blood, brain, spinal cord and liver of each rat were taken 
for the measurement of BPAU.
For sample preparation and analysis refer to 2.2.2.2 and 2.2.2.3.
2.2.8 Statistics and pharmacokinetics
2 .2 .8 . 1  Statistics
ANOVA was used for the comparisons of the concentration of BPAU or its 
metabolites in different tissues and the blood/tissue ratios. Student’s t-test was 
employed for two sample comparison. The standard errors of elimination rate 
constants were calculated according to the method given by Mead and Cumow 
(1987).The Z test was used for half life comparison. Wücoxon’s test was used for 
the comparison of ataxia scores.
2.2.8.2 Pharmacokinetics
Pharmacokinetic data were analysed according to the methods and equations 
given by Gibaldi & Perrier (10). BPAU follows apparent first order absorption and 
elim ination kinetics and a one-compartment model was employed. The area under 
curve (AUC) was estimated using the trapezoidal rule (Martin, 1986).
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2.3. RESULTS
2.3 1 Phannacokinetics of BPAU
2.3.1 . 1  Absoiption and bioavailability of BPAU
Following a single ip dose of 150 mg/kg BPAU, BPAU reached its peak 
value in blood at 4  hours and in tissues, at 6  hours after, dosing. A relatively quick 
absorption phase took place within first 6  hours after ip injection. After the first 6  
hours, the absoiption of BPAU was still continuing but much slower than over the 
first 6  hours. Some residue of BPAU was seen in the peritoneal cavity even at 72 
hours after dosing. It was difficult to estimate the amount of residue left. The 
absorption processes of BPAU from blood to brain, spinal cord and liver were 
sitnilfir to that from peritoneum to blood but different from that in muscles. The 
recovery of BPAU in the overall tissue extraction was 94.2 ± 3.7% (n=5). The 
concentration-time curves of BPAU in serum and tissues are shown in FIG 2 ^ . .
2.3.1.2 Distribution and tissue/serum ratio of BPAU 
BPAU distributes in liver, muscle, brain, and spinal cord. The order of their 
peak concentrations was spinal cord > liver > brain > muscle. Spinal cord reached 
the highest level in all tissues observed. In addition, it was also detected in fet and 
kidney at 18 hours after dosing and their value levels were similar to that in liver. 
Thus BPAU seems to distribute all over the body.
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FIG 2-4 Concentration-time curves of BPAU in serum and tissues. Rats were 
given a single bolus ip dose of 150 mg/kg BPAU. They were killed at 1, 2, 4, 6, 12, 
18, 24, 48, and 72 hours after dosing. The values are presented as mean + SE, n = 4.
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To reflect tjie partition of BPAU between serum and tissues, each value of 
BPAU in tissues (mg/g) and in serum (mg/ml) was converted into their ratios 
(tissue/serum). The results show that the tissue/serum ratio of BPAU for each tissue 
was r o u ^ y  constant during the period of 6^18 hours after dosing. The order of the 
tissue/serum ratio at 6 hours (peak point) was spinal cord (4. 6 ± 0.2) > liver (3.7 ± 
0.1) > brain (2.9 ± 0.1) > muscle (1.2 ± 0.1). The ratio in spinal cord was 
signiflcantly higher than in other tissues.
2.3.1.3 Pharmacokinetic parameters of BPAU
The pharmacokinetic behaviour of BPAU is described based on individual 
tissues observed. As shown in FIG 2-4, BPAU given intraperitoneaUy followed 
apparent first order absorption and elim ination kinetics both in serum and in tissues 
of the rats. The concentration-time data were transformed into the logarithm of 
concentration versus time data and the pharmacokinetic models were identified. All 
the data ftom serum and tissues were best fitted with a one-compartment model, seè 
A-I-B, Appendix. Fitting these data using exponential regression yielded straight 
lines and the kinetic parameters were determined according to the equations given 
by Gibaldi & Perrier (1982). The area under concentration-time curve (AUC) in 
each individual tissue is estimated using the method of trapezoidal rule (Martin, 
1986). The parameters are presented in Table 2-1. Table 2-1 shows that the 
elimination rate of BPAU in the nervous system is different fi'om non-nervous 
tissues. The half lives of BPAU in brain and spinal cord were significantly longer 
than in serum or in liver or in muscle. The value of AUC in spinal cord is the 
biggest as well, see Table 2-1.
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Table 2-1. The pharmacokinetic parameters of BPAU in serum after ip 
administration
Tissue Absorption phase Elimination phase
ka Tal/2 Co k Ti/2 AUC
(h) (lig/g) (h) (Mg. g-\ h-')
Serum 0.617 1.1 12.3^ 0.059 11.8 ± 1.7 204.5
Brain 0.410 1.7 30.4 0.045 15.5 ± 1.1* 643.1
Spinal cord 0.302 2.3 45.3 0.044 15.6 ±1.3* 982.5
Liver 0.474 1.5 46.0 0.062 11.2± 1.1 769.6
Muscle 0.226 3.1 17.6 0.059 11.6± 1.4 294.5
Co is the concentration estimated from the extrapolated line of -k/2.303 when time t is zero. 
#: The unit of BPAU in serum is pg/ml. ka: the apparent first-order absorption rate 
constant, and k: the apparent first-order elimination rate constant. Tai/2 and Tm are the half 
lives of absorption and elimination phases respectively. AUC is the area under 
concentration-time curve. *: p<0.05 (Z test, n=6) comparing with that in liver or muscle.
2.3.2 BPAU metabolism in vivo
Three metabolites of BPAU in tissue, serum and urine were primarily 
detected by HPLC in this study, see FIG 2-2 and FIG 2-3. They were further 
purified and characterised by HPLC, MS and NMR.
2.3.2.1 Purification of BPAU metabolites
As shown in FIG 2-2, BPAU and its metabolites were well separated under 
the analytical condition established in this study. The retention times of metabolites 
and parent compound, BPAU, were 5.5 min (M2), 7.5 min (M3), 9.4 min (Ml), and 
12.6 min (BPAU). Ammonium acetate significantly influenced the chromatogr^hic
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performance of M2. Under the condition of the absence of ammonium acetate in the 
mobile phase, the peak of M2 significantly delayed, broadened and even 
disappeared, whereas Ml, M3 and BPAU were not affected by ammonium acetate. 
Therefore, ammonium acetate in mobile phase is necessary for M2 analysis. For this 
reason, the purification procedure for M2 was different fi’om Ml and M3 to avoid 
the ammonium acetate in the final product, see 2.2.4.3.
Ml can be purified fi’om either liver or urine but M3 was solely purified fi’om 
mine. M2 can be purified fi’om either serum or urine but serum was the main source 
because it reached a very high concentration between 18-24 hours after BPAU 
dosing. The level of M2 in serum was higher than that in whole blood.
2.3.2.2 Identification of BPAU and its metabolites
2.3.2.2.1 Mass and NMR spectra of BPAU
The mass spectrum of starting material, BPAU, is shown in FIG 2-5. The 
molecular ion of BPAU is at m/z 255/257. The double peak results fi’om isotopes of 
bromine (Br) vhich also serves as a natural MS marker for its metabolites, see Ml, 
M2 and M3 below. Two major fingment ions at m/z 79/81 (which is not shown in 
FIG 2-5) and m/z 176 were observed. They represent the ions of Br and 
phenylacetylurea respectively and indicate the cleavage took place at the bond of 
Br-C during ionisation.
To understand the NMR spectra of BPAU and its metabolites, the molecular 
structure of BPAU and its possible transient states caused by the cheipical shifts of 
protons are shown in FIG 2-6. Proton d  can momentarily shift either to / or to g  and
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proton e can also move to g  as well. These tautoric movements can be. detected by 
NMR,
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FIG 2-5. Mass spectrum of BPAU.
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FIG 2-6 A illustration of the tautomerism of proton d  and e on BPAU 
molecule. Proton d  may transiently move to form either proton f  or ^ and e proton 
may also move to form proton g.
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The NMR spectrum of BPAU is shown in FIG 2-7. Proton, a and h on 
benzene ring are clearly displayed between Ô 7.2 and 6 7.7 ppm. The proton c is 
seen at Ô 2.5 ppm and d  is seen at around Ô 10.4 ppm. Proton e is not seen in this 
graph because the peak of protons on -NH2 is often broadened or invisible (11). 
Two shifting proton resonance peaks, /  and g, appeared at 6 7.8 and Ô 6.9 ppm 
respectively, see FIG 2-6 and FIG 2-7.
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FIG 2-7. NMR spectrum of BPAU.
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2.3.2.2.2 Mass and NMR spectra of Ml 
The mass spectrum of Ml displays a molecular ion at m/z 271/273 and three 
major fragment ions at m/z 79/81, 192 and 228/230 respectively, see FIG 2-8. The 
molecular ion is 16 mass units more than its parent compound, BPAU, see FIG 2-5 
and FIG 2-8. This suggests that a oxygen, [O], was added to BPAU to form Ml. 
The fragment ion peaks at m/z 79/81 and m/z 192 indicate the cleavage between Br 
and rest part of Ml. The ion peak at m/z 228/230 results from the cleavage between 
the secondary N and the carbon of urea, N-C(O). This indicates the [O] was not 
added to the primary N.
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FIG 2-8. Mass spectrum of M l.
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NMR spectrum of Ml is shown in FIG 2-9. Two doublet proton, peaks were 
observed between Ô 7.3 ppm and Ô 7.8 ppm which represent 2 a and 2 b protons on 
benzene ring. This clearly indicates that no substitution took place on the benzene 
ring of Ml. A single proton peak of c which represents -CH2- was seen at Ô 2.6 
ppm, but this peak is bigger than it should be. Some unrelated peaks were seen at 
5.1-5.3 and 5.9 ppm. These peaks may be from impurity of the smple. A single 
broadened proton peak was observed at 11.8 ppm which represents the proton h on 
=N-0-H. This directly indicates hydroxylation took place on the secondary N of 
BPAU to form Ml. Its molecular structure is shown in FIG 2-8 and FIG 2-9.
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FIG 2-9. NMR spectrum of M l
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Two indirect pieces of evidence for this structure were revealed by MS and 
NMR spectra. One was that the fragment ion peak at m/z 228/230 indicated the 
cleavage took place at the bond between the secondary N and C(0)-. This was 
probably due to the replacement of the proton d  on secondary N by -OH weakening 
the bond N-C and therefore, facilitating the cleavage during ionisation of Ml. This 
fragment ion peak is not seen in BPAU MS, see FIG 2-5 and FIG 2-8. The another 
evidence is that the proton peak /  disappeared. This was due to the replacement of 
proton d, which made die tautomerism between d  and /  impossible, see FIG 2-6, 
FIG 2-7 and FIG 2-9. Based on the above evidence, the molecular formula of Ml is 
proposed as following: Br(C6H4)CH2CON(OH)CONH2 .
According to the IUPAÇ nomenclature system of chemicals. Ml is named as 
3-hydroxy-5-(4-bromophenyl)-l,3-diazapentane-2,4-dione. Its common name is 
called N’-hydroxy-/?-bromophenylacetylurea (HBPAU). The molecular structure is 
as shown in FIG 2-8 and FIG 2-9.
2.3.2.23 Mass and NMR spectra of M2
The molecular ion peak of M2 is seen at m/z 254/256 which is 1 mass unit 
less than its parent compound, BPAU, see FIG 2-10. Its fragment ions are seen at 
m/z 79/81 and at m/z 176 which indicate that the cleavage took place between Br 
and the rest part of M2 during ionisation. The double ion peak indicates that the 
atom Br is still on the molecule of the metabohte.
The accurate MS indicates that M2 is composed of 9C, 6H, 30, IN and IBr. 
This shows that M2 is one [O] more and 1 N and 3 H less than BPAU (9C, 9H, 20, 
2N and 1 Br), see FIG 2-11.
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FIG 2-10. Mass spectrum of M2.
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FIG 2-11. Accurate mass spectrum of M2
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NMR spectrum shows that two doublet proton peaks were observed between 
Ô 7.3 ppm and Ô 7.8 ppm which indicate that the proton a and b on the benzene ring 
were not replaced, see FIG 2-12. A single proton peak was observed at 5 6.0 ppm 
which is likely to result from the resonance of proton c, see FIG 2-6 and FIG 2-12 
The shifting proton peaks, /  and g  disappeared, comparing FIG 7 and FIG 12. The 
resonance peak of the proton d  on =N-H is not observed in FIG 12 because the 
resonance peak of =N-H is often broadened or invisible (11).
All above evidences suggest that a ring structure was formed as shown in FIG 9 
and FIG 11. According to lUPAC nomenclature system, M2 is named 4-(4- 
bromophenyl)-3-oxapyrrohdine-2,5-dione.
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FIG 2-12. NMR spectrum of M2
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2.3.2.2.4 Mass and NMR spectra of M3
M3 has a molecular ion peak at m/z 269/271, see FIG 2-13. It is two mass 
units less than Ml and 14 mass units more than BPAU. Two fragment ion peaks are 
seen at m/z 79/81 and 191. They resulted from the cleavage between Br and the rest 
part of M3.
NMR spectrum of M3 indicates that proton a, b and c remain unchanged, see 
FIG 2-14. The singlet proton peak of g  is still seen at around 7.2 ppm and again the 
shifting proton peak /  disappeared, which indicates that the substitution took place 
on the secondary N, which made the tautomeric shift from d  to f  impossible, see 
FIG 2-6 and FIG 2-14. The resonant peak of proton / was overlapped by the 
resonant peak of the protons on DMSO which was tised as the solvent. Chemically, 
therefore, it is suggested that méthylation took place on the secondary N of BPAU.
According to lUPAC nomenclature system, it is named as 3-methyl-5-(4- 
bromophenyl)-1,3-diazapentane-2,4-dione. Its common name is N^-methyl-p- 
bromophenylacetylurea (MBPAU).
M3 is probably formed in the kidney and directly excreted through urine 
because its concentration in serum is just detectable but in urine is very high. It, 
therefore, has less toxic potential than Ml because of its direct elimination. Its 
bioformation needs further confirming.
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FIG 2-13. Mass spectrum of M3
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FIG 2-14. NMR spectrum of M3
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The proposed metabolic pathways of BPAU is shown in FIG 2-15.
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FIG 2-15. Metabolic pathways ofp-bromophenylacetylurea in vivo, 
BPAU: /?-bromophenylacetylurea
Ml : 3-hydroxy-5-(4-bromophenyl)- l,3-diazapentane-2,4-dione 
M 2:4-(4-bromophenyl)-3 -oxapyrrolidine-2,5-dione.
71
2.3.2.3 The distribution and kinetics of metabolites 
M l is the dominant metabolite of BPAU detected in tissues but a low 
concentration in serum. Its distribution pattern is similar to its parent compound 
BPAU but it stayed in tissues much longer than BPAU itself. The peak value of Ml 
was observed at 18 hours which was 12 hours later than BPAU. M2 reached a high 
concentration in serum but very low levels in tissues. M3 was mainly found in 
urine. The kinetics of M l and M2 are presented in FIG 2-16.
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FIG 2-16. The concentration-time curves of M l and M2 in serum and tissues.
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2.3.2.4 Excretion of BP AU metabolites
All three metabolites. Ml, M2 and M3 were eliminated through the kidney. 
The relative amount of each metabolite excreted from urine are shown in table 2-2. 
Table 2-2 shows that about half of absorbed BPAU was excreted in the form of M2.
Table 2-2 Excretion of Ml, M2 and M3 from rats’ urine after a single oral dose of 
150 mg/kg (586 pmol/kg) BPAU.
Absorbed BPAU Ml M2 M3 % of absorbed
(|imol./rat*) (ixmol./rat) (|imol./rat) (pimol./rat) BPAU
71.76 ±2.74 8.69 ±1.29 35.8 ± 5.25 17.65 ±4.52 86.6
n = 6. *: rat body weight 186 ± 5 g.
2.3.3 Animal model of time-dependent promotion of BPAU neuropathy by PMSF
2.3.3.1 Ataxia score
Rats were given two daily oral doses of 150 mg/kg BPAU. The model of 
time-dependent promotion was established by co-administrating 100 mg/kg PMSF 
at either 1 day before the first BPAU dose or 4 hours, 1 day or 4 days after the 
second BPAU dose. After a week’s delay, all the animals including the BPAU 
controls developed different degrees of ataxia. The ataxia scores are shown in FIG. 
2-17. BPAU alone caused minor to medium degree of ataxia. PMSF significantly 
increased BPAU-induced ataxia scores (p<0.01) when it was given either 1 day 
before or 4 hours or 1 day after BPAU doses. The strongest effect was seen in both 
the PMSF-ld-BPAU and the BPAU-4h-PMSF groups (p<0.01). The effect of PMSF
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given 1 day before BPAU was significantly stronger than that given 1 day after 
BPAU (p<0.01). No effect was observed when PMSF was given 4 days after BPAU 
dosing. PMSF alone did not induce any recognisable ataxia signs.
The development and severity of ataxia in BPAU-4h-PMSF and PMSF-ld- 
BPAU groups before day 20 were nearly the same However, their recovery time 
courses were different: The recovery of rats in BPAU-4h-PMSF group delayed 
comparing with other groups. The more affected rats, the later the recovery, see FIG 
2-17.
2.3.3.2 Weight loss
Following the administration of either BPAU or PMSF, body weight losses 
were observed in all animals. It took 3-4 days to recovery to the original weight and 
then increased again. At the appearance of ataxia signs in the BPAU-4h-PMSF or 
PMSF-ld-BPAU or BPAU-ld-PMSF groups, the weight decreased again, see FIG 
2-18. The weight loss coincided with the severity of ataxia. The order of w e i^ t loss 
is BPAU-4h-PMSF > PMSF-ld-BPAU > BPAU-ld-PMSF. There was no second 
weight loss in the BPAU-4d-PMSF group or in the BPAU or PMSF control groups 
after their rqcoveiy firom intoxication.
75
l O i
oo
X«+-*
<
T
/
/
y H H  ii— ■
12 16 20  2 4  28
Day
4 0 80
□: BPAU only; • :  BPAÜ-4h-PMSF; A: PMSF-ld-BPAU; 
*: BPAU-ld-PMSF; ▼: BPAÜ-4d-PMSF; o : PMSF only.
FIG 2-17. Development of ataxia after BPAU and/or PMSF dosing. Rats were 
given two daily doses of 150 mg/kg BPAU. The time dependent promotion of 
BPAU-induced neuropathy by PMSF was studied by co-administration of 100 
mg/kg PMSF at either 1 day before the first BPAU dose (PMSF-ld-BPAU), or 4 
hours (BPAU-4h-PMSF), 1 day (BPAU-ld-PMSF) or 4 days (BPAU-4d-PMSF) 
after the second BPAU dose. Two control groups were given either two daily doses 
of BPAU (BPAU only) or a single dose of PMSF (PMSF control).
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FIG 2-18. Body weight changes after BPAU and PMSF dosing and during the 
development of ataxia. PMSF was given at either 1 day before the first BPAU dose 
(PMSF-ld-BPAU), or 4 hours (BPAU-4h-PMSF), 1 day (BPAU-ld-PMSF) or 4 
days (BPAU-4d-PMSF) after the second BPAU dose. Two control groups were 
given either two daily doses of BPAU (BPAU only) or a single dose of PMSF 
(PMSF only).
77
2.3.3.3 Slope test
The value of the slope test in the BPAU-4h-PMSF, PMSF-ld-BPAU, and 
BPAU-ld-PMSF groups were significantly lower than that in the BPAU control 
during the period of 7-17 days after dosing (P<0.05). After that period, they were 
only occasionally significantly lower than that in BPAU control groups. There was 
no significant difference between BPAU control and BPAU-4d-PMSF groups. No 
significant decrease of slope test was observed in PMSF controls. The decrease of 
slope test appeared 1-2 days earlier than that ataxia signs did, see FIG 2-19. Data 
fi-om BPAU-ld-PMSF, and BPAU-4d-PMSF groups come between the curves of 
BPAU control and BPAU-4h-PMSF groups (They were not plotted in FIG 2-19 
because they were too close to each other to be recognised easily).
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FIG 2-19. Slope test during the development of ataxia after BPAU and
PMSF dosing. PMSF was given at either 1 day before the first BPAU dose (T  :k
PMSF-ld-BPAU), or 4 hours (O: BPAU-4h-PMSF), 1 day or 4 days after the
second BPAU dose. Two control groups were given either two daily doses of BPAU
(□: BPAU only) or a single dose of PMSF (• : PMSF control). The values from
BPAU-ld-PMSF and BPAU-4d-PMSF come between the curves of BPAU-4h-
PMSF and BPAU only control groups but not plotted in this figure for the clarity
sake.
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2.3.4 The effect of PMSF on BPAU disposition
2.3.4.1 On BPAU elimination
PMSF given either 1 day before or 4 hours after BPAU dose remarkably 
increased the BPAU levels in all tissues at 24 hours post BPAU, see FIG 2-20. The 
levels of BPAU in all observed tissues in BPAU-4h-PMSF group were significantly 
higher than that in BPAU control (p<0.01). The value in spinal cord in the PMSF- 
ld-BPAU group was 80 % higher than the BPAU control but not statistically 
significant. Taking spinal cord as an example, the BPAU level in the BPAU alone 
control group decreased to 6 % of its peak value at 24 hours after dosing. Whereas, 
the level in PMSF-ld-BPAU or in BPAU-4h-PMSF group decreased to 11% or 46% 
of the peak value at 24 hour respectively. PMSF obviously delayed BPAU 
elimination from tissues.
2.3.4.2 On the metabolism of BPAU
The effect of PMSF on Ml and M2 at 24 hours after BPAU are presented in 
FIG 2-21 and FIG 2-22. When PMSF was given 4 hours after BPAU, it significantly 
increased M l level in tissues and decreased M2 concentration in serum at 24 hours 
after dosing. When PMSF was given 1 day before BPAU, it significantly increased 
Ml level in spinal cord at 24 hours after dosing and decreased M2 concentration by 
13.5% \ ^ c h  is not statistically significant.
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FIG 2-20. Effect of PMSF on BPAU elimination. Rats were given two daily doses
of 150 mg/kg BPAU and co-administrated a single dose of 100 mg/kg PMSF at 
either 1 day before the first BPAU dosing (PMSF-ld-BPAU) or 4 hours after the 
second BPAU dosing (BPAU-4h-PMSF). The animals in above groups were killed 
at 24 hours after the secondBPAU dosing. Two BPAU control groins were only 
given two daily doses of BPAU. They were used as either BPAU control in which 
animals were killed at 24 houjts after jjhe second BPAU dosing or peak control in 
which animals were killed at 6 hours after the second BPAU dosing.
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FIG 2 -il. The effect of PMSF on M l levels in brain, spinal cord and liver.
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FIG 2-22. The effect of PMSF on BPAU, M l and M2 concentrations in serum
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2.3.4.3 On the phannacokinetics of p-BPAU and its metabolites 
About 30 % of dosed BPAU was found in faeces within first 24 hours and 
4% of total dosage was detected between 24 and 48 hours after dosing. Only 
negligible amount of dosed BPAU was excreted from urine. PMSF did not affect 
BPAU absorption. The bioavailibilities in BPAU and BPAU+PMSF groups are 
similar, see table 2-3. But PMSF significantly, changed the BPAU metabolism and 
elim ination processes. It delayed BPAU elimination, increased.Ml production and 
decreased M2, see FIG 2-23.
Table 2-3 Bioavailability of BPAU after oral dose
Dosed amount Absorbed amount Bioavailability
Treatment (lAg) ( pg) (%)
BPAU only 27.9 ± 0.7 18.410.7 65.9
BPAU + PMSF 27.3 ±1.6 17.811.5 65.1
n=5.
The pharmacokinetic parameters of both groups are presented in table 2-4. PMSF 
significantly increased AUG and prolonged elimination half life.
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Table 2-4. Comparison of phannacokinetic parameters of a single oral dose of 150 
mg/kg BPAU without or with PMSF at 4 hours after BPAU.
Treatment k V AUG Tin
(h-') 0) (pg.ml'\h'^) (hr)
BPAU alone 0.074 1.23 ±0.16 103.7 9.4 ±1.3
BPAU + PMSF 0.034 1.64 ±0.25 202.4 20.5 ±3.1*
k: elimination rate constant; V: apparent distribution volume; AUG: the area under the 
concentration t^ime curve; and Tm'. elimination half life. Data .are presented ^  Mean or 
Mean ± SE. *: p<0.01, n=5.
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FIG 2-23. Concentration-time curves of BPAU and its metabolites in whole 
blood with or without PMSF dosing. Rats in the BPAU + PMSF group were given 
150 mg/kg BPAU orally and co-administrated 100 mg/kg PMSF intraperitoneally at 
4 hours after BPAU dosing. BPAU control was given the 150 mg/kg BPAU and the 
same volume of glycerinformal (solvent) as above group. The values are expressed 
as mean ± SE, n = 5.
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Chemically, Ml and M2 are formed via different pathways. The possible 
sites for PMSF inhibition are shown in FIG 2-24. PMSF is likely to inhibit the 
initial step of M2 formation rather than the last step since accumulation of the 
intermediate was not detected.
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FIG 2-24 The possible inhibition sites of p-bromophenylacetylurea metabolism 
by phenylmethanesulphonyl fluoride.
PMSF: phenylmethanesulphonyl fluoride 
BPAU: /7-bromophenylacetylurea
M 1: 3-hydroxy-5-(4-bromophenyl)-1,3-diazapentane-2,4-dione 
M2: 4-(4-bromophenyl)-3-oxapyrrolidine-2,5-dione.
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2 .3 . 5  Age differences in the distribution and metabolism of BPAU
2.3.5. 1  Differences in BPAU distribution
At 18 hours after a single oral dose of BPAU, the distribution of BPAU in 
serum and central nervous system in both 6 -week and 1 -year old rats is presented in 
FIG 2-25. In 6 -week old rats, there is no significant difference in the BPAU 
distribution between brain and spinal cord. Whereas in 1 -year old rats, BPAU in 
spinal cord is significantly higher than that in brain (p<0.01). The levels of BPAU in 
brain and serum were not significantly different between the two groups. However, 
BPAU in the spinal cord of 6 -week old rats was significantly lower than that in 1 - 
year old rats.
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FIG 2-25. Age difference in BPAU distribution in brain and spinal cord.
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2.3.5.2 Differences in metabolism
The difference of metabolite levels between 6 -week and 1-year old rats is 
shown in FIG 2-26. M l in spinal cord in 1-year old rats was significantly higher 
than that in 6 -week old rats. In the brain, the level of BPAU in 1-year old rats was 
23 % higher than that in 6 -week old rats but was not statistically significant.
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FIG 2-26. Age differences of M l in brain and spinal cord between 6 -week and 1- 
year old rats at 18 hours after dosing.
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In serum, BPAU concentrations in both groups were similar, but Ml 
concentration in 1 -year old rats was significantly higher than that in 6 -week old rats, 
whereas M2 concentration in 1-year old rats significantly lower than that in 6 -week 
old rats, see FIG 2-27. ThisJnidicates young rats produce more M2 but less M l, by 
contrast, old rats produce somewhat more M l but markedly less M2.
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FIG 2-27. The comparison of BPAU and its metabolites in serum at 18 hours 
after dosing between 6 -week and 1 -year old rats.
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2.4 DISCUSSION
2.4.1 Metabolic and phannacokinetic factors in BPAU neurotoxicity
2.4.1 . 1  Pharmacokinetics of BPAU
Previous studies have shown that either a single higher dose or long-term 
repeated lower doses of BPAU caused the same clinical signs and pathological 
change (Diezel and Quadbeck, 1960; Cavanagh, 1968; Potkonjak, 1965). The 
mechanism of its neurotoxicity is totally unknown. This study investigated 
pharmacokinetic aspects of BPAU-induced neurotoxicity. The results revealed that 
the absorption, distribution and metabolism of BPAU in one way or another 
modified BPAU neurotoxicity.
This study shows that the absorption of BPAU is not complete either via ip 
or po doses possibly due to its poor solubility in water or other common solvents 
(Cavanagh, 1973). The bioavailabüity of po dose was found to be 65.9 %. The 
avaüabüity of ip dose of BPAU was difficult to be estimated because no iv dosing 
data was available. Since others have found that BPAU given by either ip or po 
route produced the similar degree of delayed ataxia at the same dosage (Cavanagh, 
et al., 1968, Nagata, 1986), this suggests that the absorption of BPAU via the two 
routes are similar, which indicates that BPAU can be absorbed by simple diffiision 
to pass biological membranes. It would be expected to pass blood-brain barrier 
readily due to its lipophilic property (Caldwell, et a l, 1995). A quick absorption 
phase was observed over the first 6  hours following ip injection which was similar 
to po dose. However, some intraperitoneal residue of BPAU was seen even at 72 
hours after injection. So, a slow absorption phase may occur afier an ip dose, which
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is different from the oral route in which most unabsorbed BPAU will be cleared 
from gut within 24 hours. The present results showed that the half life of BPAU in 
blood is significantly longer by ip injection than by po dose (Z test, p<0.01), see 
Table 2-1 and 2-4. The absorption difference significantly modified the rate 
constants of elimination and hence is responsible for the difference of half lives 
between ip and po doses.
BPAU reached peak value at 4 hours in blood and at 6  hours in tissues after 
ip injection. Lipid content in individual tissues plays an important role in the 
distribution of agents such as BPAU due to their lipophilic properties (Sipes, 1991). 
The central nervous system is rich in lipid (Spector, 1956). Accordingly, the levels 
of BPAU in brain and spinal cord are significantly higher than that in blood and 
muscles. Spinal cord reached the highest level in all observed tissues. The Hpid 
content is also responsible for the distribution difference between spinal cord and 
whole brain as the spinal cord contains more lipid than whole brain (Spector, 1956). 
However, die level of BPAU in liver was significantly higher than in whole brain 
and muscles although liver contain less lipid than brain (Spector, 1956). This 
suggests that liver may have other ways to uptake and store BPAU. Perhaps, BPAU 
can bind to some proteins in liver (Sipes and Gandolfi, 1991).
The interaction between toxicant and target sites begins with distribution. 
The distribution depends on the physiochemical properties of toxicants and 
physiological and biochanical constitution of individual tissues, which determine 
the partition of a compound between blood and individual tissues. This study 
showed that the tissue/serum ratio of BPAU relates to the lipid content of individual 
tissues. It reflects an equilibrate state of partition between blood and tissues. The
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greater the ratio, the easier for the compound to be absorbed by tissues and the more 
difficult for it to go back to blood. In this study, the highest ratio and longest half 
life were observed in spinal cord. This distribution feature of BPAU may partly 
explain why it specially caused spinal cord or peripheral nerve damage.
The concentration and persistence of a toxicant in target sites is directly 
relevant to the toxic response of individual tissues. In present study, each tissue 
observed is assumed to be a central compartment to describe the kinetics of BPAU 
in the particular tissue. Blood and biotransformation are taken as peripheral 
compartments. The results showed that after initial distribution, the kinetics of 
BPAU vary from tissue to tissue. BPAU in CNS has a longer half life than that in 
blood or non-nervous tissues, whereas BPAU in liver or muscle had a similar half 
life to that in blood, see Table 2-1. Therefore, as stated above, the initial distribution 
of BPAU mainly depends on its physiochemical properties and lipid content in 
individual tissues, \^ereas the elimination depends not only on lipid content but 
also the metabolic capacity in individual tissues;
This study shows that BPAU follows a one-compartment model in either 
serum or tissues \^dien BPAU is given intraperitoneally. The rate constant k in 
tissues represents the total elimination rate which includes die rates of BPAU 
penetrating back to blood and its biotransformation in situ. It is not possible to 
estimate how much the biotransformation contributes to the total elimination rate 
from the present data. BPAU is a lipid soluble substance and easy to be absorbed by 
CNS. Biotransfoimation in situ is the major way for die elimination of lipophilic 
compounds (Sipes and Gandolfi, 1991).
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It has well been demonstrated that spinal cord and peripheral nerves are the 
target sites of BPAU neurotoxicity (Cavanagh, et al., 1968, Troncoso, et al., 1982). 
This study has shown that BPAU reached the highest level and had a longest half 
life in spinal cord. Troncoso's work showed that rats given daily dose of 10 mg/kg 
BPAU continually for 8-10 weeks developed clinical ataxia (Troncoso, et al., 1982). 
The pharmacokinetic explanation for this chronic toxicity was due to BPAU 
accumulation in nervous system. No matter what biochemical mechanism may be 
involved, this distribution and phannacokinetic features of BPAU may partly be 
responsible for its selective neurotoxicity.
2.4.1.2 Metabolism of BPAU
A attempt to study the role of Hver in the detoxification of BPAU was made 
by Chen (1971). His experiment was carried out by surgically cutting off part of the 
hver or by dosing carbon tetrachloride to damage hver before BPAU dosing and. 
both treatments increased BPAU neurotoxicity. Therefore, hver was thought to be a 
major organ in BPAU detoxification (Chen, et al., 1971). But prior to the present 
study, no documented data were available about BPAU metabohsm. This study 
primarily identified three metabohtes of BPAU by using HPLC, MS and NMR 
techniques and its metabohc pathway was proposed as well, see FIG 2-15.
M l is a dominant metabohté of BPAU in ah tissues measured. It has been 
identified as a hydroxylated metabohte, see FIG 2-8 and 2-9. BPAU is transformed 
into M l in tissues by hydroxylation on the secondary N of BPAU. The distribution 
of M l was similar to its parent compound BPAU. It reached peak values in tissues 
at 18 hours, which was a 12 hour delay con^pared to BPAU itself. This indicates
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that M l stays in tissues longer than its parent compound BPAU. Comparing with 
BPAU, Ml is more likely to accumulate in tissues when repeated doses are given. 
Therefore, M l could potentially play a role in BPAU neurotoxicity.
The metabolic pathway of M2 is different from M l, see FIG 2-15. It is 
confirmed by NMR and accurate MS that a ring structure is formed after 
biotransformation. Contrary to M l, a high concentration of M2 was found iu serum 
and urine but low levels iu tissues. This indicates that M2 enters blood much 
quicker than M l once it is formed and is excreted into urine. So, it is likely to be a 
detoxificated form of metabolite.
M3 was mainly found in urine. Its metabolic pathway is not clear so far. It 
may be formed via M l or directly from BPAU by méthylation in kidney because it 
had a very low level in blood or tissue and a high level was measured in urine. 
Therefore, it has less toxic potential than M l. Some further work is needed on its 
metabolic pathway.
Due to the lipophilic property of BPAU, redistribution is limited and 
biotransformation in situ may be the main way for its elimination from tissues. This 
study shows that the distribution pattern of metabolite M l is similar to BPAU in 
each tissue. After primary distribution, the persistence of BPAU in individual 
tissues depends on metabolic capacity of these tissues. This may be responsible for 
the differences of half lives between different tissues. This study showed that the 
biotransformation of BPAU in liver was relatively quicker than brain and spinal 
cord. So, liver plays a role in general detoxification of BPAU.
Partial hepatectomy or damaging the liver by dosing carbon tetrachloride 
before administration of BPAU increased the degree of delayed ataxia (Chen, et aL,
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1971). This may be due to both the decrease of liver metabolic capacity and 
relatively decrease of distribution volume and hence increase the level of BPAU in 
nervous system because BPAU level in liver is high and hver weight on average is 
12-14 g, wiiereas the weight of central nervous system is 2.2-2.6g (brain weight is 
1.7-1.9 g and spinal cord 0.5-0.7 g) if rats body weight are 200-250g. The same 
reason may be responsible for the increased neurotoxicity by damaging hver with 
carbon tetrachloride before BPAU dosing.
Chen (1971) found that pre-treatment with sodium phénobarbital before 
giving BPAU did not alter the degree of neurotoxicity and suggested that hver 
microsomal enzymes do not play a direct role in hepatic metabohsm of BPAU. The 
present study has shown that M l is formed by N-oxidation at the secondary N on 
BPAU. It has been demonstrated that the N-oxidation of secondary or tertiary 
amines is catalysed by flavin-containing monooxygenase (FMO) (Poulsen, et aL, 
1974; Poulsen and Ziegler, 1977; Ziegler, 1980,1988, 1990; Sipes and Gandolfi, 
1991). FMO activity is present in the hver at ah mammals examined so far, and high 
activity has been observed in porcine (Ziegler and Poulsen, 1978) and human hvers 
(Gold and Ziegler, 1973). In addition to hver, FMO activity was also detected in 
mammalian lung (Wilhams, et al., 1984; Tynes, et al., 1985), brain (Bhamre, et al., 
1993) and kidney (Tynes, et al., 1985; Ziegler, 1988). There are multiple forms of 
FMO in human hver (Lemoine, et al., 1990) and in rat brain (Bhamre et al, 1993). 
In the brain, FMO preferentiaUy locahses in the neuronal ceU body (Bhamre, et al., 
1993), This is particularly important in toxicology if the metabohc activity produces 
a more toxic metabohte. Therefore, FMO may be a important enzyme in the 
formation of M l.
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At least two steps were involved in M2 formation. The enzymes involved are 
not known. The first step is probably catalysed by the P450 enzyme system 
(Caldwell, et al, 1995) and the subsequent reaction may be catalysed by a different 
enzyme to form a ring structure. This study has shown that the M2 pathway played 
an important role in BPAU detoxification. Therefore, any factors which inhibit M2 
formation may increase BPAU toxicity.
In the halogenated derivatives of phenylacetylurea, only Br- and Cl- forms 
are neurotoxic. No neurotoxicities were observed in I- and F- forms (Diezel and 
Quadbeck, 1960; Brimijoin and Nagata, 1986) although they share a very similar 
chemical structure. Their chemical properties vary from each other, which may 
significantly influence their absorption, distribution or metabolism and hence 
modify their neurotoxicity.
In conclusion, this study has screened the distribution, pharmacokinetics and 
metabolism of BPAU in the rats. These factors well reflect the interaction between 
BPAU and body. Therefore, it provided a basic knowledge about the metabolic and 
pharmacokinetic behaviours of BPAU in vivo and a better understanding in its 
neurotoxicity.
2.4.2 Time-dependent promotion of BPAU neuropathy by PMSF
Organic phosphorous compound-induced delayed neuropathy can be 
intensified by some non-neurotoxic compounds (Lotti, et a l, 1991 ). This 
phenomenon was also seen in BPAU-induced delayed neuropathy (Ray and 
Johnson, 1992, Xu, et a l, 1994 ). The promotion mechanism is not known yet. This 
study showed that the increased clinical severity of BPAU-induced delayed ataxia
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produced by PMSF depends on the time at wiiich PMSF is given. A period from one 
day before to one day after BPAU dosing is a sensitive period to PMSF promotion. 
During this period, the closer the two compound were given, the more severe the 
ataxia. The effect of PMSF given one day before BPAU was much stronger than 
one day after BPAU. No effect was observed when PMSF was given 4 days after 
BPAU, although this time point was still within the latent period before expression 
of delayed neuropathy (a subclinical stage). These changes in severity coincided 
well with pharmacokinetic process. When PMSF was given 4 hours after BPAU, its 
effect fully overlapped with BPAU and hence produced most severe ataxia. 
Whereas at 24 hours after BPAU dosing, only 6  % of the peak value of BPAU was 
left in spinal cord and accordingly a minor effect was observed. Most BPAU had 
left body at 72 hours after dosing. We can imagine that at 4 days (96 hours) after 
BPAU dosing, no BPAU was available in tissues, and hence clinically no promotion 
was observed. A strong effect of PMSF was also seen when BPAU was given 1 day 
before BPAU dosing This mày be due to the effect of PMSF lasts a longer time in 
the body and overlap with BPAU more than it was given 1 day after BPAU. The 
effect of PMSF on NTE lasts several days (Lotti, et a l, 1991). This implies that 
PMSF may exhibit a long lasting effect on BPAU metabolism as well. This time- 
dependent Character coincides well with pharmacokinetic process and clearly 
indicates that PMSF promotion depends on BPAU level in target tissues.
2.4.3 The effect of PMSF on BPAU disposition
This study has shown that the effect of PMSF on BPAU neuropathy had a 
time-dependent character, and suggested that the promotion may be caused by an
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interaction between the two compounds. The question is how PMSF interacted 
BPAU metabolism and increased BPAU neurotoxicity. The further study showed 
that PMSF significantly changed the pharmacokinetic pattern of BPAU. It 
significantly delayed BPAU elimination. By 24 hours after dosing, BPAU decreased 
to 6  % of its peak value in the spinal cord in BPAU control, but it only decreased to 
46 % of its peak value in BPAU + PMSF. This clearly indicates PMSF interfered 
with BPAU disposition.
2.4.4 Metabolic interaction between BPAU and PMSF and neurotoxic synergism
After having shown that PMSF interferes with BPAU disposition, a further 
question was how PMSF interfered with BPAU disposition. The answer may lead to 
a better understanding of the mechanism of the promotion. The primary findings in 
this study shows that PMSF can increase BPAU and its metabolite. M l levels in 
tissues and decrease M2 concentration in blood. FIG 2-24 shows the proposed 
m echanism of metabolic interaction between BPAU and PMSF. BPAU is normally 
metabolised in tissues via two distinct pathways. PMSF inhibited M2 formation. 
Thus BPAU elimination was attenuated and more BPAU has to be metabolised via 
M l pathway and hence increased BPAU and M l levels. This can well explain why 
PMSF promotion depends on BPAU level and showed a time-dependent character. 
Thus metabohc interaction between BPAU and PMSF is probably sufficient to 
explain the promotion of BPAU-induced neuropathy by PMSF.
PMSF is commonly used as a protease inhibitor. It can also inhibit a 
carboxyl esterase which is known as neuropathy target esterase (NTE) (Johnson, 
1969,1974). The present study also indicates that PMSF may inhibit other enzymes.
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PMSF can potentiate OPIDN. All OP neurotoxicants which cause delayed 
polyneuropathy are NTE inhibitors (Johnson, 1969, 1974; Lotti, et al, 1991). It was 
thought that OP-induced delayed neuropathy and its promotion by PMSF related to 
NTE inhibition. PMSF is an NTE inhibitor but does not induce the subsequent 
change transfer needed initiate neuropathy. Hence PMSF itself can not produce 
delayed ataxia. BPAU is not a NTE inhibitor (personal communication with Dr 
Johnson) but it can induce a delayed neuropathy which is similar to OPIDN and its 
neurotoxicity can also be intensified by PMSF. Thus, the metabolic interaction 
between BPAU and PMSF demonstrated in this study provides a more likely 
explanation of their neurotoxic synergism than any potential interaction at the target 
site. Therefore, the promotion of BPAU-induced neurotoxicity by PMSF represents 
a distinct model in the studies of promotion phenomena.
2.4.5 Ataxia and its evaluation.
Ataxia is a clinical sign caused by central and/or peripheral nervous damage. 
In experimental animal models of neurotoxicity , the ataxia score has widely been 
used to evaluate the neurotoxicity of neurotoxicants to animals. It has been reported 
that body weight loss had a good correlation with ataxia score (Canavagh, et al, 
1968). This study shows that body weight loss was related not only to the severity 
of ataxia but to the process Of recovery as well. In the PMSF- Id-BPAU group, the 
peak ataxia score was as high as in the BPAU-4h-PMSF group, but its body w ei^ t 
loss was less than in BPAU-4h-PMSF group during the whole period of 80 days 
observation. Similarly the recovery was better than that in BPAU-4h-PMSF.
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To attempt to find a more sensitive parameter to evaluate the muscle 
weakness, the slope test was also used in this study. The slope test was originally 
developed by Le Quesne (personal communication). This study indicated that the 
change of slope test took place 2 days earlier than the clinical signs of ataxia. This 
clearly indicates that the onset of clinical ataxia is preceded by muscle weakness. 
Therefore, the slope test has its own value in evaluating muscle weakness. However, 
when the slope value became lower than a certain degree, even a dead rat may stop 
slipping down. So it has its limit in reflecting more severe ataxia. Therefore, the 
slope test alone can not well reflect the higher degree of ataxia severity but it can be 
used as an auxiliary indicator to evaluate muscle weakness.
2.4.6 Age difference in BPAU metabolism
It was reported that adult rats were more susceptible to BPAU neurotoxicity 
than young rats (Chen, et a l, 1971). Our results show that there exist age 
differences in the distribution and metabolism of BPAU. The BPAU level in spinal 
cord in 1-year old rats was sigmficantly higher than that m 6 -week old rats. In 
addition, the relative production of M l and M2 were dramatically different. Young 
rats produce more M2  and less M l than 1-year old rats, see FIG 2-25. This 
metabolic difference may be responsible for the difference in BPAU distribution, 
and for the age-related susceptibility to BPAU neurotoxicity as it has been 
demonstrated in this study that the two metabolites M l and M2 of BPAU are 
fonned via different pathways (see FIG 2-24). M2 has been suggested to be a 
detoxicated metabolite and MI may be a toxic metabolite, see 2.4.5. Therefore, 
pharmacokinetic factors possibly relating to an age-dependent decrease of M2
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formation and the increase of M l formation, and the overall increase in parent 
concentration are the main factors for age. difference of susceptibility to BPAU 
neurotoxicity.
2.4.7 Summary
1. The interaction between BPAU and the body begins with absorption. The 
lipophilic property of BPAU and lipid content in individual tissues determines 
the exposure burden of individual tissues. BPAU reached the highest level and 
had a longest half life in spinal cord, which coincides well with its 
histopathological lesion.
2. BPAU is metabolised in vivo before it is eliminated from body. Three metabolites 
are primarily characterised and metabolic pathways have been proposed in this 
stady. BPAU is metabolised in vivo via two distinct pathways. M l <- BPAU 
M2. The M2 pathway plays a important role in BPAU detoxification. Whereas 
M l is suggested to be a toxic metabolite. M3 is also a less toxic metabolite 
because it was mainly found in urine.
3. PMSF significantly intensifred BPAU-induced delayed neuropathy. Its effect 
showed a time-dependent character. The promotion effect of PMSF depends on 
the presence of BPAU at target sites. The nearer the two compounds were given 
in time, the more severe the delayed ataxia. PMSF can inhibit the M2 pathway 
and less BPAU will be metabolised overall, though there is an increase in the M l 
pathway, and hence exaggerated BPAU neurotoxicity. The metabolic interaction 
between the two compounds underlies the promotion phenomenon and hence 
represent a distinct model in the studies of promotion phenomena.
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4. The age differences in BPAU distribution and metabolism agree well with age 
related susceptibility to BPAU induced neuropathy. Young rats, which resist to 
BPAU neurotoxicity, have a lower level of BPAU in spinal cord and produce 
more M2 but less M l than adult rats, i^ c h  are more susceptible to BPAU 
neurotoxicity than young rats. This tinther confirms that metabolism and 
pharmacokinetics of BPAU are involved in the modification of its neurotoxicity.
In conclusion, pharmacokinetic factors play a important role in BPAU 
induced neuropathy; its promotion by PMSF; and its age-related susceptibility. Any 
factors \^ c h  can change the distribution, persistence and metabolism of BPAU can 
significantly modify its neurotoxicity.
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SECTIONS METABOLISM AND PHARMACOKINETIC 
FACTORS OF Af-DNB IN ITS NEUROTOXICITY
3.1 INTRODUCTION
3.1.1 m-Dinitrobenzene and its neurotoxicity
m-Dinitrobenzene (m-DNB) is widely used as an intermediate in the chemical 
synthesis of rubber chemicals, pesticides, dyes and e^qilosives (Hartter, 1985). Its 
toxicity to man has been known for more than a hundred years. In common with 
other nitroaromatic compounds, m-DNB can cause methemoglobinemia both in 
animals (Kunz, 1942; Foster, et al., 1987) and in man (Parke, 1961; DeBethizy and 
Rickert, 1984). It can also produce testicular toxicity (Cody, et al., 1981; Levin and 
Dent, 1982; Cussum, et a/., 1986), Hver toxicity and neurotoxicity (Kunz, 1942; 
Kiese, 1949; Lazerev and Levina, 1976; Phübert, et al., 1987 and Romero, et al., 
1991).
The neurotoxicity of m-DNB in animals shows cerebral paralysis (Kunz, 1942 
and Kiese, 1949). It has been demonstrated that m-DNB can selectively cause brain 
stem damage and this damage is easier to produce by repeated lower doses or 
infusion than by a bolus dose in the experimental animals (Philbert, et al., 1987; 
Romero, et al., 1991 and Nolan, et al., 1995). In the study of m-DNB-induced 
neurotoxicity, it was noted that germ-free rats are more sensitive to m-DNB than 
conventional rats. Germ-free rats developed ataxia 24 h afrer a single dose whereas
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conventional rats developed a similar degree of ataxia only after repeated oral doses 
(Philbert, et al., 1987). Histopathological studies showed that the main lesions 
symmetrically distributed in rat brain stem (Philbert, et al., 1987 and Romero, et al., 
1991). The vulnerable regions in brain stem include cerebellar roOf, vestibular, 
superior olivary nuclei and the inferior coUiculi. Frequent petechial haemorrhages 
were also observed in these regions. The earlier change probably occurred in glial 
cells and neuronal damage secondary to ghal cells (Phübert, et al., 1987 and 
Romero, et al., 1991). m-DNB increased cerebral blood flow especially in the 
inferior coUiculi (Romero, et al., 1991). It was suggested that vascular bed may play 
an important role in the pathogenesis of these lesions, perhaps in parallel with early 
astroglial damage (Romero, et al., 1991).
The species and age differences in susceptibility to m-DNB has been 
documented (Obasaju, et a l, 1991; Linder, 1990). Rats and Hamster differ in 
susceptibility to m-DNB-induced testicular toxicity and methemoglobinemia 
(Obasaju, et a l, 1991). The half life of m-DNB is 3.0 hours in rats and 2.7 hours in 
Hamsters (McEuen and Miller, 1991). The half life prolonged with ageing (Linder,
1990). This may be responsible for the susceptibility of old rats to m-DNB-induced 
testicular toxicity (Linder, 1990 ).
3.1.2 Metabolism of m-DNB in vivo and in vitro
In vivo and in vitro studies have shown that absorbed m-DNB undergoes 
biotransformation in body or in cultured tissues (Cossum, 1985; Rickert, 1987; 
Nystrom, 1987; McEuen and Miller, 1991). The metabolic pathways were proposed 
by several researchers (Gomel, 1931; Roubal, 1946; Lipschitz, 1948; Parke, 1961;
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Rickert, 1987). FIG 3-1 shows the metabolic pathways of m-DNB. 3-Nitroamline (3- 
NA) is a major product of phase I metabolism of m-DNB in which NADPH- 
cytochrome P450 reductase is involved (Cossum and Rickert, 1985). 3-nitroaniline 
(3-NA) and 3-nitrophenyl-hydroxylamine were found in rabbit tissues after 
administration of m-DNB (Gomel, 931).
NO 2 NO HN-OH
hNOz------
m-DNB 3-NNB 3-NPH
1
NHg NHg
■NOz ^ ---- ^ ^ - N O z
HO 3-NA
4-A-2-NP
yHz NHC(0)CH3
H O - ^ ^ - N O z ^ ^ - N O z
2-A-4-NP 3-NAA
NHC(0)CH3
-NHC(0)CH3 
2.4-DAP
FIG 3-1. M ajor metabolic pathways of m-dinitrobenzene. m-DNB; m- 
dinitrobenzene; 3-NNB: 3-nitrosonitrobenzene; 3-NPH: 3-nitrophenyl-
hydroxylamine; 4-A-2-NP: 4-amino-2-nitrophenol; 3-NA: 3-nitroaniline; 2-A-4-NP:
2-amino-4-nitrophenol; 3-NAA: 3-nitroacetaniline; 2,4-DAP: 2,4-
diacetaminobenzene.
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Whereas, the major metabolites of m-DNB in rabbit urine were 2,4- 
diacetaminophenol, 1,3-diaminobenzene, 3-nitroaniline (3-NA) and 2-amino-4- 
nitrophenol (Parke, 1961). Other metabolites found included 2,4-dmitrophenol, 4- 
amino-2-nitrophenol, 3-nitrosonitrobenzene (3-NNB), 3-nitrophenylhydroxylamine, 
and 3,3 '-dinitroazoxy- benzene (Rickert, 1987). m-DNB in rat isolated hepatocytes 
was converted to 3-NA which accounted for 74 % of the added m-DNB (Cossum 
and Rickert, 1985). In rat testicular cell culture, two major metabolites 3-NA and 3- 
nitroacetanilide were found (Foster, 1987). In rat hepatocyte culture (Cossum and 
Rickert, 1985) and the brain slice incubation (Hu, et al., 1995), 3-NA and small 
amount of 3-NNB were detected. Therefore 3-NA is a key metabolite either as a 
terminal metabolite or as a intermediate for the further metabolism of m-DNB.
Administrating 3-NA to rats and finding no testicular toxicity suggested that 
3-NA is unlikely to be a toxic metabolite (Cosssum, et al., 1986). However, 3-NNB 
was found to be more toxic than m-DNB itself (Foster, 1987). This suggests that the 
metabolic intermediates produced during the transformation from m-DNB to 3-NA 
may play an important role in m-DNB-induced testicular toxicity. Chemically, 3- 
NNB is not a stable intermediate. So, it is difficult to be detected in vivo. However, 
3-NNB will be transformed into a relative stable metabolite 3-NA via 3- 
nitrophenylhydroxylamine, see FIG 3-1. Therefore, 3-NA may serve as a good 
indicator of the formation of toxic intermediates of m-DNB (McEuen and Miller,
1991).
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3.1.3 Approaches of this study
m-DNB is a multi-target toxicant and can selectively cause brain stem 
damage. The dosing regimen of m-DNB significantly modified the susceptibility of 
individual target tissues. This suggests that pharmacokinetic factors in target sites 
may play an important role in its neufotoxicity. Although the metabolism and 
peripheral pharmacokinetics of m-DNB have been reported, its pharmacokinetic 
behaviour in individual target tissues has not been studied. This study investigates 
the metabolism and pharmacokinetics of m-DNB in individual target tissues and 
some cell types to look into the roles of these factors in m-DNB-induced 
neurotoxicity.
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3.2. EXPERIM ENTS
3 2 1 Chemicals
m-Dinitrobenzene (m-DNB), 3-mtroamlme (3-NA, 98%), 4-amino-2- 
nitrophenol and 2-amino-4-nitrophenol were obtained from Aldrich. 3- 
Nitrosonitrobenzene (3-NNB) was a gift from Dr M. K._ EUis (Zeneca Central 
Toxicology Laboratory). Trypsin, collagen, poly-L-lysine, cytosine p-D- 
arabinosidc, foetal calf scrum (PCS) and the media of a-MEM and DMEM were 
purchased from Sigma; F-10 Ham’s was obtained from Gibco. Other chemicals are 
as described in 2.2.1, Section 2.
3.2,2 Infusion-lesion model of m-DNB neurotoxicity
3.2.2.1 . Animals and procedures
Intravenous infusions were : made in ■ conscious:^Fischerr344 (F344) rats, 
weight 250-280 g, via a catheter implanted into the external jugular vein. The 
catheter was placed under isofluorane anaesthesia and connected to a subcutaneous 
Alza osmotic minipump (Model 2ML1, alza Corporation) filled with m-DNB 
dissolved in DMSO. The total filling volume of each pump was 2114 ± 53 pi. The 
pumping rate was 10.26 ± 0.36 pl/h. The total dose for each infusion period was 30 
mg/kg m-DNB. The concentration of m-DNB was adjusted to give the appropriate 
dosing rate over 6 , 12, 24 hours, or 2, 4, 6 , 8  or 14 days. Two rats were used for
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each infusion period. Histopathological examination of each rat was done at the end 
of each infusion, see 3.2.2.2.
Five extra rats in 4-day infusion group were used for m-DNB measurement. 
The animals were killed by the inhalation of carbon dioxide at the end of 4-day 
infusion. Blood of each rat was sampled through heart iminediately after the death 
of animals and anticoagulated with heparin. Brain and spinal cord were removed. 
The brain was dissected into cerebral cortex, brain stem and cerebellum. Brain stem 
was ftuther dissected into the regions of coUiculi, pons and medulla oblongata. 
Sample preparation and analysis; see 3.2.3.2 and 3.2.5.
3.2.2.2 Histopathological observation
Rats for histopathological observation were kUled at 24 hours after the end of 
infusion by perfusion fixation under deep halothane anaesthesia. The ascending 
aorta was cannulated and foUowing a brief wash with saline, perfused with 10 % 
formalin, 2 % acetic acid for 12 min at a pressure of 120 mmHg. The brain and 
cervical spinal cord were removed after storage of the intact head at 4 °C for 24 
hours, sliced coronally into 5 blocks and wax embedded. Composite blocks were 
step serial sectioned at 7 pm and stained with haemotoxylin and eosin. Some large 
area semithin plastic sections were prepared from 4 % glutaraldehyde in 0.1 M 
sodium cacodylate buffer (pH 7.2).
Lesion severity was graded fi'om no abnormalities (-) through scattered 
vacuolation (+) and confluent areas of vacuolation within brain stem nuclei (-H-), to 
involvement of ^ o le  nuclei (4-4-I-).
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3.2.3 Metabolism and pharmacokinetics of m-DNB
3.2.3.1 Animals and procedures
Groups of 5 female F344 rats, weight 250-300 g, were dosed with 10 mg/kg 
m-DNB in DMSO through tail lateral vein. The animals were killed at the time 
points of 0.5, 1 , 2 , 4, 8  and 18 hour(s) after dosing. Two control rats were only 
given an equal volume of DMSO and they were killed at either 2 or 18 hours after 
injection. Animals were killed by inhalation of carbon dioxide at the end of 
experiments. Blood samples were collected through the heart immediately after 
animal death and anticoagulated with heparin. Liver, testis, brain and spinal cord 
were removed, The brain was dissected into cerebral cortex, brain stem and 
cerebellum. Brain stem was ftnther dissected into the regions of coUiculi, pons and 
medulla oblongata. All the samples were weighed and stored at -20 °C until 
analysis.
3.2.3.2 Sample preparation
The collected anticoagulated blood samples were centrifuged at 3000 g for 
10 min Plasma (1 ml) was taken from each sample and mixed with 4 ml solution of 
methanol/DMSO (95:5 by volume). Tissues were homogenated in methanol/DMSO 
solution at 100 mg tissue per ml solution. AU samples were centrifuged at 6000 g 
for 20 min. Supernatant was taken and centriftiged at 9000 g with Eppendorf 
centrifuge for 5 min m-DNB and its metaboUtes were determined by HPLC. HPLC 
analytical condition see 3.3.2.6.
The recovery of m-DNB in the analytical system was studied by 
homogenizing fi-esh rat brain in methanol/DMSO (95:5 % by volume) containing
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standard m-DNB (1 pg/ml). Seven samples were tested. The percentage of recovery 
was calculated by dividing the detected amount by the added amount.
3.2.4 m-DNB metabolism in endothelial cells and astrocytes
3.2.4.1 Astrocyte primary culture
3.2.4.1.1 Buffers and culture reagents 
Buffer Dl: This buffer consisted of a Ca- and Mg-free Hank's Balanced Salt 
Solution (HBSS) containing 140 mM NaCl, 5.4 mM KCl, 0.67 mM Na2HP0 4 , 0.22 
mM KH2PO4 , 17 mM glucose, 22mM sucrose, 10 mM HEPES buffer, lOOU/ml 
penicillin G and 100 pg/ml streptomycin. It was adjusted to pH 7.4 with 1 M 
NaOH, Sterilised by filtration through a 0.22 pm filter and stored at 4 °C until use 
within 2  days.
Trypsin solution was made up fiesh and consist of a 1.25 mg/ml trypsin solution in 
buffer D l sterilised by filtration through a 0 . 2 2  pm filter.
Collagen stock was a 0.3 mg/ml rat taü collagen solution in 0.1 % (v/v) glacial 
acetic acid to help dissolve coUagen.
Poly-L-lysine stock consisted of a 1 mg/ml poly-L-lysine [hydrobromide] (MW 
75,000 - 150,000) in 0.1 M borate buffer made up with 3.1 mg/nd H3 BO3  and 4.75 
mg/ml Na2B4 ( > 7  adjusted to pH 8.5. The solution was sterilised by filtration through 
a 0.22 pm filter and stored at -20 °C until use. The poly-L-lysine solution is 
prepared by diluting the stock solution to 1 0  pg/ml in sterile borate buffer on the 
day of the isolation procedure.
Cytosine arabinoside stock (Ara Q:_p-D-arabinoside was dissolved in HBSS at a 
concentration of 1 mM and sterilised by filtration through a 0.22 pM filter. The
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solution was diluted 1:100 in culture medium to give a final concentration of 10 
pM.
3.2.4.1.2 Culture medium
Dulbecco's Modified Eagle's Medium (DMEM) was used throu^out the 
culture. It contains 10 % foetal bovine serum, 2 mM glutamine, 1 mM sodium 
pyruvate, 0.057 mM sodium ascorbate, 26 mM sodium bicarbonate, 100 U/ml 
penicillin G and 100 pg/ml streptomycin. The medium was sterilised by filtration: 
through a 0.22 pm filter and stored at 4 °C until use within 1-1.5 months.
3.2.4.1.3 Preparation of growth surface
Astrocytes were routinely grown on 25 cm  ^ tissue culture flasks which had 
been previously coated with poly-L-lysine on its own or in combination with 
collagen for a more durable cell attachment on glass coverslips. Prior to seeding 
cells, the flask surfaces were coated with 3 ml of poly-L-lysine at room temperature 
for 1 hour. Excess poly-L-lysine was removed by washing three times with HBSS.
3.2.4.1.4 Isolation of cells
1) F344 rat pups at either day 0 or day 2 were used. The pups were soaked 
in 70 % ethanol and were killed by decapitation with scissors. The pup heads were 
placed in the centre of a lint soaked with buffer D l and held with a pair of big 
forceps. The skin was cut along the m idline with a scalpel. The soft skull was also 
cut on the m idline with another scalpel to avoid contamination and separated the 
bone with a pair of curved forceps. The whole brain was removed and transferred to 
a 50 ml beaker containing ice-cold buffer D l.
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2) Brains were transferred to a 60 nun diameter plastic dish containing 5 ml 
of buffer D l. The brain was held with the small straight forceps and the cerebrum 
was cut off at the superior coUiculi level with the small curved forceps. The brain 
was sliced longitudinally along the midline and separated into two hemispheres. 
Midbrain structures, the hippocampus and the choroid plexus were pinched off with 
a small curved forceps until just cerebral cortex was left. The two cortices were 
transferred to a moist lint and picked off meninges and surface vessels with blunt 
curved forceps. The cortices were then transferred to a 60 mm plastic dish 
containing 5 ml of buffer D l and placed on ice.
3) Dissected tissues were then chopped finely with a surgical scalpel. 
Trypsin solution (5 ml) was added to disaggregate the tissue suspension at 37 °C for 
30 min. Following the incubation period, trypsin was inactivated by adding an equal 
volume of serum-containing nutrient medium for 5 min and then spun 5 min at 
1,500 rpm. The supernatant was decanted and the brain pellets were resuspended in 
2 ml culture medium. The tissue was further dissociated to form a cell suspension 
by trituration through a fine-bore fire-polished Pasteur pipette and sedimentation. 
Cells were then filtered by gravity through a sterile 73.5 pm metal sieve to get rid of 
big cell clumps and diluted with culture medium for counting in a haemocytometer. 
Cells were then seeded at a plating density of 25,000 cells/cm^ (usually each cortex 
wül give around two or three 25 cm  ^flasks).
3.2.4.1.5 Maintenance of the cultures 
The culture medium was replaced with ft-esh medium 24 h after seeding and 
subsequently every 2-3 days. The cells were incubated at 37 °C in a water saturated
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atmosphere of 95 % air 5% CO2  At sub-confluence (days 7-9 after plating), cell 
contaminants on top of the monolayer were separated from type I astrocytes by 
shaking on a vibrax SRAŒR7 shaking system (Camlab Ltd., Cambridge, U.K.) at 
37 °C for 24 h. Detached cells, consisting mainly of oligodendrocytes, type 2 
astrocytes and 0-2A progenitors, were aspirated off and the culture medium was 
replaced. Further purification of the cell cultures was achieved at confluence (day 
14-16 after plating) by adding cytosine arabinoside (10 pM) to the culture medium 
for 5 days to kill contaminating dividing cells.
3.2.4.1.6 Exposure to wi-DNB 
Monolayer astrocytes were incubated in the medium containing 100 pM m- 
DNB for 4, 8 or 24 hours. Both cells and media were collected at the end of each 
time point for the measurements of m-DNB and its metabolites. Four flasks were 
used at each time point The cell-free control flasks were added medium containing 
100 pM m-DNB and blank control flasks with cells were added culture medium 
without m-DNB.
3.2.4.2 Endothelial cell line
Mouse endothelial cells (RBE4, P.50, clone A3) were seeded in 25 cm  ^
plastic flasks at a plating density of 25,000 cells/cm^. The cells were maintained in 
the medium of a-MEM (Sigma): FIO Ham’s (Gibco) (1:1) plus 10 % foetal calf 
serum (FCS) and the flasks were incubated under standard condition (37 °C, 5 % 
CO2 and 95 % air) until a monolayer was completed in each individual flask. The
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metabolic study of m-DNB was carried out by replacing the culture medium by the 
medium containing 100 pM m-DNB. Cells and 0.5 ml of medium were collected at 
the end of each time point for the measurements of m-DNB and its metabolites. 
Four flasks were used at each time point. The cell-free control flasks were added 
medium containing 100 pM m-DNB and blank control flasks with cells were added 
culture medium without m-DNB.
3.2.4.3 Neuroblastoma cell line
The cells of neuroblastoma (mouse NIE 115) were seeded in 25 cm  ^flasks at 
a plating density of 25,000 cells/cm^ and incubated in the medium of 10 % FCS in 
DMEM under the standard culture condition until a monolayer was formed. Then, 
the cells were exposed to the medium containing 50 pM m-DNB. 100 pi medium 
was taken at either 4, 8 or 24 hours after exposure for the determination of m-DNB 
and its metabolites
3.2.4.4 Procedures and analysis of samples
The monolayer cells in each flask were trypsinized and collected with a 5 ml 
centrifuge tpbe. Then the cells were transferred into pre-weighted 1.5 ml Eppendorf 
tube after centrifuging. The Eppendorf tubes were centrifuged at 9000 g for 3 min 
and medium in tubes was drawn out. The sample weight of each flask was obtained 
by the difference between the tube weight with cells and the weight of empty tube. 
Then the cells were homogenised in 100 pi methanol for 3-5 min and then 
centrifuged at 9000 g for 5 min The supernatant of each sample was kept for HPLC 
analysis.
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Each sample of media taken from above experiments was mixed with equal 
volume of methanol. Then they were centrifuged at 9000 g for 5 min. The 
supernatant of each sample was kept and analysed by HPLC. The HPLC analytical 
condition see 2.6.
3.2.5 Study of 3-nitrosonitrobenzene stability
3-nitrosonitrobenzene (3-NNB) is an important intermediate in m-DNB 
metabolism, see FIG 3-1. But in in vivo study, it is difficult to detect. This spiking 
study was to study its stability in tissue extraction.
Two male F344 rats, weight approximately 200 g, were used. One of them 
was dosed with 30 mg/kg of m-DNB iv and was killed by CO2  at 2 hours after 
dosing. The other rat was not dosed and was killed by CO2  as well. The brains were 
taken out immediately and stored in -20 °C fridge. The analysis were carried out 
within one week.
Rat brains were homogenised in methanol according to the ratio of 100 
mg tissue per ml. 3-NNB, m-DNB and/or 4-amino-2-nitrophenol in DMSO were 
added to the extraction to make either 5 or 10 pg/ml spiked extraction. The two 
brain tissues were also extracted by 5 % TCA and then 3-NNB was added to make 
10 pg/ml extraction. Samples were analysed by HPLC, The analytical condition see
3.2.6.I.
3.2.6 HPLC analytical condition
3.2.6.1 Gradient
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HPLC system: Waters HPLC system with a Controller 600, a tuneable 
absorbance detector 486, and an autosampler plus 717. The column was a S5 0DS2 
250 X 4.6 mm (Spherisorb), and the detector wavelength was 254 nm; The mobile 
phase (A= water, B= acetonitrile) used a gradient: maintained 5 % B for 1 min and 
then directly changed to and maintained at 50 % B at a velocity of Iml/mm for 19 
min. The injected volume of each sample was 25 or 50 pi.
3.2.6.2 Isocratic
HPLC (Philips, Pye Unicam, PU4010 pump, LDC/Milton Roy 
Spectromonitor HI). Column: S5 0DS2 250 X 4.6 mm (Spherisorb); Wavelength: 
254 nm; Mobile phase: 30% acetonitrile in 0.1 mM ammonium acetate; Velocity: 1 
ml/min. The injected volume of each sample was 50 pi.
The HPLC profile of m-DNB and its metabolites are shown in FIG 3-2.
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FIG 3-2. The HPLC profiles of /M-DNB and its metabolites.
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3.2.7 Statistics and pharmacokinetics
3.2.7.1 Statistics
Anova analysis was used for the comparisons of the concentration of m-DNB 
or its metabolites in different tissues and the blood/tissue ratio. Student-t test was 
employed for two sample comparison. The standard error of elimination rate 
constants were calculated according to the method given by Mead and Cumow 
(1987). The Z test was used for half life comparison. The statistics were carried out 
by computer on the statistics programme of MJNITAB 10.2.
3.2.7.2 Pharmacokinetics
Pharmacokinetic data were analysed according to the methods and equations 
given by Gibaldi & Perrier (10). m-DNB follows apparent first order absorption and 
elimination kinetics and one-compartment open model was employed. The 
concentration (Q) of m-DNB at any time (t) after a single iv dose was estimated by 
logCt = logCo - kt/2.303 (1)
where k is the rate constant of elimination phase.
The plasma concentration (Q) of m-DNB at any time (TJ during the infusion was 
estimated by the following equation
Ci=ri(l-e''^')/k.V (2)
where n is the infusion rate; V is the apparent distribution volume.
The time (ta) fi*om the end of infusion to decline to a certain concentration was 
calculated by the equation transformed from (1)
ta=2.303(logCo-logCt)/k (3)
The details of the calculations of pharmacokinetic parameters are in the Appendix.
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3.3. RESULTS
3.3.1 Pharmacokinetics of m-DNB
3.3.1.1 Distribution
m-DNB was determined by HPLC method. The recovery of this analytical 
system was 92.2 ±3.7%  (n=7). Following a bolus iv dose, m-DNB reached its peak 
value in tissues at 1 hour. The peak levels in different regions of the central nervous 
system are significantly higher than those in hver and testis. m-DNB does not 
evenly distribute in CNS. Its levels in spinal cord and different regions of brain stem 
are 15-52 % higher than those in cerebral cortex and cerebellum, see FIG 3-3 and 
3-4.
3.3.1.2 Pharmacokinetics
The pharmacokinetic parameters of m-DNB in blood and individual tissues 
were esthnated, m-DNB given intravenously followed apparent first order 
absorption and elimination kinetics in plasma and tissues of rats. FIG 3-3, 4 and 5 
show the concentration-time curves of m-DNB and its metabohte 3-NA in plasma 
and different tissues. m-DNB reached its peak value in tissues at 1 hour and 3-NA 
reached its peak value at 2 hours after iv injection. Most m-DNB had been 
eliminated at 18 hours after dosing. The concentration-time data were transformed 
into logarithm of concentration versus time data and the kinetic models were 
identified. All the data fi'om either plasma or tissues were best fitted by a one- 
compartment model, see A-H-A, Appendix.
121
2 0 1
• :  m—DNB 
o: 3—NA1  15-
E 10 (/)
CO
Û. c .
0-»
o> • :  m—DNÈ 
o: 3-NA1 0 -
#: m-DNB 
O: 3—NA
6 8 10 12 
Time course (h)
f i g  3-3 Concentration-time curves of m-dlnitrobenzene and 3-nitroanlllne in 
plasma, testis and liver. The data were obtained by giving a single iv dose of 10 
mgdcg m-DNB. The values are presented as mean ± SE, n=5.
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FIG 3-4 Concentration-time curves of m-dinitrobenzeiie and 3-nitroaniline in 
the regions in brain stem. The data were obtained by giving a single iv dose of 10 
mg/kg w-DNB. The values are presented as mean ± SE, n=5.
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FIG 3nS Concentration-time curves of m-dinitrobenzene and 3-nitroaniline in 
cerebral coetex, cerebellum and spinal cord. The data were obtained by giving a 
single iv dose of 10 mg/kg m-DNB. The values are presented as mean ± SE, n=5.
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Fitting these data using non-linear least square regression yields straight lines for 
the elimination phase, and the kinetic parameters were determined according to the 
equations given by Gibaldi & Perrier (1975). The parameters of m-DNB in blood 
are presented in Table 3-1.
Table 3-1. The pharmacokinetic parameters of m-DNB in plasma following a single 
iv dose of lOmg/kg.
Xo Co V k AUC Ti/2
(mg) (mg/l) ®  (h‘‘) (mg.hr \T^) (h) .
2.76 2.79 0.989 0.237 11.78 2.92 ±0.12
k; elimination rate constant; V: apparent distribution volume; AUC: the area under the
concentration-time curve; and Tm elimination half life. Half-life is presented as Mean ± SE,
n=5.
Table 3-2. The pharmacokmetic parameters of m-DNB in tissues
Tissue Co k Tm AUC
(Hg/ml) (h ') (h) (pg.ml'\h'^)
Medulla 3.66 0.237 ± 0.010 3.0 ± 0.2 17.7
-Pons —- —3.21 — 0:238 ±0:015------- 2:9*±'0.2“ " 15.8 ----
Colliculi 3.17 0.237 ± 0.013 2.9 ± 0.2 15.2
Cerebellum 2.88 0.228 ± 0.018 3.0 ±0.2 14.4
Cortex 2.07 0.203 ± Ô.019 3.4 ±0.3 11.9
Spinal cord 4.09 0.222 ± 0.053 3.1 ±0.6 19.4
Liver 2.20 0.546 ± 0.072 1.3 ± 0 .2 ’ " 0.7
Testis 2.29 0.152 ±0.031 4.6 ± 0.8’ 2.7
Co is the concentration estimated from the extrapolated line of -k/2.303 when time t is zero; 
k; the apparent first-order elimination rate constant. T1/2 is the half life of elimination phase. 
AUG; the area under the concentraticm-time curve. Data are presented as mean ± SE, 
(n=5).*: p<0.05; **: p< 0.01 (Z test) for liver or testis comparing with brain areas.
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The half lives and AUC of m-DNB in tissues are shown in Table 3-2. The half life 
in liver was signiticantiy shorter than that in blood and other tissues. Whereas the 
half life in testis was signiticantiy longer than that in blood and other tissues. The 
half lives in different regions of CNS are similar to that in blood. AUC in central 
nervous system was much higher than that in non-nervous system.
3.3.1.3 m-DNB metabolism in vivo
The main metabolite of m-DNB detected in all tissues was 3-NA. Its 
distribution in the central nervous system paralleled that of m-DNB after 2 hours. 
However, liver
Table 3-3 The pharmacokinetic parameters of 3-NA
Tissue k Ti/2
(h-') (h)
Blood 0.155 ±0.041 4.47 ± 0.45
Medulla 0.260 ±0.048 2.66 ±0.41
Pons 0.213 ±0.047 3.26 ± 0.58
Colliculi 0.215 ± 0.055 3.22 ±0.66
Cerebellum 0.242 ± 0.047 2.86 ± 0.46
Cortex 0.206 ±0.031 3.37 ± 0.44
Spinal cord 0.147 ± 0.034 3.98 ± 0.64
Liver 0.147 ±0.012 4.70 ±0.70
Testis 0.184 ±0.068 3.77 ±0.61
k: the apparent first-order elimination rate constant. T1/2 is the half life of elimination phase 
of 3-NA Data are presented as Mean ± SE, n=5.
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reached the highest concentration of 3-NA which is 16 times higher than m-DNB. 3- 
NA reached its peak value in tissues at 2 hours after iv injection. This was a one 
hour delay compared with its parent compound, m-DNB, see FIG 3-3, 4 & 5. The 
half lives of 3-NA in different tissues are presented m Table 3-3.
3.3.1.4 Infusion studies
Distribution pattern: A  total intravenous dose of: 30 mg/kg m-DNB was 
infused within 4 days. m-DNB in plasma and tissues were measured at the end of 
infusion The concentration of m-DNB was 2.8 ± 0.4 pM in plasma, 3.8 ± 0.4 
nmol/g in medulla oblongata, 3.6 ± 0.5 nmol/g in colliculi, 2.6 ± 0.5 nmol/g in pons, 
2.4 ± 0.4 nmol/g in cerebellum, and 2.3 ± 0.3 nmol/g in cerebral cortex. The 
distribution pattern of m-DNB in the brain after infusion is similar to that after bolus 
iv dose.
Tissue/plasma ratio: In order to compare the relative distribution between 
different tissues and accumulation between bolus dosing and infusion, tissue/plasma 
ratio was calculated. Tissue/plasma ratio for each tissue was obtained by dividing 
the peak value (pg/g) of m-DNB in each tissue by its concentration (pg/ml) in 
plasma at the same time point. The tissue/plasma ratios of tissues in infusion were 
generally higher than that in bolus dose, see FIG 3-6, and the ratios in colliculi and 
medulla oblongata in infusion were significantly higher than in bolus dose. This 
indicates that infusion allowed more m-DNB to accumulate in central nervous 
system than a single bolus dose, especially in some regions of brain stem.
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FIG 3-6 Comparisons of tissue/plasma ratios in different regions in brain 
between infusion and boius doses. The infusion study was done by infusing 30 
mg/kg m-DNB to rats over 4 days. m-DNB levels in plasma or tissues were 
measured at the end of experiment. The ratios from bolus dose are the tissue peak 
values versus the plasma value at the same time point after a single iv dose of 
lOmg/kg m-DNB. The tissue/plasma ratio of each tissue was obtained by dividing 
tissues concentration (pg/mg) by plasma concentration (pg/ml). The data are 
presented as mean ± SD, n= 5.
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3.3.2 Musion-lesion model of m-DNB-induced neurotoxicity
A total of 30 mg/kg of m-DNB was infused over either 6, 12 or 24 hours, or 
2, 4, 6, 8 or 14 days. The histopathological lesions in each infusion are shown in 
Table 3-4. To illustrate how the blood concentration of m-DNB relates to its 
histological lesion, the theoretical infusion curve for each infusion period was 
calculated based on pharmacokinetic parameters and constants given in table 3-1. 
The concentration-time curves of infusion are shown in FIG 3-7.
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f ig  3-7. The infusîon-Iesîoii model of m-DNB neurotoxicity: Theoretical 
concentration-time curves of m-DNB in the infusions of different periods and their 
correspondent histopathological lesions.
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Duration Pathological score Ataxia score*
Bolus - 0
- 0
6 hours - 0
-  . 0
12 hours - 0
-m - 4
1 day +  ■ 3
+ + 5
2 days -H-+ 2
+ + + 2
4 days -I-++ 1
-H-+ 1
+ + + 3
+ + + 2
6 days + + 1
.+++ 1
8 days - 2
- 2
14 days - 2
- 2
*: the evaluation system of ataxia score see 2.2.5.2.1, Section 2 .
The plasma steady-state level of m-DNB at the end of the 4-day infiision was 
2.8 ± 0.4 pM. The predicted value was 2.9 pM which is within the normal range of 
the real value. Thus it is reasonable to estimate the infusion curve of m-DNB in 
plasma by using the pharmacokinetic rate constants and parameters obtained from 
the above pharmacokinetic study. The infusion curves were plotted according to the 
equation (2) stated in 3.2.7.2 in this section. When the infusions end, m-DNB wiU 
decline according to equation (1). All the theoretical curves of infusions are 
presented in FIG. 3-7. As shown in FIG 3-7, the steady state level of 6-day infusion 
is 1.95 pM which is the minimum plasma concentration associated with lesion
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formation. Therefore this concentration is taken as the plasma concentration 
threshold of lesion. The time (Td ) needed to decline from the end level or steady 
state of infrision to 1.95 pM was next estimated by the equation (3), see 3.2.7.2. 
Thus the time (Tm) over which plasma concentration was maintained above 
threshold can be estimated by Td + T, (T, is infusion time). Tm in each case of 
infusion is presented in table 3-5.
Table 3-5. The time maintaining the level of m-DNB above lesion threshold in each 
infusion.
Infusion group Ti Td Tm
(h) (h) (h)
6h 6 12.8 18.8
12 h* 12 10.7 22.7
24 h* 24 8.0 32.0
2d* 48 4.9 52.9
4d* 96 1.8 97.8
6 d* 144 0.0 144 0
Ti is the infusion time; Tm is the time over which plasma concentration was maintained 
above the neuropathic threshold; Td: the time needed from the end level or ^eady state of 
infusion declining to lesion threshold, 1.95 pM. *: lesion produced.
3.3.3 Metabolism of m-DNB in vitro
3 3 3 1 Metabolism of m-DNB in astrocytes and endothelia cells 
Cell culture studies show that the cell types of endothelial cells.
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astrocytes and neuroblastomal cells are all able to metabolise m-DNB. 3-NA was 
the main metabolite detected in both media or cells, see FIG 3-8 and 3-9.
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FIG 3-8. Chromatogram of m-DNB and its metabolites in the medium of 
endothelial cells at 24 hours after incubation.
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FIG 3-9. Chromatogram of m-DNB and its metabolites in washed endothelial 
cells at 4 hours after incubation.
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3-NA accumulated in media in a constant rate. A active intermediate 3-NNB was 
detected in either endothelial cells or astrocytes at 4-hour, but not at 8 or 24 hours, 
see FIG 3-9. One unidentified peak was also detected, see FIG 3-8 and 3-9. The 
unknown peak came out after 3-NA in HPLC graphs and it was mainly detected at 4 
and 8 hour incubation, but not at 24 hours. The concentration-^time curves of m- 
DNB and 3-NA in medium are shown in FIG 3-10. The decreasing levels of m-DNB 
and corresponding increase in 3-NA in the medium are presented in Table 3-6. 
These changes were quicker than those seen in astrocyte medium but they are not 
statistically significant.
The spontaneous loss of m-DNB culture dishes with a initial concentration of 
100 pM was 4.3-8 3 % in the control cell-free medium. This loss presumably 
reflected evaporation, or movement in tp the plastic dishes. No metabolites were 
detected in the cell-free control media. The control values of m-DNB at 24 hours 
were taken as 100 % to calculate the. active loss .due to metabolism:. .
Table 3-6. Biotransformation of m-DNB in cultured endothelia cells and astrocytes
Cell type % o f  m-DNB loss Loss rate o f  m-DNB Production rate o f  3-
(nmol.g'\h'^) N A
(nmol.g'\h'^)
Endothelia 46.5 ±  1.9* 875 ± 78 135 ± 11
Astrocyte 41.5 ± 0 .5 837 ± 151 122 ± 22
a: values are presented as Mean ±  SE.
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One flask of neuroblastomal cells cultured with a initial concentration of 25 
|iM m-DNB showed a net m-DNB loss rate of 632.4 nmol/g/ h and a 3-NA 
production rate of 116.9 nmol/g/h during the first 24-hour culture. This clearly 
showed the metabolic ability of neuroblastomal cells for m^DNB.
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FIG 3-10. Concentration-time curves of m-DNB and 3-NA in the media of 
astrocytes and endothelial cells after exposing to an initial concentration of 100 
pM m-DNB. The data àre presented as mean ± SE, n = 4.
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The levels of m-DNB and its metabolite 3-NA in cells are presented in FIG 
3-11. Their levels in endothelial cells at all time points were similar. In astrocytes, 
the level of m-DNB at 24 hours was significantly higher than that at 4 or 8 hours 
after exposure (p<0.01).
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FIG 3-11. Concentration-time curves of m-DNB and 3-NA in astrocytes and 
endothelial cells after exposing to an initial concentration of 100 pM. m-DNB. 
The data are presented as mean ± SE, n -  4.
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3.3.3.2 Stability of 3-NNB in bfain extract
FIG 3-12 shows'the HPLC profile of m-DNB and 3-NNB standards in 
methanol. It indicates that 3-NNB is stable in methanol.
0 . 0 5
0 . 0 4
0 . 0 3
0 . 0 2
0 . 0 1
0 . 0 0 - A _.
; - N N B
Vj
O.CO :  . 0 0  4 . 0 0  ' 6 . 0 0  3 . 0 0  1 0 . 0 0  1 2 . 0 0  1 4 . 0 0  1 6 . 0 0 .  1 3 . 0 0  Zc.O-..
FIG 3-12. Chromatogram of m-DNB and 3-NNB in methanol.
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FIG 3-13. Chromatogram of m-DNB and 3-NNB in brain extract. m-DNB 
remains but 3-NNB degrades to 4-A-2-NP.
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When m-DNB and 3-NNB were added to the extraction of fresh brain tissue, 
the peak of m-DNB remained unchanged but only a small peak of 3-NNB left and a 
new peak appeared at the retention time of 10.8 min, see FIG 3-13. This indicates 
that most 3-NNB has been degraded into a new metabolite.
When equal amount of m-DNB, 3-NNB and 4-ammo-2-nitrophenol standards 
were spiked to brain extraction, again the peak of m-DNB was not changed but the 
peak of 3-NNB was nearly disappeared. However, the peak of 4-amino-2- 
nitrophenol was nearly doubled, see FIG 3-14. This means that the retention time of 
degraded product is identical to that of the authentic standard of 4-amino-2- 
nitrophenol. This HPLC profile highly suggests that the degraded product of 3-NNB 
is 4-amino-2-nitrophenol.
3-NNB was also spiked with the extraction of brain tissue from the rat dosed 
with 30 mg/kg. The chromatogram showed the same result as in the fresh tissue 
extraction. 3-NNB was quickly, degraded and a new peak appeared at the retention 
time of 10.8 min as well. This suggests that the new peak is not a normally 
detectable metabolite of m-DNB in vivo.
However, when brain tissue was extracted with 5 % TCA solution and then it 
was spiked with 3-NNB, 3-NNB was not changed. This means 3-NNB is stable 
under the extraction conditions used to prepare brain tissue for HPLC using TCA.
Both 4-amino-2-nitrophenol and 2-amino-4-nitrophenol are metabolites of m- 
DNB, see FIG 3-1. Both standards were tested in the HPLC analytical system used 
in this study. Although they have similar chemical structure, their HPLC 
performance were different. 4-Amino-2-nitrophenol had a very sharp peak at the 
retention time 10.8 min, whereas 2-amino-4-nitrophenol had a broader flat peak
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which was difficult to recognise. Therefore, spiked 3-NNB in brain extract was 
likely to be transformed to 4-amino-2-nitrophenol rather than 2-amino-4- 
nitrophenol.
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FIG 3-14. Chromatogram of m-DNB, 3-NNB and 4-amino-2-nitrophenol in 
brain ex tract m-DNB remained but the peak of 3-NNB is greatly reduced and the 
peak of 4-amino-2-nitrophenol is doubled.
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3.4 DISCUSSION
3.4.1 Phannacokmetics of m-DNB in individual tissues
It has been reported that there are age and species differences in the whole 
body absorption and elimination of m-DNB (McEuen and Miller 1991; Brown, et 
al, 1994). However, little is known about m-DNB distribution and elimination in 
individual tissues. This study investigated the absorption^ distribution, metabolism 
and elimination of m-DNB in different target tissues of the rat. The result shows that 
after initial distribution, the peak level of m-DNB was higher in CNS than that in 
other tissues. m-DNB levels in the regions in brain stem were higher than that in 
other regions. In agreement with this, this distribution profile correlates well with 
regional hpid content of brain (Gospe, et a l, 1988). Brain stem is the target site of 
m-DNB-induced neurotoxicity (Philbert, et a l, 1987; Nolan, et a l, 1995). The gross 
distribution of m-DNB agrees with the histopathlogical lesions and might be 
responsible (at least in part) for the selective regional vulnerability to m-DNB 
neurotoxicity. The present study also shows that m-DNB in different tissues follows 
different elimination rates. The half life of m-DNB in blood is 2.9 hr which is in 
agreement with 3.0 hours obtained by McEuen and Miller (1991) and similar to 3.3 
hours reported by Brown (1994) from 75-day-old group of Sprague-Dawley rats. 
This study shows that the half lives in different regions in the central nervous 
system of rats ranged from 2.9 to 3.1 hours, which were very similar to that in 
blood. However the half life in Ever was signiticantiy shorter than that in blood or 
other tissues. By contrast, in testis the half life was signiticantiy longer than that in 
blood or other tissues. Hence m-DNB in liver and testis did not follow the same
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kinetics as in blood. These indicate that pharmacokinetic behaviour of the 
compound varied from tissue to tissue, and that the pharmacokinetic data obtained 
from blood could not be extrapolated to individual tissues. The pharmacokinetic 
differences between tissues reflect the physiological and biochemical differences in 
m-DNB distribution and elimination, and may contribute to the differences in tissue 
susceptibility to m-DNB.
m-DNB is a lipophilic compound. The central nervous system (CNS) is rich 
in lipid. So m-DNB can be absorbed by CNS by simple (Effusion and tends to 
accumulate in CNS. Whatever the mechanism of m-DNB toxicity might be, the 
level and duration of m-DNB in target tissues are primarily responsible for its toxic 
lesions. This has been shown in species or age (Efferences in susceptibiEties to m- 
DNB in testicular toxicity. Rats are more sensitive than hamster to m-DNB 
testicular toxicity. When the same dosage of 25 mg/kg m-DNB was given to both 
species, the blood peak concentration measured in hamster was only half of the rats' 
value (Obasaju, et a l, 1991). Old rats are more sensitive to m-DNB than younger 
rats (Linder, et a l, 1990). The age (Efference in m-DNB pharmacokinetics has been 
reported, the half life of m-DNB in Sprague-Dawley rats being 1.91 hours in 31- 
day-old group and 4.53 hours in 120-day-old group rats (Brown, et al, 1994). 
Germ-free rats are more susceptible to m-DNB induced neurotoxicity than 
conventional ones. A single oral dose of 25 mg/kg m-DNB which (Ed not produce 
neurotoxicity in conventional rats produced brain lesion m germ-free rats because 
germ-free rats have no microbial nitroreductase activity in gut to remove m-DNB 
prior to absorption (Philbert, et a/., 1987). In ad(Etion, although a single dose of 30 
mg/kg m-DNB can not produce neurotoxicity in conventional rats, when the same
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dosage was split into several doses, it caused brain lesion (Philbert, et al., 1987). 
Our infusion studies showed that when a total dose of 30 mg/kg m-DNB was 
infused within 6 hours, it did not produce brain lesions. However, when the same 
dosage was infused over from 12 to 144 hours, the brain histopathological damage 
was produced, This indicates that once a threshold of m-DNB is exceeded, time 
factor will play a more important role than a transiently high concentration in 
producing brain damage.
Compared with m-DNB-induced neurotoxicity, a single dose of 25 mg/kg m- 
DNB which can not produce brain damage can produce testicular damage in the 
conventional rat. This study showed that m-DNB has a significantly longer half life 
in testis than that in blood or CNS. Therefore, the pharmacokinetic differences may 
partly be responsible for the susceptibility of testis to m-DNB.
3.4.2 Infusion-lesion model of m-DNB
m-DNB is a multi-target toxicant. Repeated doses readily produced 
neurotoxicity (Philbert, et al., 1987). This implied that pharmacokinetic factors play 
a role in m-DNB neurotoxicity. In infusion-lesion model, we studied the link 
between blood concentration and brain lesion. Theoretically, there must be a dose 
threshold in any chemical induced lesion. In our experiments, when a total dose of 
3Qmg/kg m-DNB was infused within 6 days, the plasma concentration was 1.95 pM 
which caused brain damage. When the same dosage was infused within either 8 or 
14 days, the plasma concentration were 15 and 0.8 jjM respectively, which did not 
produce brain damage, see FIG 3-7. Therefore, the m-DNB concentration of 1.95 p 
M was considered as the blood concentration threshold of brain lesion. However,
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when the same total dose was infused within 6 hours, the plasma concentration 
reached as high as 34.7pM and the Tm was 18.8 hours which did not produce 
histopathological damage in brain either. But damage was observed when the same 
total dosage was infused within 12 hours or up to 6 days when the plasma 
concentration was from 21.9 pM to 1.95 pM and the Tm was 22.3 to 144 hours, see 
table 3-5. This clearly shows that a longer Tm has more neurotoxic potential than a 
instmtaneously higher blood concentration for m-DNB neurotoxicity. Thus the time 
factor plays an important role in m-DNB neurotoxicity once a threshold is exceeded. 
This study also showed that infusion can cause m-DNB accumulation in brain 
because the tissue/plasma ratio in brain after infusion was significantly higher than 
that after a bolus dose. This may have been because a constant blood concentration 
provided a constant source of m-DNB for metabolic activation td 
nitrosonitrobenzene. This might explain why split doses or infusion more readily 
produced brain lesions than a bolus dose (Philbert, et a/., 1987; Nolan, et al., 1995). 
This model may suggest that long-term exposing to a low level of m-DNB will 
increase the potential of neurotoxicity.
3.4.3 In vivo and in vitro metabolism of m-DNB
This study showed that 3-NA was the major metabolite of m-DNB phase I 
metabolism in vivo and in cultured cells. It was reported that 3-NA accounted for 74 
% radioactivity of dosed m-DNB in rat urine (Cossum and Rickert, 1985; McEuen 
and Miller, 1991). However after oral administration of m-DNB to F-344 rats, 3- 
aminoacetanilide (3-AA) excretion accounted for 21% of dosed m-DNB (Nystrom 
and Rickert, 1987). But 3-AA was not detected in either rat or hamster after ip
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administration (McEuen and Miller, 1991), nor after iv injection in the present 
study. This metabohc difference caused by different dosing routes suggests tiiat m- 
DNB after oral adm inistration could have been catalysed by the gastrointestinal tract 
microflora before absorption (Richert, 1987). This may explain why germ-free rats 
are more susceptible to m-DNB-induced neurotoxicity than conventional rats 
(Philbert, et al., 1987).
The present study shows that 3-NA in liver was 17-fbld higher than its parent 
compound, m-DNB and the half life of m-DNB in liver was significantly shorter 
than that in blood and other tissues, see table 3-2. These clearly indicate rapid 
transformation of m-DNB in liver. This is in agr eement with Cossum and Rickeit's 
findings that m-DNB is a P450-NADPH-reductase dependent substrate (Cossum 
and Rickert, 1985). Liver is rich in this enzyme system. Therefore it is easy to 
understand the rapid metabolism of m-DNB in liver. In addition, P450 enzyme 
systern generally distributes in many extrahepatic tissues. Lung, kidney, 
gastrointestinal mucosa, brain and spinal cord all possess P450 isoenzymes 
(Caldwell, 1995; Anandatheerthavarada, et al., 1993; Haglund, 1984). With in vitro 
studies, it has been demonstrated that besides liver, testis (Foster, 1987) and brain 
slices (Hu, et al., 1995) all have the ability to transform m-DNB into 3-NA. This 
study shows that cultured endothelial cells, astrocytes, or neuroblastomal cells were 
all able to metabolise m-DNB into 3-NA, see FIG 3-8 and 3-9. This study also 
shows that tiie distribution of 3-NA in CNS is similar to its parent compound, m- 
DNB. The distribution feature of 3-NA might reflect the in situ metabolism of m- 
DNB. This suggests that the in situ metabolism of m-DNB may play a important 
role in its elim ination from individual tissues, especially from CNS.
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It is difficult to estimate the metabolic rate of a foreign compound in 
individual tissues in vivo. However, integrating the concentrations of parent 
compound and its elimination half life as well as the concentration of metabolite 
enable us to estimate the relative metabolic activity of each individual tissue. The 
lowest level and the shortest half life of m-DNB together with the highest 3-NA 
level in liver clearly indicate the rapid metabolism of m-DNB in liver. 3-NA in testis 
was also significantly higher than m-DNB. 3-AN is different firom m-DNB in 
physiochemical properties. It is more water soluble than m-DNB. Testis contains 
more water and less lipids than liver and brain (Spector, 1956). Therefore the 
redistribution of 3-AN may partly contribute to the concentration of 3-NA in testis. 
On the other hand, the lowest level and the longest half life of m-DNB in testis 
indicate the slow metabolism of m-DNB in testis.
3.4.4 3-Nitrosonitrobenzene
3-Nitrosonitrobenzene is a common intermediate in the metabolism of either 
p~ or m-DNB (Cossum and Rickert, 1985). It is normally difficult to detect in vivo. 
But i^ e n  a high concentration of p- or m-DNB was co-cultured with microsomes,
4- or 3-NNB was detected at early incubation stage but not later (Cossum and 
Rickert, 1985). The present study found a similar metabolic phenomenon with m- 
DNB in the cultured endothelial cells or astrocytes. 3-NNB was present in 
endothelial cells or astrocytes at 4 hour incubation but not at 8 or 24 hour 
incubation, see FIG 3-9, 3-NNB could also be detected in brain slices incubated 
with m-DNB (Hu, et al., 1995). This evidence demonstrated that 3-NNB must have 
been produced during the mietabolism of m-DNB.
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In order to study the stability of 3-NNB, 3-NNB was spiked with the 
methanol extraction of fresh brain tissue or the brmn tissue dosed with m-DNB. To 
our surprise, 3-NNB was quickly degraded into 4-amino-2-nitrophenol in brain 
extraction. However, 3-NNB was stable in methanol. It was also stable in the 
extraction by 5 % TCA solution. This clearly suggested that there must be 
something in the extraction which can initiate the chemical reaction of 3-NNB and 
transforms it into 4-amino-2-nitrophenol. Further work has demonstrated that 
ascorbic acid can initiate above reaction in room temperature (personal 
communication from Hu, et a i, 1995). When equal molar ascorbic acid was added 
to the 3-NNB standard solution, 3-NNB was completely converted into 4-amino-i- 
nitrophenol. However, when glutathione (GSH) was added to the 3-NNB standard 
solution, 3-NNB was degraded into 3-NA. The evidence from this chemical reaction 
indicates that 3-NNB is normally difficult to detect in in vivo studies because 
ascorbic acid and GSH in normal tissues are sufficient to neutralise 3-NNB. On the 
other hand, if ascorbic acid is involved in the transformation of 3-NNB, 4-amino-2- 
nitrophenol should be detected in tissue extraction but, in fact, 4-amino-2- 
nitrophenol was not detected in vivo. Therefore ascorbic acid is unlikely to play an 
important role in neutralising 3-NNB. But GSH may be involved in the 
detoxification of 3-NNB. It has been demonstrated that depleting GSH in brain can 
increase the susceptibility of brain towards m-DNB (Hu, et al., 1996). Therefore, 
normally, 3-NNB can be quickly removed by GSH or/and other mechanism once it 
is produced. When the detoxification system fails to remove 3-NNB in time, it will 
accumulate in cells and cause damage.
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3.4.5 Metabolism of m-DNB and its neurotoxicity
m-DNB is converted into 3-nitroaniline (3-NA) through multiple steps, see 
FIG 3-1. It has been suggested that the process of conversion of an aromatic nitro 
group to an amine is likely to proceed through a number of reactive intermediates 
(Mason and Josephy, 1984). This study indicates that m-DNB is quickly converted 
to 3-NA in liver. m-DNB is a P450-NADPH-rediictase dependent substrate (Cossum 
and Rickert, 1985). Brain microsomal P450 levels are approximately 2.5-4 % of the 
specific contents of the hepatic tissue (Warner, 1988). But mitochondrial P450 
content in brain is significantly higher than the microsomal P450 content, in contrast 
to the liver (Walther, et a l, 1986; Bhagwar, et a l, 1995). Brain exhibits regional 
differences in the distribution of P450. Maximal P450 levels have been detected in 
olfactory lobes, cerebellum and brain stem (Anandatheerthavarada, et a l, 1993). On 
the other hand, the endogenous nucleophile, glutathione is relatively low in brain 
stem (Ravindranath, 1989). Therefore, the presence of high amounts of P450 in brain 
stem coupled with the low levels of glutathione may render the brain stem 
particularly vulnerable to damage through P450-mediated bioactivation of 
xenobiotics to reactive electrophüic metabolites (Ravindranath, 1995). This might 
explain the selective susceptibility of brain stem to m-DNB.
Cossum, et a l, (1987) showed that while a single ip dose of m-DNB caused 
testicular lesions, an equal molar dose of 3-NA had no effect when administered in 
vivo in conventional rats. But damage was produced by 3-NNB. In vivo and in vitro 
studies of the conjugated metabolite, 3-nitro^cetanilide (3-NAA) also showed no 
testicular toxicity (Foster, et a l, 1987; McEuen and Müler, 1991). In rat testicular 
cell culture, it has been demonstrated that 3-NNB is more toxic than m-DNB itself
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(Foster, et al., 1987). This might suggest that metabolic activation may be the 
common mechanism in either testicular toxicity or neurotoxicity induced by m- 
DNB. Thus, the results obtained from the infusion-lesion model ruay be explained 
by the toxic effect of m-DNB not directly depending on w-DNB level in the target 
site but more directly depending on the level of its toxic intermediate. The level ôf 
the toxic intermediate depends on two factors, its production rate and removal rate. 
It may not be proportional to the level of m-DNB because of the metabolic 
saturation. In this case, a lower concentration with a longer exposure time can 
provide a constant source of activated intermediate and hence have more toxic 
potential than a higher concentration with a shorter exposure time. This might 
explain how dosing regimen modifies susceptibility of rats to w-DNB.
3.4.6 Summary
This study investigated the metabolic and phaimaookinetic behaviour of m- 
DNB in individual target tissues, and an infusion-lesion model of m-DMB-induced 
neurotoxicity.
1. m-DNB reached higher concentrations in the vulnerable regions in the brain stem 
than in other parts in the CNS. m-DNB in different tissues follows different 
pharmacokinetic process after systematic exposure to a single dose of m-DNB. 
The half lives in brain regions are similar to that in blood but different from those 
in testis or liver. This indicates that blood concentration of m-DNB is important 
in maintaining a certain level of it in brain.
2. In vivo and in vitro metabolism studies show that m-DNB was mainly 
transformed into 3-NA. The activated intermediate, 3-NNB, was detected in the
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cultured astrocytes and endothelial cells. This indicates that 3-NNB must have 
been produced during m-DNB metabolism.
3. The infusion-lesion model has revealed that once a blood threshold of lesion is 
exceeded, the time over which m-DNB exceeds its threshold toxic level is crucial 
in producing brain lesion, but not a instantaneous h i^ e r concentration. This 
suggests that, up to a point, long-term exposure to a low level of m-DNB will 
increase the potential of neurotoxicity.
In conclusion, the metabolic and pharmacokinetic factors of m-DNB have a 
strong influence on its neurotoxicity. Absorbed m-DNB is metabolised in tissues 
before it is eliminated from body. This biotransformation is a important way for 
tissues to eliminate the lipophilic compound and, on the other hand» produces an 
activated intermediate, 3-NNB, which can cause cell damages if it is not cleared by 
cells. Glutathione can reduce 3-NNB to 3-nitroaniline and detoxify it. Brain stem 
contains relatively lower level of glutathione and higher level of P450 than some 
other regions in CNS and, therefore, is particularly vulnerable to damage through 
P450-mediated bioactivation of m^DNB. Long-tenn exposure to a certain low level 
of m-DNB is readily able to produce neurotoxicity. This may be due to the 
depletion of glutathione or other factors. Therefore the dosing regimen can 
significantly modify the pharmacokinetics of m-DNB and hence modify its 
neurotoxicity.
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SECTION 4. GENERAL DISCUSSION
4.1 Introduction
Over 100 years ago, a German pathologist, Franz Nissl observed that 
particular agents consistently resulted in characteristic injury to neurons of defined 
areas of the brain. His studies stimulated later pathologists to propose the hypothesis 
that the cells in particular regions of the brain, by virtue of unique biochemical or 
anatomic features, are vulnerable to intoxication by certain classes of xenobiotics 
and not by others. This tiieory became known as pathoclisis (Vogt, et al., 1922). 
The basis of pathoclisis is the tremendous regional heterogeneity in brain. Each 
region may have its distinct physiological and biochemical properties which, in turn, 
may have a distinct response towards neurotoxicants. This part of the thesis will 
discuss the aspects of metabolism and pharmacokinetics in the selective 
neurotoxicities induced by BPAU and m-DNB,
4.2 Distribution and neurotoxicity
Both BPAU and m-DNB can induce selective neurotoxicities in defined 
regions or parts in the nervous system. BPAU can produce delayed ataxia The 
typical onset of BPAU induced delayed ataxia took place at day 7 or afterwards 
after dosing. The major pathological damages can be observed in spinal cord and 
peripheral nerves in rats after either a single higher dose or repeated lower doses of 
BPAU (Cavanagh, til., 1968; Fossom, et al., 1985). m-DNB can cause brain stem 
damage in the rats after repeated lower doses or infusion (Philbert, et al., 1987;
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Nülauel, ei al., 1995). In common, both compounds reached highei levels at then 
target sites within the CNS.
The distribution patterns of xenobiotics mainly depends on their 
physiochemical properties and lipid content of individual tissues. Both BPAU and 
m-DNB are lipophilic compounds. The central nervous system (CNS) is rich in 
lipids. Therefore, lipophilic compounds readilly distribute to and accumulate in 
CNS. On the other hand, the CNS is far from a homogenous organ in lipid content 
as well as histological structure and physiological function. It has been 
demonstrated that the regional lipid content of brain correlates well with the 
regional distribution levels of toluene, a lipophilic neurotoxicant (Gospe, et al., 
1988). The regional distribution of m-DNB is similar to toluene. Thus all toxic^ts 
have their own physiological properties and distribution patterns and hence may 
produce distinct effects. Obviously, the distribution features of BPAU and m DNB 
at least partly play a role in their selective neurotoxicities.
4.3 Duration and neurotoxicity
Duration of a toxicant in target sites is another important factor in chemical- 
induced lesions. Dosing regimen, in fact, mainly modifies the duration of a toxicant 
in target sites. This study showed that a single dose of 30 mg/kg of m-DNB can not 
induce neurotoxicity (Nolan, et al., 1995). However, if the same total dose is split 
into 4 smaller doses within 24 hours, brain damage is produced (Philbert, et al., 
1987). The half lives of m-DNB in different regions of CNS are similar to that in 
blood. This indicates that the elimination rate of m-DNB in brain parallel with that 
in blood. Therefore, blood concentration is important in maintaining a certain level
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of m-DNB in brain and in producing neurotoxicity. This study has demonstrated, in 
the infiision-lesion model, that once a concentration threshold is exceeded, a certain 
minimum time threshold is also needed, it being easier to produce lesion by infusion 
than with à instant high blood concentration (see Fig. 3-7 and table 3-4&5, Section 
3). In addition, this study has also shown that the distribution pattern of a single iv 
dose of 10 mg/kg m-DNB in different regions of brain was similar to that of an 
infusion but the tissue/plasma ratios in infusion were significantly higher in some 
regions than that in single dose, see FIG 3-6. This implies that the dosing regimen 
does not influence the distribution pattern of m-DNB within the brain, but infusion 
allows m-DNB to accumulate in brain in comparison with a single bolus dose and 
hence prolongs exposure time. This may partly explain why repeated doses or 
infusion of m-DNB is easier to produce lesion tiian a single dose (Philbert, et al., 
1987; Nolanet, et al., 1995).
The similar phenomenon was also seen in BPAU-induced neuropathy. A 
single dose of either 100, 200 or 400 mg/kg BPAU produced different degrees of 
delayed ataxia within 1-2 week(s) after dosing (Diezel and Quadbeck, 1960; 
Canavagh, 1968; Fossom, 1985; Nagata, 1986). However, rats were given a daily 
dose of either 40 or 10 mg/kg BPAU for two or six months induced the similar 
clinical ataxia to that in single higher doses (Fossom, et al., 1985). This obviously 
indicates that the repeated lower daily doses allow BPAU or its toxic effects to 
accumulate in target sites and prolong exposure time until a certain lesion threshold 
is exceeded and produce lesions. Therefore, a toxicant may have its own distinct 
distribution feature no matter how it is dosed but the dosing regimen can 
dramatically change the duration of a toxicant and hence can modify its toxicity.
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On the other hand, the pharmacokinetics of a toxicant in différait tissues 
varies. This may greatly modify the susceptibility of individual tissues to the 
toxicant. The present study has shown that, after initial distribution, the half lives of 
BPAU in brain and spinal cord are longer than that in blood, muscle or liver (see 
table 2-1, Section 2). m-DNB is a multi-target toxicant. Testis is more susceptible 
than other tissues. A single dose of 25 mg/kg m-DNB is high enough to produce 
testicular toxicity (Linder, et al., 1990). In agreement with this, the half life of m- 
DNB in testis was longer than in other tissues (see table 3-2, Section 3). Thus the 
pharmacokinetic behavior of a toxicant in individual tissues, in fact, is a matter of 
its duration in these tissues and hence modifies their susceptibility to the toxicant.
In addition, some factors such as age and metabolic inhibitors can modify the 
elimination of a toxicant and, therefore, modify the toxicity of the toxicant. The 
present study has demonstrated that the elimination of BPAU fi*om spinal cord in 1- 
year old rats, which are more susceptible to BPAU neurotoxicity than young ones 
(Chen and Cavanagh, 1971), was slower than 6-week old rats (see 2.3.5.2, Section 
2). PMSF interfered with BPAU metabolism and prolonged BPAU half lives in 
target sites and hence intensified BPAU-induced delayed ataxia (see 2.3.4, Section 
2).
In brieL the persistence, or maintaining time of a certain level, of a toxicant 
in target sites is an important factor in the susceptibility of individual tissues to 
toxicants. Dosing regimen, the physiological and biochemical properties of 
individual tissues and some factors can influence the duration of neurotoxicants and 
hence modify their neurotoxicities.
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Another example of time-dependent neurotoxicity is provided by
organophosphates. A distinctive feature of the toxicology of organophosphorus
agents is that, because of the covalent nature of the enzyme-organophosphate
reaction and of the covalent nature of the ageing reaction, the extent of their
biological effects is dependent on product of both concentration and time (Johnson,
1992). This is contrast to the reversible equilibrium reactions commonly seen in
pharmacology, which eventually come to a time-independent steady state. Thus with
organophosphorus agents . high concentration, short time effects and low
concentration, long time effects can be equivalent. This gives a special significance
to the rate ôf biological disposal of organophosphates, which can not only limit the
duration, but also the severity of effects.
Several mechanisms may be involved in the toxic damage due to the
persistence of a toxicant in target sites. We assume that any cells have their own
tolerant limits or thresholds to a particular toxicant. Long-term exposing to a certain
level of a toxicant will allow no time for cells to recoveiy and surpass the tolerant
limits of cells due to the depletion of endogenous detoxicants, such as glutathione
depletion which may result in free radical mediated damage (Halliwell, 1989, 1992),
and prolonged specific enzyme inhibition which wül disturb normal fimctions of
cells. Therefore, persistence of a neurotoxicant in target sites is an important aspect
in producing neurotoxicity.
4.4 Metabolism and neurotoxicity
Metabolism is the process whereby body actively acts on xenobiotics. Non 
polar, highly lipophilic compounds may be retained tor longer periods in tissue
lipids since these are relatively low in xenobiotic metabolic capacity (Caldwell, et 
al., 1995). Most of these compounds may undergo enzymatic metabolism which 
may introduce or uncover a functional group suitable for subsequent conjugation or 
for excretion. However, the introduced functional group may greatly change both 
the physicochemical properties and biological effect of a toxicant. As a result, its 
toxicity may be reduced or increased. The increase of biological effect after 
metabolism is also called metabolic activation (Caldwell, et al., 1995),
Metabolic activation is believed to play an important role in m-DNB-induced 
testicular toxicity (Nystrom and Richert, 1987). By in vitro study of testicular 
toxicity, it has been demonstrated that 3-NNB, a intermediate of m-DNB, is more 
toxic than m-DNB itself (Foster, et al., 1987). The metabolites of m-DNB, 3-NA 
and 3-NAA did not induce testicular lesions (Foster et al, 1987; McEuen and Miller, 
1991). 3-NNB is a important step of m-DNB metabolism and it is transformed into 
3-NA (see FIG 3-1, Section 3). Therefore the present of 3-NA indicates that 3-NNB 
must have been produced during m-DNB metabolism. Chemically, 3-NNB is a 
reactive intermediate. Our in vivo and in vitro studies have demonstrate that brain 
tissue can actively metabolize m-DNB (see Section 3). Therefore m-DNB induced 
neurotoxicity is believed to be caüsed by its activated intermediate(s). This may 
explain why a lower blood concentration of m-DNB maintained a longer time is 
more neurotoxic than a more transient higher concentration (see Fig. 3-7). This 
phenomenon may indicate that m-DNB-induced neurotoxicity is not directly caused 
by m-DNB itself  ^but its activated intermediate. A higher level of m-DNB may not 
increase the product of such an intermediate if there is a metabolic saturation. 
However, a certain level of m-DNB maintained over a longer time could allow the
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activated intennediate or its lesion to accumulate in cells, and hence produce 
neurotoxicity.
m-DNB is a P450-NADPH-reductase dependent substrate (Cossum and 
Rickert, 1985). P450 levels in olfactory lobes, cerebellum and brain stem are higher 
than in other regions (Anandatheerthavarada, et al., 1993). In vitro study has shown 
that glutathione can directly degrade 3-NNB into 3-NA. Artificially depleting 
glutathione in brain stem increased regional susceptibility to m-DNB (personal 
communication with Hu, 1996). This indicates that glutathione may play an 
important role in protecting brain from m-DNB-induced damage. The presence of 
high amounts of P450 and relatively low levels of glutathione in the brain stem 
(Ravindranath, ct al., 1989), may render the brain stem particularly vulnerable to the 
damage through P450-mediated bioactivation of m-DNB. In the present study, the 
activated intermediate of m-DNB, 3-NNB was detected by in vitro study (see 
3.3.3.1, Section 3). Therefore, metabolic activation is likely to involve in m-DNB- 
induced neurotoxic damage.
Metabolism also plays a role in BPAU-induced neurotoxicity. The current 
study has primarily demonstrated that BPAU is metabolised to M l, M2 and M3 in 
vivo (see Fig. 2-15, Section 2). Although there is no, so far, direct data to show the 
toxicity of M l, the following three points may suggest that the M l pathway may 
increase BPAU neurotoxicity whereas M2 pathway plays a important role in BPAU 
detoxification. The first evidence is that pharmacokinetically. M l reached a high 
levels in tissues and stayed in tissues much longer than its parent compound, BPAU 
(see Section 2), whereas M2 reached very high concentration in serum but very low 
levels in tissues. These two metabolites are formed via different pathways and can
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be excreted through urine. The distribution pattern of these two metabolites clearly 
suggested their different biological importance. The second evidence was from the 
promotion study of BPAU neuropathy by PMSF. PMSF which can significantly 
intensify BPAU-induced delayed ataxia interferes with BPAU metabolism. It 
increased BPAU and M l levels in tissues and decreased M2 concentration in serum. 
PMSF inhibited die M2 pathway and increased M l production and parent 
accumulation and hCnce increased BPAU neurotoxicity (see Section2). The third 
evidence was obtained from the comparison study of age-dependent metabolism of 
BPAU. It was reported that adult rats are more susceptible to BPAU than young 
ones (Chen and Cavanagh, 1971). This study has demonstrated that adult rats 
produce more M l and retain more parent but less M2 than young rats (see Section 
2). Therefore, BPAU metabolism plays ^n important role in its delayed 
neurotoxicity either by influencing the concentration of parent BPAU iu tissues, or 
possibly by generating a toxic metabolite.
In conclusion, this study clearly shows that BPAU and m-DNB undergo 
metabolism before they are excreted. Their neurotoxicities closely related to their 
metabolism. This may suggest a common process for the neurotoxicities induced by 
some lipophilic neurotoxicants.
4.5 Metabolic interaction and neurotoxic synergism
Co^exposure to two or more compounds can produce a more severe 
neurotoxicity than exposure to these individual compounds. The most rescent 
disastrous incidence in man which may be related to such effect is the Gulf-War 
syndrome which claimed approximately 30,000 victims out of three quarter of a
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million troops (Aboudonia, et a l, 1996). It bas now been demonstrated in hens that 
co-exposure to just sub-toxic levels of a anti-nerve agent ^pyridostigmine bromide), 
the insect repellent DEBT, and the insecticide permethrin produced more severe 
neurotoxicity than exposure to these individual agents (Aboudonia, et al., 1996). It 
is possible that exposure to multiple agents was responsible for Gulf-war syndrome 
(Aboudonia, et al., 1996) although it is far from clear if the levels of exposure 
encountered by troops would have been high enough to allow the pharmacokinetic 
saturation effects seen in the hen studies. Another phenomenon which has puzzled 
neurotoxicologists for the last decade is the ’promotion'. This term was originally 
used to describe the phenomenon that organophosphorous compound induced 
delayed neuropathy (OPIDN) can be promoted (or enhanced) by some non­
neurotoxicants (Lotti, et al., 1991; Veronesi and Paddla, 1985; Pope and Padilla, 
1990; Lotti, et al., 1991). Phenylmethanesulfonyl fluoride (PMSF) is a commonly 
used potentiator. The mechanism of OPIDN is believed to relate to irreversible 
inhibition and subsequent aging of NTE. Similarly to OPs, PMSF can also inhibit 
NTE, but itself does not induce delayed neuropathy. When PMSF was given before 
OP administration, it could protect animals from OPIDN. This protective effect of 
PMSF was thought to be due to a reversible pre-occupation of NTE to prevent it 
from subsequently binding irreversible NTE inhibitor. However, when it was given 
after OPs, it could enhance OPIDN. Interestingly, /7-bromophenylacetylurea 
(BPAU) can not inhibit NTE (Johnson, 1969) but can induce clinically delayed 
ataxia in rats closely similar to OPIDN in chicken (Cavanagh, et al., 1968). BPAU- 
induced delayed neuropathy can also be intensified by PMSF (Johnson and Ray, 
1992; Xu, et al., 1993). This suggests that PMSF can also act on a site other than
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NTE to promote either OPIDN (Fioroni, et al., 1995) or BPAU-induced delayed 
neuropathy. The promotion site is still unknown in the case of OPIDN.
The current study has shown that, in the case of BPAU, the promotion of 
delayed neuropathy by PMSF is due to the metabolic interaction between the two 
compounds (see Fig. 2-24). PMSF can inhibit the M2 pathway, which plays an 
important role in BPAU detoxification, leading to parent accumulation and 
increased M l production (which might be a toxic metabolite) and hence intensified 
BPAU neurotoxicity. PMSF is well known as a protease inhibitor. This study 
clearly indicates that PMSF may also inhibit enzymes which are involved in 
xenobiotic metabolism.
In short, neurotoxic synergy is a particular phenomenon seen when animals 
or humans are simultaneously co-exposed to two or more chemicals. Previous 
studies have not established a understandable explanation for its mechanism. This 
study demonstrated a distinct model of metabolic interaction and promotion of 
neuropathy. It may have general importance in understanding the promotion 
phenomenon of neurotoxicities.
4.6 Summary
Metabolic and pharmacokinetic factors in the neurotoxicities of BPAU and 
m-DNB were investigated. The approach in this study is different fi*om conventional 
studies focusing strictly on the site of action. It focuses instead on the 
pharmacokinetic behaviour of the neurotoxicants, BPAU and m-DNB, and 
metabolic factors in their neurotoxicities.
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1. The distribution of the two neurotoxicants is a relatively passive process which 
depends on their physicochemical properties and the biochemical and 
physiological institutions of individual target sites. In common, both BPAU and 
m-DNB are lipophilic compounds and they reached higher concentrations in 
target sites in the CNS. In contrast, the metabolic processes of the two 
neurotoxicants in body are active process. These processes may play a crucial 
role for some neurotoxicants to produce toxic damage. Both BPAU and m-DNB 
are metabolised in tissues before they are excreted. Their metabolism closely 
relates to their neurotoxicities.
2. The identification and characterization of BPAU metabolites. M l, M2 and M3, 
represent the significant progress in this study. Two major metabolic pathways 
have been proposed: Mlc= BPAU =>M2. M3 may be formed either directly from 
BPAU or via M l. PMSF increased M l and decreased M2, with a net reduction in 
BPAU disposal, and hence intensified BPAU-induced delayed neuropathy. On 
this basis, the metabolic interaction between BPAU and PMSF was clarified and 
an understandable mechanism of the promotion of BPAU-induced delayed 
neuropathy by PMSF was established. It may have general importance in 
understanding neurotoxic synergism between two or more toxicants. The study of 
BPAU metabolism in the rats of different ages showed that 1-year old rats 
produced more M l and less M2 than 6-week old rats. This also provided a 
mechanistic understanding in age-dependent susceptibility to BPAU.
3. In vivo and in vitro studies have demonstrated that m-DNB can be metabolised in 
brain. The major metabolite is 3-NA. The activated intermediate 3-NNB was 
detected in cell culture. This suggests that 3-NNB must have been produced
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during m-DNB metabolism and may play an important role in m-DNB-induced 
neurotoxicity. The infusion-lesion model has revealed that once a threshold of m- 
DNB is exceeded, the time during which m-DNB is maintained above the 
threshold is an important factor in producing brain lesion, rather than a higher 
instantaneous blood concentration. This model may explain why repeated doses 
or infusion more readily induce neurotoxicity and suggests longrtenn exposure to 
a lower level of m-DNB wül increase the potential of neurotoxicity.
In conclusion, pharmacokinetic factors play important roles in inducing and 
modifying the neurotoxicities induced by either BPAU and m-DNB. It suggests that 
metabolism and pharmacokinetic approaches have a great potential in understanding 
the mechanism of the neurotoxicities induced by neurotoxicants.
4.7 Possible future studies
4.7.1 BPAU enzymatic metabolism
As indicated in Section 2, BPAU was metabolized in vivo into M l, M2 and 
M3. PMSF can inhibit the M2 pathway and increase the M l pathway and hence 
exaggerate BPAU neurotoxicity. Furthermore, old rats which are susceptible to 
BPAU neurotoxicity produced more M l and less M2 than younger ones. It would 
be interesting to know what enzymes are involved in the two metabolic pathways 
and what are their biological importance in the detoxification of toxicants. It may 
have general importance in studying the potential intoxication or detoxification of 
drugs or other xenobiotics.
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4.7.2 The biochemical mechanism of brain cells tolerating m-DNB-induced 
neurotoxicity
The current study has revealed that brain damage induced by m-DNB 
depends on not only its concentration but also the time during which a certain 
concentration is maintained. In other words, there exist two factors, concentration 
threshold and time threshold, in m-DNB-induced neurotoxicity. Conventional 
studies pay much attention to dosage which relates to the concentration in target 
sites but little attention to the time threshold which may represent the critical factor 
for target cells. The tolerance limit varies from tissue to tissue and from species to 
species of animals. The question is what mechanism lies behind the toleration or 
susceptibility of individual tissues to m-DNB. The regional distribution of some 
enzyme systems, the cellular specificity of the toxicant, and the biochemical 
mechanism of detoxification in target cells are far from clear. These factors are 
important in understanding the interaction between target cells and m-DNB, or 
related compounds. Therefore some further work is needed on these areas to clarify 
the response, toleration and recoveiy or degeneration of target cells after m-DNB 
exposure.
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A-L BPAU
A-I-A. A illustration of the model analysis and exponential regressions of BPAU 
pharmacokinetics.
Following a single ip dose of 150 mg/kg BPAU, the absorption and elimination 
processes of BPAU showed the first order kinetics in both serum and individual tissues. 
Therefore, the pharmacokinetic data of BPAU fi-om serum is taken as a example here to 
show its model analysis. FIG A-1 illustrates the semi-logrithmic versus concentration-time 
curve of BPAU in serum. The data is best fitted Avith an one-compartment model.
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FIG A-1. A illustration of non-linear fitting and model analysis of BPAU 
pharmacokinetics —  data from serum after a single ip dose.
The exponential regressions of BPAU pharmacokinetic data and calculations of 
elimination rate constants were carried out on a computer using the statistical software
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MINITAB 10. The rate constants and half lives Were calculated according to the equations 
given by Gibaldi & Perrier (1982) and the standard error of rate constant in each tissue was 
obtained using the method given by Mead & Cumow (1987). The exponential regression of 
the absorption phase was done using the residual method given by Gibaldi & Perrier (1982).
A-I-B. Calculations of the phanqacoldnetic parameters of BPAU in serum and 
individual tissues after a single ip dose
A-I-B-a. Serum
1. Correlation and regression of pharmacokinetic data:
r = -0.967; r^  = 0.935. p<0.001.
A = Co = 11.39 (|ig/ml)
B = -0.0255
k = 2.303 X 0.0255-0.0587 
where r is the correlation coefficient, A is the concentration when time t=0, B is the slope, 
and k is the elimination rate constant..
2. Analysis of variation of BPAU exponential regression:
The results of variation analysis are shown in Table A-1.
Table A-1. Analysis of variation of BPAU exponential regression in serum.
Source DF SS MS F P
Régression 1 3.447 3.447 14.0 0.001
Error 22 5.406 0.246*
Total 23 8.853
*: Stc.
3. Standard error of slope:
S %  = >/( Ste /Sa) = V(0.246/12672) = 0.0044
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where SE(k) is the standard error of slope; Stc is the mean of the error of square variance 
(see Table A-1 : *); Stt is the sum of squares of time.
k« =  2.303SE(k) = 2.303 x 0.0044 = 0.0101 
where k* is the standard error of rate constant.
4. Half life
tia = 0.693/k ± [0.693/k -  0.693/(k+k^)]
= 0.693/0.0587 ± [0.693/0.0587 -  0.693/(0.0587+0.0101)]
= 11.8 ± 1.7(h)
A-I-B-b. Brain
1. Correlation and regression of pharmacokinetic data:
r = -0.939; ^  = 0.882. p<0.001.
A = Co -  28.3 (ng/g)
B = -0.0194
k = 2.303 X 0.0194 -  0.0447
2. Analysis of variation of BPAU exponential regression:
The results of variation analysis are show in Table A-2.
Table A-2. Analysis of variation of BPAU exponential regression in brain
Source DF SS MS F P
Regression 1 4.774 4.774 163.5 0.000
Error 22 0.6425 0.029*
Total
*. c
23 5.416
3. Standard error of slope:
SE(k) =  V( Stt /Stt) = V(0.029/12672) = 0.0015
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= 2.303SE(k) = 2.303 x 0.0015 = 0.0035
4. Half life
tm = 0.693/k ± [0.693/k -  0.693/(k+k«)]
= 0.693/0.0447 ± [0.693/0.0447 -  0.693/(0.0447+0.0035)]
= 15.5 ± 1.1(h)
A-I-B-e. Spinal cord
1. Correlation and regression of pharmacokinetic data:
r = -0.917; r^  = 0.841. p<0.001.
A = Co = 44.3 (pg/g)
B = -0.0193
k = 2.303 X 0.0193 = 0.0444
2. Analysis of variation of BPAU exponential regression:
The results of variation analysis are shown in Table A-3.
Table A-3, Analysis of variation of BPAU exponential regression in spinal cord
Source DF SS MS F P
Regression 1 4.696 4.696 116.9 0.000
Error 22 0.8834 0.040*
Total 23 5.579
Stc.
3. Standard error of slope:
SE(k) =  V( Stt /Stt) = V(0.040/12672) = 0.0018 
ktt = 2.303SEflc) -  2.303 x 0.0018 = 0.0041
4. Half life
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tw = 0.693/k ± [0.693/k -  0.693/(k+k«)]
= 0.693/0.0444 ± [0.693/0.0444 -  0.693/(0.0444+0.0041)]
= 15.6 ± 1.3(h)
A-I-B-d. Liver
1. Correlation and regression of pharmacokinetic data:
r = -0.887; ^  = 0.787. jXO.OOl.
A = Co = 42.7 (|ig/g)
B = -0,0269
k = 2.303 X 0.0269 = 0.062
2. Analysis of variation of BPAU exponential régression:
The results of variation analysis are shown in Table A-4.
Table A-4. Analysis of variation of BPAU exponential regression in liver.
Source DF SS MS F P
Regression 1 8.386 8.386 136.6 0.000
Error 22 1.351 0.061*
Total 23 9.737
Stc.
3. Standard error of slope:
SE® = V( Stt /Stt) = -7(0.061/12672) = 0.0022 
k . = 2.303 SE(t) = 2.303 x 6.0022 = 0.0051
4. Half life
Xm = 0.693/k ± [0.693/k -  0.693/(k+ktt)]
= 0.693/0.062 ± [0.693/0.062 -  0.693/(0.062+0.0051)] 
= 11.2± 1.1(h)
16S
A-I-B-e. Muscle
1. Correlation and regression of pharmacokinetic data:
r = -0.976; r^  = 0.953. p<0.001.
A = Co= 17.6 (pg/g)
B = -0,0259
k = 2.303 X 0.0259 = 0.0597
2. Analysis of variation ofiBPAU exponential regression:
The results of variation analysis are shown in Table A-5.
Table A-5. Analysis of variation of BPAU exponential regression in muscle.
Source DF SS MS F P
Regression 1 6.923 6.923 42.2 0.000
Error 22 3.608 0.164*
Total 23 10.531
Stc.
3. Standard error of slope:
SE(k) = V( Stc /Stt) = V (0.164/12672) = 0.0036 
k* = 2.303SE(k) =  2.303 x 0.0036 = 0.0082
4. Half life
ti/2 = 0.693/k ± [0.693/k -  0.693/(k+k«,)]
= 0.693/0.0597 ± [0.693/0.0597- 0.693/(0.0597+0.0082)] 
= 11.6 ± 1.4(h)
A-I-B-f. BPAU only, in whole blood after a single oral dose
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1. Correlation and regression of pharmacokinetic data; 
r =  -0.8725; =  0.761. p<0.001.
A  =  Co=14.8(M.g/ml)
B  = .0.032
k =  2.303 X 0.032 =  0.074
2. Analyas o f  variation o f  BPAU exponential regression:
The results o f  variation analyris are shown in Table A-6.
o f  exponential regression in blood-BPAU+PMSF
Table A-6. Analysis o f  the variation
Source
Regression
Error
3. Standard error o f  slope:
SE(k) = -7( Stt /Stt) = -7(0.021/3888) = 0.0023 
kw = 2.303SE(k) = 2.303 x 0.0023 = 0.0054
4. Half life
tu2 = 0.693/k ±  [0.693/k -  0.693/(k+ktt)l
= 0.693/0.074 ±  [0.693/0.074 -  0.693/(0.074+0.0054)]
= 9.4 ±  0.7 (h)
A-I-B-g. BPAU + PMSF, in whole blood after a single oral dose 
1. Correlation and regression o f  pharmacokinetic data.
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r = -Ô.8892; = 0.7906. p<0.001.
A = Co = 11.2 (pg/ml)
B = -0.0147
k = 2.303 X 0.0147.= 0.034
2. Analysis of variation of BPAU exponential regression:
The results of variation analysis are shown in Table A-7.
Table A-7. Analysis of the variation of exponential regression in blood—BPAU only.
Source DF . SS MS F P
Regression 1 0.809 0.089 29.51 0.000
Error 16 0.438 0.027*
Total 17 1.247
Stc.
3. Standard error of slope:
S%) = V( Stt /Stt) = V(0.027/3888) = 0.0026 
ktt = 2.303SE(k) = 2.303 x 0.0026 = 0.006
4. Half life
tic = 0.693/k ± [0.693/k -  0.693/(k+k»)]
= 0.693/0.0339 ± [0.693/0.0339 -  0.693/(0.0339+0.006)] 
= 20.4 ±3.1 (h)
A-I-C. Area under concentration-time curve (AUC) of BPAU
In tissues, the pharmacokinetic characteristics of BPAU are similar to that in blood 
after ip or po dose. There is an absorption phase which allows the xenobiotic to enter
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tissues from blood. Therefore, the estimation of AUC in tissues is different from that in 
blood after iv dose. The estimation of AUC in each tissue is calculated using the trapezoidal 
rule (Martin, 1986). The trapezoidal rule is illustrated in FIG A-2, here the data from serum 
is plotted and taken as a example.
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FIG A-2. A illustration of AUC calculation of BPAU in individual tissue using 
trapezoidal rule— data from spinal cord after a single ip dose.
Â-I-C-CL Serum, ip dose 
AUC = (0+6.6)/2 + (6.6+8.3)/2 + 2(8.3+10.7)/2 + 2(10.7+10.7)/2 + 6(10.7+5.5)/2 + 
6(5.5+3.8)/2 + 6(3.8+2.7)/2 + 24(2.7+0.94)72 + 24(0.94+0.2)72 
= 204.5 (pg. ml"\ h'^ )
Arl-C-b. Brain, ip dose
172
AUC = (0+16.7)/2 + (16.7+17.5)/2 + 2(17.5+24.1)/2 + 2(24.1+30.2)/2 + 6(30.2+18.1)/2 
+ 6(18.1+9.8)/2 + 6(9.8+8.7)/2 + 24(8.7+5.0)/2 + 24(5.0+1.l)/2 
= 643.1 (ng. g‘‘.h'*)
A-l-C-c. Spinal cord, ip dose 
AUC = (0+23.l)/2 + (23.1+26.6)72 + 2(26.6+38.2)72 + (38.2+48.1)72 + 6(48.1+28.0)72 + 
6(28.0+15.3)72 + 6(15.3+13.9)72 + 24(13.9+ 6.5)72 + 24(6.5+2.2)72 
= 982.5(ng.g‘.h»)
A-I-C-d Liver, ip dose 
AUC = (0+24.1)72 + (24.1+29.1)72 + 2(29.1+38.0)72 + 2(38.0+ 38.4)72 + 6(38.4+22.1)72 
+ 6(22.1+13.6)72 + 6(13.6+10.4)72 + 24(10.4+3.9)72 + 24(3.9+0.7)72
= 769.6 ( n è g ‘. h ‘)
A-I-C-e, Muscle, ip dose 
AUC = (0+8.5)72 + (8.5+9.8)72 + 2(9.8+10.3)72 + 2(10.3+12.5)72 + 6(12.5+11.2)72 + 
6(11.2+5.1)72 + 6(5.1+4.3)72 + 24(4.3+1.5)72 + 24(1.5+0.2)72 
= 294.5 (pg. g '\ h'^ )
A-I-C-f. BPAU alone, in whole blood — oral dose 
AUC = 6(0+9.48)72 + 6(9.48+6.48)72 + 6(6.48+2.66)72 
= 103.7 (pg. ml'\ h'^ )
A-I-C~g. BPAU + PMSF, in whole blood — oral dose 
AUC = 6(0+9.64)72 + 6(9.64+8.96)72 + 6(8.96+4.58)72 + 24(4.58 + 1.84)72 
-  202.4 (pg. ml"\ h'^ )
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A-IL ifi-DNB
A-H-A. Model detennination of m-DNB pharmacokinetics
Following a single ip dose of 10 mg/kg m-DNB, the absorption and elimination 
processes of BPAU showed the first order kinetics in both serum and individaul tissues. 
Therefore, the pharmacokihetic data of m-DNB fi-om serum is taken as a example here to 
show its model analysis. FIG A-3 illustrates the semi-logrithmic versus concentration-time 
curve of m-DNB in Serum. The data is best fitted with a one-compartment model.
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FIG A-3. A illustration of non-linear fitting and model analysis of m-DNB 
pharmacokinetics —  data from plasma after a single iv dose.
A-n-B. Exponential regressions and calculations of the pharmacokinetic parameters 
of m-DNB in serum and individual tissues after a single ip dose
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The exponential regressions of m-DNB pharmacokinetic data and calculations of 
elimination rate constants were carried out as described for BPAU, see A-I-B.
A-II-B-a Whole blood
1. Correlation and regression of pharmacokinetic data:
r = -0.975; = 0.951. p<0.001.
A = Co = 2.79 (|ig/ml)
B = -0.103
k = 2.303 X 0.103 = 0.237
2. Analysis of variation of m-DNB exponential regression:
The results of variation analysis are shown in Table A-8.
Table A-8. Analysis of variation of m-DNB exponential regression in whole blood.
Source DF SS MS F P
Regression 1 11.876 11.876 536.5 0.000
Error 28 0.620 0.022’"
Total 29 12.496
-
$ •: Stc-
3. Standard error of slope:
SE(k, = V( Stt /Stt) ^  V(0.022/l 111) = 0.0044 
where SEd) is the standard error of slop; Sk is the mean of the error of square variance (see 
Table A-8: *); Stt is the sum of squares of time.
k«, -  2.303SE(k) = 2.303 x 0.0044 = 0.0101 
where k» is the standard error of rate constant.
4. Half life
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tia = 0.693/k ± [0.693/k -  0.693/(k+k«)]
= 0.693/0.237 ± [0.693/0.237 -  0.693/(0.237+0.0101)]
= 2.9 ±0.1 (h)
A-II-B-b. Plasma
1. Correlation and regression of pharmacokinetic data:
r = -0.959; ?  = 0.0.920. p<0.001.
A = Co = 3.2 (pg/ml)
B = -0.0976
k = 2,303 X 0,0976 = 0,224
2. Analysis of variation of m-DNB exponential regression:
The results of variation analysis are shown in Table A-9.
Table A-9. Analysis of variation of m-DNB exponential regression in plasma.
Source DF SS MS F P
Regression 1 8.998 8.998 179.6 0.000
Error 23 1.152 0.050* •
Total 24 10.150
‘:Stc.
3. Standard error of slope:
SEd) = V( Ste /S«) = V(0.05/956) = 0.0072 
k.. = 2.303SEd) = 2.303 x 0.0072 = 0.0166
4. Half life
tia = 0.693/k ± [0.693/k -  0.693/(k+k«)]
= 0.693/0.224 ± [0.693/0.224 -  0.693/(0.224+0.0166.)]
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= 3.1 ± 0.2(h)
A-II-B-c. Medulla
1. Correlation and regression o f  pharmacokinetic data:
r =  -0.943; r^  =  0.889. p<0.001.
A  = Co = 3.7 (pg/g)
B = -0.1003
k = 2.303 X 0.1003 =0.231
2. Analysis o f  variation o f  m-DNB exponential regression:
The results o f  variation analysis are shown in Table A-10.
Table A-10. Analysis o f  variation o f  m-DNB exponential regression in medulla.
Source DF SS MS F P
Regression 1 9.610 9.610 187.5 0.000
Error 23 1.179 0.051*
Total 24 10.798
*: Stc.
3. Standard error of slope:
SEd) = V( Ste /S«) = V(0.051/956) = 0.0073 
k., = 2.303SEd) = 2.303 x 0.0073 = 0.0168
4. Half life
tia = 0.693/k ± [0.693/k -  0.693/Oc+k.)]
-0.693/0.231 ± [0.693/0.231 -  0.693/(0.231+0.0168)] 
= 3.0 ± 0.2(h)
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A-II-B-d Ports
1. Correlation and regression o f  pharmacokinetic data:
r = -0.959; ^  =  0.920. p<0.001.
A  = Co = 3.2 (pg/g)
B = -0.1033
k = 2 .303 x 0 ,1 0 3 3  = 0.238
2. Analysis o f  variation o f  m-DNB non-linear regression:
The results o f  variation analysis are shown in Table A -11.
Table A -11. Analysis o f  variation o f  m-DNB exponential regression in pons.
Soürpe DF SS MS F P
Regression 1 10.21 10.210 263 0.000
Error 23 0.98 0.039*
Total 24 11.10
*.: Stc-
3. Standard eiror of slope:
SEd) =  V( Ste /Stt) = V(0.039/956) = 0.0064 
k . = 2.303SEd) = 2.303 x 0.0064 = 0.015
4. Half life
tM = 0.693/k ± [0.693/k -  0.693/(k+k«)]
= 0.693/0.238 ± [0.693/0.238 -  0.693/(0.238+0.015)] 
= 2.9 ± 0.2 (h)
A-II-B-e. Coliculi
1. Correlation add regression of pharmacokinetic data:
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r =-0.969; r^  = 0.939. p<0.001.
A  = Co = 3.2 (pg/g)
B = -0.103
k = 2.303 x 0.103 = 0.237
2. Analysis o f  variation o f  m-DNB exponential regression:
The results o f  variation analysis are shown in Table A-12.
Table A-12. Analysis o f  variation o f  m-DNB exponential regression in coliculi.
Source DF SS MS F P
Regression 1 10.150 10.150 357 0.000
Error 23 0.653 0.028*
Total 24 10.803
* . Stc
3. Standard error of slope:
SEd) = V( Stt /Stt) = V(0.028/956) = 0.0055 
ktt = 2.303SEd) = 2.303 x 0.0055 = 0.0127
4. Half 116
tid = 0.693/k ± [0.693/k -  0.693/(k+ktt)]
= 0.693/0.237 ± [0.693/0.237 -  0.693/(0.237+0.0127)] 
= 2.9 ± 0.2(h)
Cerehelltan
1. Correlation and regression of pharmacokinetic data: 
r -  -0.938, ?  -  0.880. p<0.001.
A = Co = 2.9 (pg/g)
B  -  -0.099
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k = 2.303 X 0.099 = 0.228
2. Analysis of variation of m-DNB exponential regression:
The results of variation analysis are shown in Table A-13.
Table A-13. Analysis of variation of m-DNB exponential regression in cerebellum.
Source DF SS MS F P
Regression 1 9.37 9.370 165.6 0:000
Error 23 1.30 0.057*
Total 24 10.67
*. Stc-
3. Standard error of slope:
SEd) = V(Stt /Stt) = V(0.057/956) = 0.0077 
ktt = 2.303SEd) = 2.303 x 0.0077 = 0.018
4. Half life
tifl = 0.693/k ± [0.693/k -  0.693/(k+ktt)l
= 0.693/0.228 ± [0.693/0.228 -  0.693/(0.228+0.018)] 
= 3.0 + 0.2(h)
A-II-B-g. Cerebral cortex
1. Correlation and regression of pharmacokinetic data:
r = -0.915; ^  = 0.837. p<0.001.
A = Co = 2.07 (pg/g)
B = -0.088
k = 2.303 X 0.088 = 0.203
2. Analysis of variation of m-DNB exponential regression:
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The results of variation analysis are shown in Table A-14.
Table A-14. Analysis of Variation of m-DNB exponential regression in cerebral cortex.
Source DF SS MS F P
Regression 1 7.32 7.320 106 0.000
Error 23 1.59 0.069*
Total 24 8.91
Stc.
3. Standard error of slope:
SEd) = V( Sic /Stt) = V(0.069/956) = 0.0084 
ktt = 2.303SEd) = 2.303 x 0.0084 = 0.019
4. Half life
tia = 0.693/k ± [0.693/k -  0.693/(k+k»)]
= 0.693/0.203 ± [0.693/0.203 -  0.693/(0.203+0.019)] 
= 3.4 ± 0.3(h)
A-U-B-h. Spinal cord
1. Correlation and regression of pharmacokinetic data:
r = -0.940; r^  = 0.884. p<0.001.
A = Co = 4.1 (pg/g)
B = -0.096
k = 2.303 X 0.096 = 0.221
2. Analysis of variation of m-DNB exponential regression:
The results of variation analysis are shown in Table A-15.
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Table A-15. Analysis of variation of m-DNB exponential regression in spinal cord.
Source DF SS MS F P
Regression 1 13.20 13.200 176 0.000
Error 23 1.72 0.075*
Total 24 14.92
*: Stc.
3. Standard error of slope:
SEd, = V(Stt /Stt) = V(0.075/1418) = 0.023 
k« = 2.303SEd) = 2.303 x 0.023 = 0.053
4. Half life
= 0.693/k ± [0.693/k -  0.693/(k+k.)]
= 0.693/0.221 ± [0.693/0.221 -  0.693/(0.221+0.053)] 
= 3.1 ± 0.6(h)
A-II-B-i. Liver
1. Correlation and regression of pharmacokinetic data:
r = -0.904; r^  = 0.817. p<0.001.
A = Co = 0.46 (pg/g)
B = -0.237
k = 2.303 X 0.237 = 0.546
2. Analysis of variation of m-DNB exponential regression:
The results of variation analysis are shown in Table A-16.
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Table A-16. Analysis of variation of m-DNB exponential regression in liver.
Source DF SS MS F P
Regression 1 1.310 1.310 58.1 0.000
Error 14 0.293 0.023*
Total 15 1.603
*.: Stc.
3. Standard error of slope:
SEd) = V( Stt /Stt) = V(0.023/23.3) = 0.031 
ktt = 2,303SEd) = 2.303 x 0.031 = 0.071
4. Half life
tin = 0.693/k ± [0.693/k -  0.693/(k+k»)]
= 0.693/0.546 ± [0.693/0.546 -  0.693/(0.546+0.071)] 
= 1.3 ± 0.2(h)
A-Ii-B-J. Testis
1. Correlation and regression of pharmacokinetic data:
r = -0.7346; r^  = 0.540. p<0.0025.
A = Co = 0.438 (pg/g)
B = -0.066
k = 2.303 X 0.066 = 0.152
2. Analysis of variation of m-DNB exponential regression:
The results of variation analysis are shown in Table A-17.
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Table A-17. Analysis of Variation of m-DNB exponential regression in testis.
Source DF SS MS F P
Regression 1 0.623 0.623 23.21 0.000
Error 18 0.484 0.027*
Total 19 1.107
Stc-
3. Standard error of slope:
SEd) = V( Stt /Stt) = V(0.027/144) = 0.014 
ktt = 2.303SEd) = 2.303 x 0,014 = 0.032
4. Half life
tin = 0.693/k ± [0.693/k -  0.693/(k+ktt)]
= 0.693/0.152 ± [0.693/0.152 -  0.693/(0.152+0.032)] 
= 4.6 ± 0.8 (h)
A-II-C. The Area under concentration-time curves (AUC) of m-DNB in blood after a 
single iv dose
In one-compartment model, when a single iv dose of m-DNB is given, the AUC is 
estimated by the following equation (Gibaldi & Perrier, 1982).
AUC = dose/(V.^ ) 
where V is apparent distribution volume; k is elimination rate constant.
V = dose/Co 
where Co is the concentration when t = 0.
Dose = 2.76 (mg/rat)
Co = 2.79 (mg /L)
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V = 2.70/279 = 0.989 (L)
AUC = 2.76/(0.989 x 0.237)
= 11.8(mg.L'.h‘>
= 11.8 (ng.inl‘.h’')
A-H-D. The Area under concentration-time ciirves (AUC) of m-DNB in individual
tissues after a single iv dose
In tissues, the pharmacokinetics of w DNB are similar to blood after an oral dose. 
There is an absorption phase which allows m-DNB enter tissues from blood. Therefore, the 
estimation of AUC in tissues is different from that in blood after iv dosing. The estimation 
ôf AUC in each tissue is calculated using the trapezoidal rule (Martin, 1986). The 
trapezoidal rule is illustrated in FIG A-4. The concentration-time data of m-DNB from 
medulla is plotted and taken as a example.
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FIG A-4. A illustration of AUC calculation of m-DNB in individual tissues using 
trapezoidal rule —  data from pons after a single iv dose.
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A-II-D-a. Medulla
AUC = 0.5(0+2.016)/2 + 0.5(2.016+2.3 ll)/2 + (2.311+2.046)/2 + 2(2.046+ 1.992)/2 + 
4(1.992+0.803)72 +10(0.803+0.062)72 
= 17.7(ng.g‘.h-‘)
A-II-D-b. Pons
AUC = 0.5(0+1.524)72 + 0,5(1.524+2.113)72 + (2.113+1.597)72 + 2(1.597+ 1.55)72 + 
4(1.55+0.884)72+10(0.884+0.037)72 
= 15.8(jtg.g-‘.h:‘)
A-U-D-c. Coliculi
AUC = 0.5(0+1.948)72 + 0.5(1.948+2.028)72 + (2.028+1.653)72 + 2(1.653+1.578)72 + 
4(1.578+0.765)72 + 10(0.765 + 0.037)72 
= 15.2(ng.g‘.h-')
A-Tl-D-d. Cerebral cortéx 
AUC = 05(0+1 187)72 + 0.5(1.187+1.522)72 + (1.522+1.268)72 + 2(1.268+ 1.258)72 + 
4(1.258+0.586)72 +10(0.586+0.077)72 
= 11.9(ng.g-‘.h-‘)
A-Il-D-e. Cerebellum
AUC = 0.5(0+1.299)72 + 0.5(1.299+1.758)72 + (1.758+1.582)72 + 2(1.582 + 1.528)72 + 
4(1.528+0.745)72+10(0.745+0.05)72 
= 14,4 (pg.g \h '‘)
A-II-D-f. Spinal cord
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AUC =0.5((H-1.690)/2 + 0.5(1.69+2.042)/2 + (2.042+2.206)/2 + 2(2.206 + 2.158)/2 + 
4(2.158+0.984)72 + 10(0.984+0.067)72 
= 19.4 (ng.g\h ')
A-II-D-g. Liver
AUC = 0.5(0+0.18)72 +0,5(0.18+0.286)72 + (0.286+0.166)72 + 2(0.166+0.041)72 + 
4(0.041+0)72 
= 0.7(ng.g‘.h-')
A-II-D-h. Testis
AUC = 0.5(0+0.278)72 + 0.5(0.278+0.389)72 + (0.389+0.329)72 + 2(0.329+0.256)72 + 
4(0.256+0.145)72 +10(0.145+0)72 
= 2.7 (ng.g-‘.h‘)
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